WO2019222354A1 - Compositions and methods for reducing spliceopathy and treating rna dominance disorders - Google Patents

Compositions and methods for reducing spliceopathy and treating rna dominance disorders Download PDF

Info

Publication number
WO2019222354A1
WO2019222354A1 PCT/US2019/032423 US2019032423W WO2019222354A1 WO 2019222354 A1 WO2019222354 A1 WO 2019222354A1 US 2019032423 W US2019032423 W US 2019032423W WO 2019222354 A1 WO2019222354 A1 WO 2019222354A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid sequence
interfering rna
rna
viral vector
Prior art date
Application number
PCT/US2019/032423
Other languages
French (fr)
Inventor
Joel CHAMBERLAIN
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17/054,474 priority Critical patent/US20210269825A1/en
Priority to MX2020012269A priority patent/MX2020012269A/en
Priority to JP2020563947A priority patent/JP2021522836A/en
Priority to AU2019268346A priority patent/AU2019268346A1/en
Priority to EP19803882.0A priority patent/EP3793566A4/en
Priority to CN201980047374.XA priority patent/CN112469421A/en
Priority to MA51938A priority patent/MA51938B1/en
Priority to KR1020207036197A priority patent/KR20210010549A/en
Application filed by University Of Washington filed Critical University Of Washington
Priority to CA3098249A priority patent/CA3098249A1/en
Priority to BR112020023298-0A priority patent/BR112020023298A2/en
Priority to SG11202011151VA priority patent/SG11202011151VA/en
Publication of WO2019222354A1 publication Critical patent/WO2019222354A1/en
Priority to PH12020551913A priority patent/PH12020551913A1/en
Priority to CONC2020/0015239A priority patent/CO2020015239A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Definitions

  • the invention relates to the field of nucleic acid biotechnology and provides compositions and methods for treating genetic disorders associated with improper ribonucleic acid splicing.
  • RNA transcripts containing aberrantly expanded repeat regions leads to the onset of RNA dominance, a pathology that underlies various heritable genetic disorders, including myotonic dystrophy type 1 , among others.
  • RNA dominance is the most common form of muscular dystrophy, and occurs with an estimate frequency of about 1 in 7,500 human adults.
  • RNA dominance results from a gain-of-function mutation in RNA transcripts that imparts these molecules with undesired biological activity.
  • RNA dominance is effectuated by the presence of expanded CUG trinucleotide repeats in RNA transcript that encode dystrophia myotonica protein kinase (DMPK), which sequester RNA proteins that control RNA splicing, such as muscleblind-like protein, by virtue of the elevated avidity of these expansion regions for such splicing factor proteins.
  • DMPK dystrophia myotonica protein kinase
  • RNA ribonucleic acid
  • compositions described herein that may be used to treat such disorders include nucleic acids containing interfering RNA constructs that suppress the expression of RNA transcripts containing aberrantly expanded repeat regions, such as siRNA, miRNA, and shRNA constructs that anneal to portions of nuclear-retained, repeat-expanded RNA transcripts and promote the degradation of these pathological transcripts by way of various cellular processes.
  • the present disclosure additionally features vectors, such as viral vectors, encoding such interfering RNA constructs.
  • Exemplary viral vectors described herein that encode interfering RNA constructs e.g., siRNA, miRNA, or shRNA
  • interfering RNA constructs e.g., siRNA, miRNA, or shRNA
  • AAV vectors such as pseudotyped AAV2/8 and AAV2/9 vectors.
  • a patient experiencing a spliceopathy and/or having a disease associated with RNA dominance can be administered a nucleic acid containing an interfering RNA construct, or a vector encoding the same, so as to reduce the expression of RNA transcripts containing expanded repeat regions and release splicing factor proteins that are sequestered by repeat-expanded RNA.
  • compositions and methods described herein can be used to treat patients having myotonic dystrophy, as such patients may be administered an interfering RNA construct or a viral vector, such as an AAV vector, encoding such a construct, thereby reducing the expression of RNA transcripts encoding dystrophia myotonica protein kinase (DMPK).
  • DMPK dystrophia myotonica protein kinase
  • Wild-type DMPK RNA constructs typically contain from about 5 to about 37 CUG trinucleotide repeats in the 3’ untranslated region (UTR) of such transcripts.
  • UTR untranslated region
  • compositions and methods described herein can be used to treat patients expressing this mutant DMPK RNA, thereby releasing splicing factors to orchestrate the proper splicing of proteins associated with muscle function and treating an underlying cause of myotonic dystrophy.
  • compositions and methods described herein can be used to reduce spliceopathy in, and treat one or more underlying causes of, various other disorders associated with RNA dominance and the expression of repeat- expanded RNA transcripts.
  • the present disclosure is based, in part, on the surprising discovery that interfering RNA constructs that anneal to repeat-expanded RNA targets at sites distal from the expanded repeat region can be used to suppress the expression of such RNA transcripts and effectively release splicing factor proteins that would otherwise be sequestered by these molecules.
  • the compositions and methods described herein can thus attenuate the expression and nuclear retention of pathological RNA transcripts without the need to contain complementary nucleotide repeat motifs. This property provides an important clinical benefit. Nucleotide repeats are ubiquitous in mammalian genomes, such as in the genomes of human patients.
  • RNA transcripts that do not have nucleotide repeats enables the selective suppression of transcripts that give rise to RNA dominance disorders without disrupting the expression of other transcripts, such as those encoding other genes that happen to contain nucleotide repeat regions but that do not aberrantly sequester splicing factor proteins.
  • the expression of RNA transcripts that contain pathological nucleotide repeat expansions can be diminished, while preserving the expression of important healthy RNA transcripts (for example, an RNA transcript encoding a non-target gene that happens to contain a nucleotide repeat), as well as their downstream protein products.
  • the invention features a viral vector containing one or more transgenes encoding an interfering RNA.
  • the viral vector may contain from one to five such transgenes, from one to 10 such transgenes, from one to 15 such transgenes, from one to 20 such transgenes, from one to 50 such transgenes, from one to 100 such transgenes, from one to 1 ,000 such transgenes, or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 1 00, 1 ,000, or more, such transgenes).
  • the interfering RNA(s) may be at least 5, at least 10, at least 17, at least 19, or more, nucleotides in length, (e.g., at least 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 1 7, 18, 1 9, or more, nucleotides in length, such as from 17 to 24, 18 to 23, or 19 to 22 nucleotides in length).
  • the interfering RNA(s) may, e.g., each be, independently, from 10-35 nucleotides in length. In some embodiments, the interfering RNA(s) are 10 nucleotides in length. In some embodiments, the interfering RNA(s) are 1 1 nucleotides in length. In some embodiments, the interfering RNA(s) are 12 nucleotides in length. In some embodiments, the interfering RNA(s) are 13 nucleotides in length. In some embodiments, the interfering RNA(s) are 14 nucleotides in length. In some embodiments, the interfering RNA(s) are 15 nucleotides in length.
  • the interfering RNA(s) are 16 nucleotides in length. In some embodiments, the interfering RNA(s) are 17 nucleotides in length. In some embodiments, the interfering RNA(s) are 18 nucleotides in length. In some embodiments, the interfering RNA(s) are 19 nucleotides in length. In some embodiments, the interfering RNA(s) are 20 nucleotides in length. In some embodiments, the interfering RNA(s) are 21 nucleotides in length. In some embodiments, the interfering RNA(s) are 22 nucleotides in length. In some embodiments, the interfering RNA(s) are 23 nucleotides in length.
  • the interfering RNA(s) are 24 nucleotides in length. In some embodiments, the interfering RNA(s) are 25 nucleotides in length. In some embodiments, the interfering RNA(s) are 26 nucleotides in length. In some embodiments, the interfering RNA(s) are 27 nucleotides in length. In some embodiments, the interfering RNA(s) are 28 nucleotides in length. In some embodiments, the interfering RNA(s) are 29 nucleotides in length. In some embodiments, the interfering RNA(s) are 30 nucleotides in length. In some embodiments, the interfering RNA(s) are 31 nucleotides in length.
  • the interfering RNA(s) are 32 nucleotides in length. In some embodiments, the interfering RNA(s) are 33 nucleotides in length. In some embodiments, the interfering RNA(s) are 34 nucleotides in length. In some embodiments, the interfering RNA(s) are 35 nucleotides in length.
  • the interfering RNA(s) contain a portion that anneals to an endogenous RNA transcript containing an expanded repeat region.
  • the portion of each interfering RNA(s) may anneal to a segment of the endogenous RNA transcript that does not overlap with the expanded repeat region.
  • the endogenous RNA transcript encodes human DMPK and contains an expanded repeat region.
  • the expanded repeat region may contain, for example, 50 or more CUG trinucleotide repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinucleotide repeats, 210 trinucleotide repeats, 220 trinu
  • 1 ,400 trinucleotide repeats 1 ,500 trinucleotide repeats, 1 ,600 trinucleotide repeats, 1 ,700 trinucleotide repeats, 1 ,800 trinucleotide repeats, 1 ,900 trinucleotide repeats, 2,000 trinucleotide repeats, 2,100 trinucleotide repeats, 2,200 trinucleotide repeats, 2,300 trinucleotide repeats, 2,400 trinucleotide repeats, 2,500 trinucleotide repeats, 2,600 trinucleotide repeats, 2,700 trinucleotide repeats, 2,800 trinucleotide repeats, 2,900 trinucleotide repeats, 3,000 trinucleotide repeats, 3,100 trinucleotide repeats, 3,200 trinucleotide repeats, 3,300 trinucleotide repeats, 3,400 tri
  • the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the endogenous RNA transcript contains a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the endogenous RNA transcript may contain, for example, a portion having the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
  • the viral vector further comprises a transgene encoding human DMPK, such as a codon-optimized human DMPK that, upon transcription, does not anneal to the interfering RNA.
  • a transgene encoding human DMPK such as a codon-optimized human DMPK that, upon transcription, does not anneal to the interfering RNA.
  • the DMPK transcript expressed by the transgene encoding human DMPK may be less than 85% complementary to the interfering RNA (e.g., less than 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1 % complementary, or less).
  • the transgene encoding human DMPK may be operably linked to the transgene(s) encoding the interfering RNA, for example, such that the interfering RNA(s) and the DMPK are expressed from the same promoter. This may be effectuated, for instance, by the placement of an internal ribosomal entry site (IRES) between the transgene(s) encoding the interfering RNA(s) and the transgene encoding human DMPK.
  • IRS internal ribosomal entry site
  • the transgene(s) encoding the interfering RNA(s) and the transgene encoding human DMPK are each operably linked to separate promoters.
  • the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript having the nucleic acid sequence of any one of SEQ ID NOs: 3-39.
  • the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of exons 1 -15 of human DMPK RNA (e.g., to a segment within exon 1 , exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 9, exon 10, exon 1 1 , exon 12, exon
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%,
  • each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g.,
  • each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -1 5 of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of introns 1 -14 of human DMPK RNA (e.g., to a segment within intron 1 , intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 10, intron 1 1 , intron 12, intron 13, or intron 14 of human DMPK RNA).
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript containing an exon-intron boundary within human DMPK (e.g., to a segment containing the boundary between exon 1 and intron 1 , between intron 1 and exon 2, between exon 2 and intron 2, between intron 2 and exon 3, between exon 3 and intron 3, between intron 3 and exon 4, between exon 4 and intron 4, between intron 4 and exon 5, between exon 5 and intron 5, between intron
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%,
  • each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • each interfering RNA anneals to a segment of the endogenous RNA transcript within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100%
  • each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the segment within human DMPK is from about 10 to about 80 nucleotides in length.
  • the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
  • nucleotides 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleo
  • the segment within human DMPK is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleot
  • the segment within human DMPK is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length.
  • the segment is 18 nucleotides in length.
  • the segment is 19 nucleotides in length.
  • the segment is 20 nucleotides in length.
  • the segment is 21 nucleotides in length.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches).
  • nucleotide mismatches e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches.
  • interfering RNA may anneal to the endogenous RNA transcript encoding human DMKPK with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
  • the interfering RNA contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
  • the interfering RNA may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of ay one of SEQ ID NOs: 3-161 .
  • the interfering RNA contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of ay one of SEQ ID NOs: 3-161 .
  • the interfering RNA contains a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3- 161 .
  • the interfering RNA is a miRNA having a combination of passenger and guide strands shown in Table 5, herein.
  • the endogenous RNA transcript contains human chromosome 9 open reading frame 72 (C90RF72) and an expanded repeat region.
  • the expanded repeat region may contain, for example, greater than 25 GGGGCC (SEQ ID NO: 1 62) hexanucleotide repeats, such as from about
  • the expanded repeat region may contain 700 hexanucleotide repeats, 710 hexanucleotide repeats, 720 hexanucleotide repeats, 730 hexanucleotide repeats, 740 hexanucleotide repeats, 750 hexanucleotide repeats, 760 hexanucleotide repeats, 770 hexanucleotide repeats, 780 hexanucleotide repeats, 790 hexanucleotide repeats, 800 hexanucleotide repeats, 810 hexanucleotide repeats, 820 hexanucleotide repeats, 830 hexanucleotide repeats, 840 hexanucleotide repeats, 850 hexanucleotide repeats.
  • the expanded repeat region may contain greater than 30 hexanucleotide repeats, such as 30 hexanucleotide repeats, 40 hexanucleotide repeats, 50
  • hexanucleotide repeats 60 CUG hexanucleotide repeats, 70 hexanucleotide repeats, 80 hexanucleotide repeats, 90 hexanucleotide repeats, 100 hexanucleotide repeats, 1 10 hexanucleotide repeats, 120 hexanucleotide repeats, 130 hexanucleotide repeats, 140 hexanucleotide repeats, 150 hexanucleotide repeats, 160 hexanucleotide repeats, 170 hexanucleotide repeats, 180 hexanucleotide repeats, 190 hexanucleotide repeats, 200 hexanucleotide repeats, 210 hexanucleotide repeats, 220 hexanucleotide repeats, 230 hexanucleotide repeats,
  • the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163.
  • the endogenous RNA transcript may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163.
  • the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163. In some embodiments, the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 163.
  • the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165.
  • the endogenous RNA transcript may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165.
  • the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165. In some embodiments, the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 165.
  • the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
  • RNA transcript may contain, for example, a portion having at least 90% sequence identity
  • the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 166.
  • the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 166.
  • the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166.
  • 90% complementary e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary
  • each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166.
  • the segment within human C90RF72 is from about 10 to about 80 nucleotides in length.
  • the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
  • nucleotides 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleo
  • the segment within human C90RF72 is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleo
  • the segment within human C90RF72 is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length. In some embodiments, the segment is 18 nucleotides in length. In some embodiments, the segment is 19 nucleotides in length. In some embodiments, the segment is 20 nucleotides in length. In some embodiments, the segment is 21 nucleotides in length.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches).
  • nucleotide mismatches e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches.
  • the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with no more than two nucleotide mismatches.
  • interfering RNA may anneal to the endogenous RNA transcript encoding human C90RF72 with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
  • the interfering RNA is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA), such as a U6 miRNA.
  • the miRNA may be based, for example, on the endogenous human miR30a nucleic acid sequence, having one or more nucleic acid substitutions as needed for complementarity to a target mRNA (e.g., a target mRNA described herein).
  • the viral vector may contain, for example, a primary miRNA (pri-miRNA) transcript encoding a mature miRNA.
  • the viral vector contains a pre-miRNA transcript encoding a mature miRNA.
  • the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron.
  • the promoter may be, for example, a desmin promoter, a phosphoglycerate kinase (PGK) promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a promoter within intron 1 of ocular paired like homeodomain 3 (PITX3).
  • PGK phosphoglycerate kinase
  • the viral vector is an AAV, adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus.
  • the viral vector may be, for example, an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhI O, or AAVrh74 serotype.
  • the viral vector is a pseudotyped AAV, such as an AAV2/8 or AAV/29 vector.
  • the viral vector may contain a recombinant capsid protein.
  • the viral vector is a synthetic virus, such as a chimeric virus, mosaic virus, or pseudotyped virus, and/or a synthetic virus that contains a foreign protein, synthetic polymer, nanoparticle, or small molecule.
  • the invention features a nucleic acid encoding or containing an interfering RNA that contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 1 00% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-1 61 .
  • sequence identity e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 1 00% sequence identity
  • the interfering RNA contains a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
  • the interfering RNA may contain, for example, a portion having at least 95% sequence identity (e.g.,
  • the interfering RNA contains a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3-1 61 .
  • the interfering RNA is a miRNA having a combination of passenger and guide strands shown in Table 5, herein.
  • the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of exons 1 -15 of human DMPK RNA (e.g., to a segment within exon 1 , exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 9, exon 10, exon 1 1 , exon 12, exon 13, exon 14, or exon 15 of human DMPK RNA).
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • 95% complementary e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
  • the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of introns 1 -14 of human DMPK RNA (e.g., to a segment within intron 1 , intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 10, intron 1 1 , intron 12, intron 13, or intron 14 of human DMPK RNA).
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
  • each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK containing an exon-intron boundary within human
  • DMPK e.g., to a segment containing the boundary between exon 1 and intron 1 , between intron 1 and exon 2, between exon 2 and intron 2, between intron 2 and exon 3, between exon 3 and intron 3, between intron 3 and exon 4, between exon 4 and intron 4, between intron 4 and exon 5, between exon 5 and intron 5, between intron 5 and exon 6, between exon 6 and intron 6, between intron 6 and exon 7, between exon 7 and intron 7, between intron 7 and exon 8, between exon 8 and intron 8, between intron
  • each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary
  • each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
  • each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
  • each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
  • the segment within human DMPK is from about 10 to about 80 nucleotides in length.
  • the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
  • nucleotides 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleo
  • the segment within human DMPK is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleot
  • the segment within human DMPK is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length.
  • the segment is 18 nucleotides in length.
  • the segment is 19 nucleotides in length.
  • the segment is 20 nucleotides in length.
  • the segment is 21 nucleotides in length.
  • the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches).
  • nucleotide mismatches e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches.
  • the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches.
  • the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches.
  • interfering RNA may anneal to the endogenous RNA transcript encoding human DMKPK with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
  • the interfering RNA is a siRNA, a shRNA, or a miRNA, such as a U6 miRNA.
  • the miRNA may be based, for example, on the endogenous human miR30a nucleic acid sequence, having one or more nucleic acid substitutions as needed for complementarity to a target mRNA (e.g., a target mRNA described herein).
  • the nucleic acid may contain, for example, a pri-miRNA transcript encoding a mature miRNA.
  • the viral vector contains a pre-miRNA transcript encoding a mature miRNA.
  • the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron.
  • the promoter may be, for example, a desmin promoter, a PGK promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a promoter within intron 1 of ocular PITX3.
  • the invention features a vector containing the nucleic acid of any of the above aspects or embodiments.
  • the vector may be, for example, an AAV (e.g., an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhl 0, or AAVrh74 serotype, or a pseudotyped AAV, such as an AAV2/8 or AAV/29 vector), adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus (e.g., a chimeric virus, mosaic virus, or pseudotyped virus, and/or a synthetic virus that contains a foreign protein, synthetic polymer, nanoparticle, or small molecule), and may contain one or more recombinant capsid proteins.
  • AAV e.g., an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7
  • the invention features a composition containing the nucleic acid of any of the above aspects or embodiments.
  • the composition may be, for example, a liposome, vesicle, synthetic vesicle, exosome, synthetic exosome, dendrimer, or nanoparticle.
  • the invention features a pharmaceutical composition containing the nucleic acid of any of the above aspects or embodiments.
  • the pharmaceutical composition may further contain a pharmaceutically acceptable carrier, diluent, or excipient.
  • the invention features a method of reducing the occurrence of spliceopathy (e.g., of an mRNA transcript for which splicing is regulated, in part, by the activity of muscleblind-like protein) in a patient, such as a human patient, in need thereof.
  • the method may include administering to the patient a therapeutically effective amount of the vector or composition of any of the above aspects or embodiments.
  • the patient has myotonic dystrophy.
  • the patient may exhibit an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein.
  • the invention features a method of treating a disorder characterized by nuclear retention of RNA containing an expanded repeat region in a patient, such as a human patient, in need thereof by administering to the patient a therapeutically effective amount of the vector or composition of any of the above aspects or embodiments.
  • the disorder may be, for example, myotonic dystrophy, and the nuclear-retained RNA may be DMPK RNA.
  • the disorder is amyotrophic lateral sclerosis and the nuclear-retrained RNA is C90RF72 RNA.
  • the patient may exhibit an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein.
  • the patient may exhibit an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold,
  • SERCA1 mRNA containing exon 22 by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold
  • the patient may exhibit a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
  • the patient may exhibit a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 1 0%, 1 1 %, 12%, 13%, 14%, 15%, 1 6%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%,
  • ZASP ZO-2 associated speckle protein
  • the patient upon administration of the vector or composition to the patient, the patient exhibits an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor, RYR1 , cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2- fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold,
  • RNA or protein detection assay described herein.
  • the vector or composition is administered to the patient by way of intravenous, intrathecal, intracerebroventricular,
  • intraparenchymal intracisternal, intradermal, transdermal, parenteral, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, or oral administration.
  • the invention features a kit containing the vector or composition of any of the above aspects or embodiments.
  • the kit may further contain a package insert instructing a user of the kit to administer the vector or composition to the patient to reduce the occurrence of a spliceopathy in the patient, such as spliceopathy of an mRNA transcript for which splicing is regulated, in part, by the activity of muscleblind-like protein.
  • the invention features a kit containing the vector or composition of any of the above aspects or embodiments and a package insert that instructs a user of the kit to administer the vector or composition to the patient to reduce the occurrence of a spliceopathy in the patient to treat a disorder characterized by nuclear retention of RNA containing an expanded repeat region.
  • the disorder may be, for example, myotonic dystrophy, and the nuclear-retained RNA may be DMPK RNA.
  • the disorder is amyotrophic lateral sclerosis and the nuclear-retrained RNA is C90RF72 RNA.
  • the term“about” refers to a value that is within 10% above or below the value being described.
  • the phrase“about 1 00 nucleic acid residues” refers to a value of from 90 to 1 10 nucleic acid residues.
  • anneal refers to the formation of a stable duplex of nucleic acids by way of hybridization mediated by inter-strand hydrogen bonding, for example, according to Watson-Crick base pairing.
  • the nucleic acids of the duplex may be, for example, at least 50% complementary to one another (e.g., about 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%,
  • the "stable duplex" formed upon the annealing of one nucleic acid to another is a duplex structure that is not denatured by a stringent wash.
  • Exemplary stringent wash conditions include temperatures of about 5° C less than the melting temperature of an individual strand of the duplex and low concentrations of monovalent salts, such as monovalent salt concentrations (e.g., NaCI concentrations) of less than 0.2 M (e.g., 0.2 M, 0.19 M, 0.18 M, 0.17 M, 0.16 M, 0.15 M, 0.14 M, 0.13 M, 0.12 M, 0.1 1 M, 0.1 M, 0.09 M, 0.08 M, 0.07 M, 0.06 M, 0.05 M, 0.04 M, 0.03 M, 0.02 M, 0.01 M, or less).
  • monovalent salt concentrations e.g., NaCI concentrations
  • the terms“conservative mutation,”“conservative substitution,” or“conservative amino acid substitution” refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally-occurring amino acids in Table 1 below.
  • conservative amino acid families include, e.g., (i) G, A, V, L, I, P, and M; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W.
  • a conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family (e.g., a substitution of Ser for Thr or Lys for Arg).
  • the terms“dystrophia myotonica protein kinase” and its abbreviation,“DMPK,” refer to the serine/threonine kinase protein involved in the regulation of skeletal muscle structure and function, for example, in human subjects.
  • the terms“dystrophia myotonica protein kinase” and“DMPK” are used interchangeably herein and refer not only to wild-type forms of the DMPK gene, but also to variants of wild-type DMPK proteins and nucleic acids encoding the same.
  • the nucleic acid sequences of two isoforms of human DMPK mRNA are provided herein as SEQ ID NOs: 1 and 2, which correspond to GenBank Accession Nos. BC026328.1 and BC062553.1 , respectively (3’ UTRs not included). These nucleic acid sequences are provided in Table 2, below.
  • the terms“dystrophia myotonica protein kinase” and“DMPK” as used herein include, for example, forms of the human DMPK gene that have a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% identical to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2) and/or forms of the human DMPK gene that encode a DMPK protein having one or more (e.g., up to 25) conservative amino acid substitutions relative to a wild- type DMPK protein.
  • DMPK RNA transcripts containing expanded CUG trinucleotide repeat regions relative to the length of the CUG trinucleotide repeat region of a wild-type DMPK mRNA transcript additionally include DMPK RNA transcripts containing expanded CUG trinucleotide repeat regions relative to the length of the CUG trinucleotide repeat region of a wild-type DMPK mRNA transcript.
  • the expanded repeat region may contain, for example, 50 or more CUG trinucleotide repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinucleotide repeats, 210 trinucleotide repeats, 220 trinu
  • interfering RNA refers to a RNA, such as a short interfering RNA
  • siRNA siRNA
  • miRNA micro RNA
  • shRNA short hairpin RNA
  • RNA transcript by way of (i) annealing to the target RNA transcript, thereby forming a nucleic acid duplex; and (ii) promoting the nuclease-mediated degradation of the RNA transcript and/or (iii) slowing, inhibiting, or preventing the translation of the RNA transcript, such as by sterically precluding the formation of a functional ribosome-RNA transcript complex or otherwise attenuating formation of a functional protein product from the target RNA transcript.
  • Interfering RNAs as described herein may be provided to a patient, such as a human patient having myotonic dystrophy, in the form of, for example, a single- or double-stranded oligonucleotide, or in the form of a vector (e.g., a viral vector, such as an adeno- associated viral vector described herein) containing a transgene encoding the interfering RNA.
  • a patient such as a human patient having myotonic dystrophy
  • a vector e.g., a viral vector, such as an adeno- associated viral vector described herein
  • RNA platforms are described, for example, in Lam et al. , Molecular Therapy - Nucleic Acids 4:e252 (2015); Rao et al., Advanced Drug Delivery Reviews 61 :746-769 (2009); and Borel et al., Molecular Therapy 22:692-701 (2014), the disclosures of each of which are incorporated herein by reference in their entirety.
  • the“length” of a nucleic acid refers to the linear size of the nucleic acid as assessed by measuring the quantity of nucleotides from the 5’ to the 3’ end of the nucleic acid.
  • the term“myotonic dystrophy” refers to an inherited muscle wasting disorder characterized by the nuclear retention of RNA transcripts encoding DMPK and containing an expanded CUG trinucleotide repeat region in the 3’ untranslated region (UTR), such as an expanded CUG trinucleotide repeat region having from 50 to 4,000 CUG repeats. Wild-type RMPK RNA transcripts, by comparison, typically contain from 5 to 37 CUG repeats in the 3' UTR. In patients having myotonic dystrophy, the expanded CUG repeat region interacts with RNA-binding splicing factors, such as muscleblind-like protein.
  • UTR untranslated region
  • DM1 myotonic dystrophy
  • skeletal muscle is often the most severely affected tissue, but the disease also imparts toxic effects on cardiac and smooth muscle, the ocular lens, and the brain.
  • the cranial, distal limb, and diaphragm muscles are preferentially affected.
  • Manual dexterity is compromised early, which causes several decades of severe disability.
  • the median age at death of myotonic dystrophy patients is 55 years, which is usually caused by respiratory failure (de Die-Smulders C E, et al., Brain 121 :1557-1563 (1998)).
  • the term“operably linked” refers to a first molecule (e.g., a first nucleic acid) joined to a second molecule (e.g., a second nucleic acid), wherein the molecules are so arranged that the first molecule affects the function of the second molecule.
  • the two molecules may or may not be part of a single contiguous molecule and may or may not be adjacent to one another.
  • a promoter is operably linked to a transcribable polynucleotide molecule if the promoter modulates transcription of the transcribable polynucleotide molecule of interest in a cell.
  • two portions of a transcription regulatory element are operably linked to one another if they are joined such that the transcription activating functionality of one portion is not adversely affected by the presence of the other portion.
  • Two transcription regulatory elements may be operably linked to one another by way of a linker nucleic acid (e.g., an intervening non-coding nucleic acid) or may be operably linked to one another with no intervening nucleotides present.
  • one segment of a nucleic acid molecule is considered to“overlap with” another segment of the same nucleic acid molecule if the two segments share one or more constituent nucleotides.
  • two segments of the same nucleic acid molecule are considered to“overlap with” one another if the two segments share 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or more, constituent nucleotides.
  • the two segments are not considered to“overlap with” one another if the two segments have zero constituent nucleotides in common.
  • Percent (%) sequence complementarity with respect to a reference polynucleotide sequence is defined as the percentage of nucleic acids in a candidate sequence that are complementary to the nucleic acids in the reference polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence complementarity.
  • a given nucleotide is considered to be“complementary” to a reference nucleotide as described herein if the two nucleotides form canonical Watson-Crick base pairs.
  • Watson-Crick base pairs in the context of the present disclosure include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs.
  • a proper Watson-Crick base pair is referred to in this context as a“match,” while each unpaired nucleotide, and each incorrectly paired nucleotide, is referred to as a“mismatch.”
  • Alignment for purposes of determining percent nucleic acid sequence complementarity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal complementarity over the full length of the sequences being compared.
  • the percent sequence complementarity of a given nucleic acid sequence, A, to a given nucleic acid sequence, B, is calculated as follows:
  • X is the number of complementary base pairs in an alignment (e.g., as executed by computer software, such as BLAST) in that program’s alignment of A and B
  • Y is the total number of nucleic acids in B.
  • the percent sequence complementarity of A to B will not equal the percent sequence complementarity of B to A.
  • a query nucleic acid sequence is considered to be“completely complementary” to a reference nucleic acid sequence if the query nucleic acid sequence has 100% sequence complementarity to the reference nucleic acid sequence.
  • Percent (%) sequence identity with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software.
  • percent sequence identity values may be generated using the sequence comparison computer program BLAST.
  • percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:
  • X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program’s alignment of A and B
  • Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.
  • the term“pharmaceutical composition” refers to a mixture containing a therapeutic agent, such as a nucleic acid or vector described herein, optionally in combination with one or more pharmaceutically acceptable excipients, diluents, and/or carriers, to be administered to a subject, such as a mammal, e.g., a human, in order to prevent, treat or control a particular disease or condition affecting or that may affect the subject.
  • the term“pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.
  • the term“repeat region” refers to segments within a gene of interest or an RNA transcript thereof containing nucleic acid repeats, such as the poly CTG sequence in the 3” UTR of the human DMPK gene (or the poly CUG sequence in the 3’ UTR of the RNA transcript thereof).
  • a repeat region is considered to be an“expanded repeat region,” a“repeat expansion,” or the like, if the number of nucleotide repeats in the repeat region exceeds the quantity of repeats ordinarily found in the repeat region of a wild-type form of the gene or RNA transcript thereof.
  • the 3’ UTRs of wild-type human DMPK genes typically contain from 5 to 37 CTG or CUG repeats.
  • “Expanded repeat regions” and “repeat expansions” in the context of the DMPK gene or an RNA transcript thereof thus refer to repeat regions containing greater than 37 CTG or CUG repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinu
  • RNA dominance refers to a pathology that is induced by the expression and nuclear retention of RNA transcripts containing expanded repeat regions relative to the quantity of repeat regions, if any, contained by a wild-type form of the RNA transcript of interest.
  • the toxic effects of RNA dominance are a manifestation, for example, of the binding interaction between the expanded repeat regions of the pathologic, mutant RNA transcripts with splicing factor proteins, which promotes the sequestration of splicing factors away from pre-mRNA transcripts, thereby engendering spliceopathy among such substrates.
  • Exemplary disorders associated with RNA dominance are myotonic dystrophy and amyotrophic lateral sclerosis, as described herein, among others.
  • sample refers to a specimen (e.g., blood, blood component (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placental or dermal), pancreatic fluid, chorionic villus sample, or cells) isolated from a subject.
  • the subject may be, for example, a patient suffering from a disease described herein, such as a heritable muscle wasting disorder (e.g., muscular dystrophy, such as myotonic dystrophy (e.g., myotonic dystrophy type I).
  • a heritable muscle wasting disorder e.g., muscular dystrophy, such as myotonic dystrophy (e.g., myotonic dystrophy type I).
  • phrases“specifically binds” and“binds” refer to a binding reaction which is determinative of the presence of a particular molecule, such as an RNA transcript, in a heterogeneous population of ions, salts, small molecules, and/or proteins that is recognized, e.g., by a ligand or receptor, such as an RNA-binding splicing factor protein, with particularity.
  • a ligand e.g., an RNA-binding protein described herein
  • a ligand that specifically binds to a species (e.g., an RNA transcript) may bind to the species, e.g., with a KD of less than 1 mM.
  • a ligand that specifically binds to a species may bind to the species with a KD of up to 100 mM (e.g., between 1 pM and 100 mM).
  • a ligand that does not exhibit specific binding to another molecule may exhibit a KD of greater than 1 mM (e.g., 1 pM, 100 pM, 500 pM,
  • assay formats may be used to determine the affinity of a ligand for a specific protein.
  • solid-phase ELISA assays are routinely used to identify ligands that specifically bind a target protein. See, e.g., Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999), for a description of assay formats and conditions that can be used to determine specific protein binding.
  • spliceopathy refers to a change in the splicing pattern of an mRNA transcript that leads to the expression of one or more alternative splice products relative to a wild-type form of the mRNA transcript of interest. Spliceopathy can lead to a toxic loss of function if, for example, the mRNA transcript is spliced in such a way that one or more exons necessary for the activity of the encoded protein are no longer present in the mRNA transcript upon translation. Additionally or alternatively, toxic loss of function may occur due to the aberrant inclusion of one or more introns, for example, in a manner that precludes the proper folding of the encoded protein.
  • the terms“subject” and“patient” refer to an organism that receives treatment for a particular disease or condition as described herein (such as a heritable muscle-wasting disorder, e.g., myotonic dystrophy).
  • a particular disease or condition as described herein such as a heritable muscle-wasting disorder, e.g., myotonic dystrophy.
  • subjects and patients include mammals, such as humans, receiving treatment for a disease or condition described herein.
  • transcription regulatory element refers to a nucleic acid that controls, at least in part, the transcription of a gene of interest. Transcription regulatory elements may include promoters, enhancers, and other nucleic acids (e.g., polyadenylation signals) that control or help to control gene transcription. Examples of transcription regulatory elements are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, CA, 1990).
  • the terms“treat” or“treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of a heritable muscle-wasting disorder, for example, myotonic dystrophy, and particularly, type I myotonic dystrophy.
  • beneficial or desired clinical results that are indicative of successful treatment include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e. , not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment of a patient having myotonic dystrophy may manifest in one or more detectable changes, such as a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions (e.g., a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions of 1 % or more, such as a decrease of 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%,
  • a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions e.g., a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions of 1 % or more, such as a decrease of 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%,
  • DMPK RNA transcripts containing expanded CUG trinucleotide repeat regions by the patient prior to administration of a therapeutic agent, such as a vector or nucleic acid described herein.
  • RNA-seq assays methods that can be used to assess RNA expression levels are known in the art and include RNA-seq assays and polymerase chain reaction techniques described herein. Additional clinical indications of successful treatment of a CPVT patient include alleviation of spliceopathy, for example, of an RNA transcript that is spliced in a manner that is dependent upon muscleblind-like protein. For example, observations that signal successful treatment of a patient having myotonic dystrophy include a finding that the patient exhibits an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein following administration of a therapeutic agent, such as a therapeutic agent described herein.
  • a therapeutic agent such as a therapeutic agent described herein.
  • indicators that signal successful treatment of myotonic dystrophy include a determination that the patient exhibits an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold,
  • SERCA1 sarcoplasmic/endoplasmic reticulum calcium ATPase 1
  • Treatment of myotonic dystrophy may also manifest as a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about
  • CLCN1 chloride voltage-gated channel 1
  • successful treatment may be signaled by a determination that the patient exhibits a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%,
  • ZASP ZO-2 associated speckle protein
  • RNA or protein detection assay described herein.
  • Successful treatment of myotonic dystrophy may also be signaled by a finding that, following the therapy, the patient exhibits an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor,
  • RYR1 cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1.4- fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6- fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8- fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5- fold, 5.1 -fold, 5.2-fold, 5.3-fold, 5.4-fold,
  • the term“vector” refers to a nucleic acid, e.g., DNA or RNA, that may function as a vehicle for the delivery of a gene of interest into a cell (e.g., a mammalian cell, such as a human cell), tissue, organ, or organism, such as a patient undergoing treatment for a disease or condition described herein, for purposes of expressing an encoded transgene.
  • a cell e.g., a mammalian cell, such as a human cell
  • tissue e.g., a mammalian cell, such as a human cell
  • exemplary vectors useful in conjunction with the compositions and methods described herein are plasmids, DNA vectors, RNA vectors, virions, or other suitable replicon (e.g., viral vector).
  • vectors have been developed for the delivery of polynucleotides encoding exogenous proteins into a prokaryotic or eukaryotic cell. Examples of such expression vectors are disclosed in, e.g., WO 1994/1 1026, the disclosure of which is incorporated herein by reference.
  • Expression vectors described herein contain a polynucleotide sequence as well as, e.g., additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell.
  • Certain vectors that can be used for the expression of transgenes described herein include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription.
  • kits for expression of transgenes contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements include, e.g., 5’ and 3’ untranslated regions, an internal ribosomal entry site (IRES), and polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector.
  • the expression vectors described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, or nourseothricin.
  • FIG. 1 is a diagram showing the structure of human dystrophia myotonica protein kinase (DMPK) RNA, including the configuration of exons (represented by shaded rectangular boxes) and the site of the CUG trinucleotide repeat region. Numerical values from 600 to 12,600 along the bottom of the figure indicate nucleotide position along the length of the DMPK RNA transcript.
  • the diagram shows the regions within the DMPK RNA transcript to which various exemplary interfering RNA constructs described herein anneal by way of sequence complementarity.
  • FIGS. 2A - 2C are diagrams showing the schematics of three generations of rAAV vectors encoding interfering RNA molecules (rAAV-RNAi vectors) targeting several genes of interest, such as those associated with RNA dominance.
  • the rAAV plasmid pARAP4 includes the human alkaline phosphatase reporter gene (Hu Aik Phos) reporter gene, expressed from the Rous Sarcoma Virus (RSV) promoter, and the SV40 polyadenylation sequence, pA.
  • the inverted terminal repeats (ITRs) originate from rAAV2, and the genomes are packaged in rAAV6 capsids.
  • the newest vector modification removes the RSV promoter sequence to prevent Hu Aik Phos expression that limited rAAV-RNAi efficacy at higher doses due muscle cell toxicity.
  • FIG. 3A is a diagram showing exemplary routes of administration of rAAV-RNAi vectors into murine models of RNA dominance disorders, such as myotonic dystrophy.
  • FIGS. 3B and 3C are diagrams comparing various characteristics of myotonic dystrophy type I (DM1 ) and the murine HSA LR model of this disease.
  • HSA LR mice show characteristics of myotonic dystrophy resembling DM in humans.
  • the HSA LR transgene is derived from insertion of a (CTG)2so repeat in the 3’ UTR of the human skeletal actin (HSA) gene. When the transgene is expressed in mouse skeletal muscle, myotonic discharges are evident, splicing alterations occur in a variety of mRNAs, and nuclear foci containing the expanded transgenic mRNA and splicing factors are present.
  • CCG human skeletal actin
  • FIG. 4 is a diagram showing the characteristics of HSA LR mice transduced with rAAV6 HSA miR DM10, as described in Example 1 , below.
  • Human placental alkaline phosphatase (AP) staining indicates presence of the viral genome with active reporter gene expression.
  • FIGS. 5A and 5B are graphs quantifying HSA mRNA and expression of the HSA miRDMI 0 in seven individual HSA LR mice transduced as described in Example 1 , below. mRNA expression shown was assessed by qPCR at 8 weeks post-rAAV injection.
  • FIGS. 6A - 6E are diagrams demonstrating that rAAV6 HSA miR DM10 systemic injection improves splicing of Atp2a (SERCA1 ) and CLCN1 in the tibialis anterior (TA) muscle, as described in Example 1 , below.
  • SERCA1 Atp2a
  • CLCN1 tibialis anterior
  • a different RNAi hairpin, miR DM4 is not as effective at reversing these splicing defects.
  • FIGS. 7A - 7C are diagrams showing the structure and activity of re-engineered rAAV-miR DM10 and -miR DM4 evaluated in vivo. Intramuscular injection of vectors without the RSV promoter to prevent
  • FIG. 7A shows a schematic diagram of the rAAV genome lacking the RSV promoter sequence as the‘new DM10’ and‘new DM4’ labeled on the gels in FIG. 7B.
  • FIG. 7B shows analysis of splicing patterns for Atp2a1/Serca1 following IM injection of ‘new DM10’ and‘new DM4’ into the TA muscle compared to Aik Phos expressing‘old DM10.’
  • L low dose of 5x10 9 vector genomes
  • H high dose of 5x10 10 vector genomes. no RSV promoter
  • + RSV present in vector genome.
  • the high dose was chosen because it elicited some muscle regeneration as marked by the presence of central nuclei (CN) with IM injection of Hu Aik Phos expressing vectors. However, no evidence of muscle turnover was observed at this high dose of rAAV DM10 lacking RSV, new DM10 and new DM4.
  • FIG. 8A is a diagram showing how purified plasmids expressing the DMPK-targeting miRNAs were transfected into HEK293 cells and RNA was isolated and subjected to RT-qPCR to evaluate DMPK transcript engagement by the RISC complex and Dicer cleavage.
  • FIG. 8B is a graph showing the evaluation of the gene silencing activity of U6 DMPK miRNAs.
  • Candidate therapeutic miRNA expression cassettes a and b showed reduction of the endogenous DMPK mRNA 48hrs after transfection of HEK293 cells with 1.5 pg of plasmid DNA compared to a plasmid with no miRNA expression cassette. Eight biological replicates were assayed per plasmid and control.
  • “a” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 42 and a guide strand having the nucleic acid sequence of SEQ ID NO: 79
  • “b” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 44 and a guide strand having the nucleic acid sequence of SEQ ID NO: 81
  • “c” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 46 and a guide strand having the nucleic acid sequence of SEQ ID NO: 83
  • “d” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 47 and a guide strand having the nucleic acid sequence of SEQ ID NO: 84
  • “none” represents cells not treated with an anti-DMPK miRNA.
  • FIG. 9 is a graph showing the ability of various siRNA molecules described herein to
  • DMPK expression in HEK293 cells downregulate DMPK expression in HEK293 cells, as described in Example 4, below.
  • Values along the y- axis represent normalized DMPK expression, and the x-axis shows the anti-DMPK siRNA molecules tested.
  • the first entry on the x-axis corresponds to treatment of HEK293 cells with transfection vehicle only, and the second entry on the x-axis represents treatment with an siRNA having a scrambled nucleic acid sequence as a negative control.
  • siRNA molecules having a specified sequence identifier number are described herein, for example, in Table 4, below.
  • siRNA molecules labeled“Anti-DMPK” followed by an alphanumeric identifier are commercially available from Thermo Fisher Scientific.
  • compositions and methods described herein are useful for reducing the occurrence of spliceopathy and for treating disorders associated with ribonucleic acid (RNA) dominance, such as myotonic dystrophy and amyotrophic lateral sclerosis, among others.
  • RNA ribonucleic acid
  • the compositions described herein include nucleic acids containing interfering RNA constructs that suppress the expression of RNA transcripts containing aberrantly expanded repeat regions. This activity provides an important physiological benefit, as various RNA transcripts harboring such repeat expansions exhibit a heightened avidity for RNA splicing factors. This avidity manifests in sequestration of RNA splicing factors away from other pre-mRNA substrates, thereby disrupting the proper splicing of these transcripts.
  • compositions described herein may ameliorate this pathology by diminishing the expression of RNA transcripts harboring expanded nucleotide repeats, thus releasing sequestered splicing factors so that they may properly regulate the splicing of various other pre-mRNA transcripts.
  • the compositions and methods described herein may be used to treat disorders, such as myotonic dystrophy, associated with expression of dystrophia myotonica protein kinase (DMPK) RNA transcripts containing an expanded CUG trinucleotide repeat region.
  • disorders such as myotonic dystrophy
  • DMPK dystrophia myotonica protein kinase
  • compositions and methods described herein may be used to treat amyotrophic lateral sclerosis, characterized by elevated expression of C90RF72 RNA transcripts containing GGGGCC (SEQ ID NO: 162) hexanucleotide repeats.
  • the interfering RNA constructs described herein may be in any of a variety of forms, such as short interfering RNA (siRNA), short hairpin RNA (shRNA), or micro RNA (miRNA).
  • the interfering RNAs described herein may additionally be encoded by a vector, such as a viral vector.
  • a vector such as a viral vector.
  • adeno-associated viral (AAV) vectors such as pseudotyped AAV vectors (e.g., AAV2/8 and AAV2/9 vectors) containing transgenes encoding interfering RNA constructs that attenuate the expression of RNA transcripts harboring expanded nucleotide repeats.
  • compositions and methods described herein provide, among other benefits, the
  • RNA transcripts that contain pathological nucleotide repeat expansions can be diminished, while preserving the expression of important healthy RNA transcripts and their encoded protein products.
  • This advantageous feature is based, in part, on the surprising discovery that interfering RNA constructs that anneal to repeat-expanded RNA targets at sites remote from the expanded repeat region can be used to suppress the expression of these RNA transcripts and release splicing factor proteins that would otherwise be sequestered by these molecules.
  • the compositions and methods described herein can thus attenuate the expression and nuclear retention of pathological RNA transcripts without the necessity of containing complementary nucleotide repeat motifs.
  • RNA constructs that may be used in conjunction with the compositions and methods described herein, as well as a description of vectors encoding such constructs and procedures that may be used to treat disorders associated with spliceopathy, such as myotonic dystrophy and amyotrophic lateral sclerosis.
  • a patient experiencing a spliceopathy and/or having a disease associated with RNA dominance can be administered a nucleic acid containing an interfering RNA construct, or a vector encoding the same, so as to reduce the expression of RNA transcripts containing expanded repeat regions.
  • this activity provides the beneficial effect of releasing RNA-binding proteins that bind with high avidity to the repeat expansion regions of pathologic RNA transcripts.
  • RNA-binding proteins The release of such RNA-binding proteins is important, as the proteins sequestered by binding to repeat-expanded RNA transcripts include splicing factors that would ordinarily be available to modulate the proper splicing of various pre-mRNA transcripts.
  • splicing factors such as muscleblind-like protein, which regulates the splicing of various transcripts that encode proteins having important roles in regulating muscle function, are sequestered from important pre-mRNA substrates.
  • the compositions and methods described herein may treat RNA dominance disorders by promoting the degradation of RNA transcripts containing expanded nucleotide repeat regions, thereby effectuating the release of significant RNA-binding proteins from such transcripts.
  • Myotonic dystrophy type I is the most common form of muscular dystrophy in adults, and occurs with an estimated frequency of 1 in 7,500 (Harper P S., Myotonic Dystrophy. London: W.B. Saunders Company; 2001 ).
  • This disease is an autosomal dominant disorder caused by expansion of a non-coding CTG repeat in the human DMPK1 gene.
  • DMPK1 is a gene encoding a cytosolic serine/threonine kinase (Brook et al. , Cell. 68:799-808 (1992)).
  • the expanded CTG repeat is located in the 3' untranslated region (UTR) of DMPK1 .
  • UTR 3' untranslated region
  • This mutation leads to RNA dominance, a process in which expression of RNA containing an expanded CUG repeat (CUGexp) induces cell dysfunction (Osborne R J and Thornton C A., Human Molecular Genetics. 15:R162-R169 (2006)).
  • the mutant form of the DMPK mRNA, harboring large CUG repeats, are fully transcribed and polyadenylated, but remain trapped in the nucleus (Davis et al., Proc. Natl. Acad. Sci. U.S.A 94:7388-
  • mutant, nuclear-retained mRNAs are one of the most important pathological features of myotonic dystrophy type I.
  • the DMPK gene normally has from about 5 to about 37 CTG repeats in the 3' UTR. In myotonic dystrophy type I, this number is significantly expanded, and may be in the range, for example, of from 50 to greater than 4,000 repeats.
  • the CUGexp tract in the ensuing RNA transcript interacts with RNA-binding splicing factor proteins, including muscleblind-like protein.
  • the enhanced avidity engendered by the expanded CUG repeat region causes the mutant transcript to retain such splicing factor proteins in nuclear foci.
  • the toxicity of this mutant RNA stems from the sequestration of RNA-binding splicing factor proteins away from other pre-mRNA substrates, including those that encode proteins that have important roles in regulating muscle function.
  • myotonic dystrophy type I skeletal muscle is the most severely affected tissue, but the disease also has important effects on cardiac and smooth muscle, ocular lens, and the brain. Among muscle tissue, the cranial, distal limb, and diaphragm muscles are often preferentially affected. Manual dexterity is compromised early, which causes several decades of severe disability. The median age at death is 55 years, which usually from respiratory failure (de Die-Smulders C E, et al. , Brain 121 (Pt 8):1557-1563 (1998)).
  • Symptoms of myotonic dystrophy include, without limitation, myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids (ptosis), weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts. In children, symptoms may also include
  • Myotonic dystrophy patients that may be treated using the compositions and methods described herein include patients, such as human patient, having myotonic dystrophy type I, and that express a DMPK RNA transcript harboring a CUG repeat expansion.
  • Exemplary DMPK RNA transcripts that may be expressed by a patient undergoing treatment with the compositions and methods described herein are set forth in GenBank Accession Nos.
  • a patient such as a patient suffering from myotonic dystrophy (e.g., myotonic dystrophy type I) may be administered a vector encoding, or a composition containing, an interfering RNA that anneals to and suppresses the expression of pathologic
  • myotonic dystrophy e.g., myotonic dystrophy type I
  • compositions and methods described herein may selectively attenuate the expression of DMPK mRNA transcripts containing expanded CUG repeats, such as DMPK mRNA transcripts containing from about 50 to about 4,000, or more, CUG repeats.
  • DMPK mRNA transcripts containing expanded CUG repeats such as DMPK mRNA transcripts containing from about 50 to about 4,000, or more, CUG repeats.
  • RNA molecules described herein may activate ribonucleases, such as nuclear ribonucleases, that specifically digest nuclear-retained DMPK transcripts harboring CUG repeat expansions.
  • the decrease in mutant DMPK mRNA expression may be a decrease of, for example, about 1 % or more, such as a decrease of 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, relative to the expression of DMPK mRNA transcripts containing expanded CUG trinucleotide repeat regions by the patient prior to administration of a therapeutic agent described herein, such as a vector or nucleic acid described herein.
  • Methods that can be used to assess RNA expression levels are known in the art and include RNA-seq assays and polymerase chain reaction techniques described herein
  • compositions and methods described herein can be used to correct one or more spliceopathies in a patient, such as a patient suffering from myotonic dystrophy (e.g., myotonic dystrophy type I).
  • myotonic dystrophy e.g., myotonic dystrophy type I
  • the ability of the interfering RNA molecules described herein to anneal to, and suppresses the expression of, pathologic DMPK transcripts e.g., DMPK transcripts containing expanded CUG repeat regions
  • pathologic DMPK transcripts e.g., DMPK transcripts containing expanded CUG repeat regions
  • splicing factors such as muscleblind-like protein
  • This release of splicing factors may, in turn, effectuate corrective splicing of one or more RNA transcript substrates of these splicing factors.
  • the patient upon administration of the vector or composition to a patient suffering from myotonic dystrophy, the patient may exhibit an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles.
  • SERCA1 sarcoplasmic/endoplasmic reticulum calcium ATPase 1
  • the increase in expression of SERCA1 mRNA transcripts containing exon 22 may be an increase of, for example, about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold,
  • the patient upon administration of a vector or composition described herein to a patient suffering from myotonic dystrophy, the patient may exhibit a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles.
  • CLCN1 chloride voltage-gated channel 1
  • the decrease in expression of CLCN1 mRNA transcripts containing exon 7a may be a decrease of, for example, about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
  • the patient may exhibit a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , for example, in the tibialis anterior,
  • ZASP ZO-2 associated speckle protein
  • the decrease in expression of ZASP mRNA transcripts containing exon 1 1 may be a decrease of, for example, about 1 % to about 1 00% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
  • the patient may exhibit an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor, RYR1 , cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold,
  • beneficial treatment effects of the compositions and methods described herein, such as the ability of the interfering RNA molecules described herein, and the vectors encoding the same, to (i) suppress pathologic DMPK RNA expression and/or (ii) restore correct splicing of proteins involved in regulating muscle function may manifest clinically in a variety of ways.
  • patients having myotonic dystrophy such as myotonic dystrophy type I, may exhibit an improvement in cranial, distal limb, and/or diaphragmatic muscle function.
  • the improvement in muscle function may be observed, for example, as an increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions.
  • a patient suffering from myotonic dystrophy may exhibit an increase in cranial, distal limb, and/or diaphragmatic muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions.
  • the increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions may be, for example, an increase of 1 % or more, such as an increase of from 1 % to 25%, from 1 % to 50%, from 1 % to 75%, from 1 % to 100%, from 1 % to 500%, from 1 % to 1 ,000%, or more, such as an increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions of about 1 %, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 80%, 900%, 1 ,000%, or more.
  • a patient having myotonic dystrophy may be administered an interfering RNA molecule or vector encoding the same so as to facilitate and/or accelerate muscle relaxation.
  • the compositions and methods described herein may be used to accelerate muscle relaxation by suppressing the onset of spontaneous action potentials caused by fluctuations in chloride ion concentration.
  • this beneficial activity may be caused by the restoration of correct splicing of CLCN1 mRNA, for example, such that the expression of CLCN1 mRNA containing exon 7a in the patient is reduced.
  • CLCN1 channel protein regulates chloride ion concentration
  • correcting the splicing pattern of CLCN1 mRNA transcripts may engender a reduction in the onset of spontaneous action potentials and an improvement in muscle relaxation speed, thereby ameliorating myotonia.
  • Suppression of myotonia can be evaluated using a variety of techniques known in the art, for example, by way of electromyography.
  • electromyography on the left and right quadriceps, left and right gastrocnemius muscles, left and right tibialis anterior muscles, and/or lumbar paraspinals muscles can be performed to assess the effects of the compositions and methods described herein on myotonia in a patient, such as a human patient having myotonic dystrophy.
  • Electromyography protocols have been described, for example, in Kanadia et al., Science 302:1978-1980 (2003)).
  • electromyography may be performed using 30-gauge concentric needle electrodes and a minimum of 10 needle insertions for each muscle.
  • an average myotonia grade may be determined for a subject, such as a human patient or a model organism (e.g., a murine model of muscular dystrophy described herein). This grade can then be compared to the average myotonia grade of the patient or model organism determined prior to administration of a therapeutic agent described herein (e.g., an interfering RNA molecule or a vector encoding the same).
  • a therapeutic agent described herein e.g., an interfering RNA molecule or a vector encoding the same.
  • a patient having myotonic dystrophy such as myotonic dystrophy type 1
  • myotonic dystrophy type 1 may be administered an interfering RNA molecule or vector encoding the same so as to attenuate or altogether eliminate one or more symptoms of myotonic dystrophy.
  • symptoms of myotonic dystrophy include, without limitation, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, ptosis, weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts.
  • symptoms may also include
  • compositions and methods described herein may be used to alleviate one or more, or all, of the foregoing symptoms.
  • compositions and methods described herein provide beneficial clinical effects that may last for extended periods of time.
  • a patient having myotonic dystrophy e.g., myotonic dystrophy type I
  • myotonic dystrophy type I may exhibit (i) a reduction in pathologic DMPK RNA expression (e.g., a reduction in expression of DMPK RNA harboring from about 50 to about 4,000 CUG repeats, or more), (ii) an improvement in muscle function (such as an improvement in muscle mass and/or muscle activity, e.g., in the cranial, distal limb, and diaphragm muscle) and/or (iii) alleviation of one or more symptoms of myotonic dystrophy, for a period of one or more days, weeks, months, or years.
  • DMPK RNA expression e.g., a reduction in expression of DMPK RNA harboring from about 50 to about 4,000 CUG repeats, or more
  • an improvement in muscle function such as an improvement in muscle
  • the beneficial therapeutic effects described herein may be achieved for a period of at least 30 days, at least 35 days, at least 40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 76 days, at least 77 days, at least 78 days, at least 79 days, at least 80 days, at least 85 days, at least 90 days, at least 95 days, at least 100 days, at least 105 days, at least 1 10 days, at least 1 15 days, at least 120 days, or at least 1 year.
  • an appropriate mouse model may be utilized.
  • the HSA (human skeletal actin) LR (long repeat) mouse model is an established model for myotonic dystrophy type 1 (see, e.g., Mankodi et al., Science 289:1769 (2000), the disclosure of which is incorporated herein by reference as it pertains to the HSA LR mouse.
  • These mice carry a human skeletal actin (hACTAI ) transgene containing an expanded CTG region.
  • the hACTAI transgene in HSA LR mice contains 220 CTG repeats inserted in the 3' UTR of the gene.
  • the hACTAI -CUGexp RNA transcript Upon transcription, the hACTAI -CUGexp RNA transcript accumulates in nuclear foci in skeletal muscles and results in myotonia similar to that observed in human myotonic dystrophy type 1 , for example, due to the binding of CUG repeat expansions to splicing factors and the sequestration of these splicing factors from pre-mRNA transcripts encoding genes that play an important role in regulating muscle function (see, e.g., Mankodi et al., Mol. Cell 10:35 (2002), and Lin et al., Hum. Mol. Genet. 15:2087 (2006), the disclosures of each of which are incorporated herein by reference as they pertain to the HSA LR mouse).
  • HSA LR myotonic dystrophy type I mice can be generated using methods known in the art, for example, by insertion into the genome of FVB/N mice of a hACTAI transgene with 250 CUG repeats in the 3' UTR of human skeletal actin. The transgene is subsequently expressed in the mice as a CUG repeat expansion in hACTAI RNA. This repeat-expanded RNA is retained in the nucleus, forming nuclear inclusions similar to those observed in human tissue samples of patients with myotonic dystrophy.
  • compositions may be designed so as to anneal to a region of the hACTAI RNA transcript, for example, at a site distal from the CUG repeat expansion. This may be accomplished, for example, by designing an interfering
  • RNA molecule that is at least 85% complementary (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to a segment of hACTAI RNA that does not overlap with the CUG repeat expansion region.
  • the suppression of repeat-expanded hACTAI RNA, and the concomitant increase in correctly spliced SERCA1 mRNA (and, thus, functional SERCA1 protein), can then be assessed using RNA and protein detection methods known in the art and described herein.
  • total RNA may be purified from the HSA LR mouse at one or more, or all, of the tibialis anterior, gastrocnemius, and quadriceps muscle using the RNeasy Lipid Tissue Mini Kit (Qiagen®), according to the manufacturer's instructions.
  • RT-PCR may be performed with, for example, the Superscript III One-Step RT-PCR System and Platinum Taq Polymerase (Invitrogen®), using gene-specific primers for cDNA synthesis and PCR amplification.
  • the forward and reverse primers for SERCA1 have been described, for example, in Bennett and Swayze, Annu Rev. Pharmacol. 50:259-293 (2010)).
  • PCR products may be separated on agarose gels, stained with SybrGreen I Nucleic Acid Gel Stain (Invitrogen®), and imaged using a Fujifilm LAS-3000 Intelligent Dark Box.
  • Restoration of correct splicing of the SERCA1 gene by an interfering RNA molecule, or vector encoding the same, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles of the HSA LR mouse, may be a predictor of the therapeutic efficacy of an interfering RNA molecule, or vector encoding the same, that anneals to a similar site on human DMPK RNA.
  • LC15 mice Line A, which are transgenic mice containing the entire human DMPK 3'UTR (developed by Wheeler et al, University of Rochester). These mice are the second generation of mice backcrossed to an FVB background. The DMPK transgene is expressed in these mice as a CUG repeat in the DMPK RNA transcript, which is retained in the nucleus, thereby forming nuclear inclusions similar to those observed in human tissue samples of patients with myotonic dystrophy.
  • LC15 mice may express DMPK RNA transcripts containing from about 350 to about 400 CUG repeats. These mice display early signs of myotonic dystrophy type I and do not display any myotonia in their muscle tissues.
  • DMSXL mice are generated by way of successive breeding of mice having a high level of CTG repeat instability, and, as a result, DMSXL mice express DMPK RNA transcripts containing >1 ,000 CUG trinucleotide repeats in the 3’ UTR.
  • DMSXL mice and methods for producing the same are described in detail, for example, in Gomes-Pereira et al., PLoS Genet. 3:e52 (2007), and Huguet et al., A, PLoS Genet. 8:e1003043 (2012), the disclosures of each of which are incorporated herein by reference in their entirety. Additional Disorders Characterized by Nuclear Retention of Repeat- Expanded RNA
  • myotonic dystrophy type II disorders characterized by the expression and nuclear retention of RNA transcripts harboring expanded repeat regions and that may be treated using the compositions and methods described herein include myotonic dystrophy type II and amyotrophic lateral sclerosis, among others.
  • myotonic dystrophy type II patients may express a mutant version of the cellular nucleic acid binding protein (CNBP) gene (also known as the zinc finger protein 9 (ZNF9) gene) harboring a CCUG (SEQ ID NO: 164) repeat expansion.
  • CNBP cellular nucleic acid binding protein
  • ZNF9 zinc finger protein 9
  • C90RF72 harboring expanded GGGGCC (SEQ ID NO: 162) repeats.
  • RNA transcripts such as pathologic CNBP and C90RF72 transcripts harboring CCUG (SEQ ID NO: 164) and GGGGCC (SEQ ID NO: 162) repeats, respectively, include various molecular biology techniques known in the art and described herein.
  • a patient having a spliceopathy and/or a disorder characterized by RNA dominance may be administered an interfering RNA molecule, a composition containing the same, or a vector encoding the same, so as to suppress the expression of a mutant RNA transcript containing an expanded repeat region.
  • the target RNA transcript to be suppressed is human DMPK RNA containing expanded CUG repeat regions in the 3’ UTR of the transcript.
  • the target RNA transcript to be suppressed is human ZNF9 RNA containing expanded CCUG (SEQ ID NO: 164) repeat regions.
  • the target RNA transcript to be suppressed is human C90RF72 RNA containing expanded GGGGCC (SEQ ID NO: 162) repeat regions.
  • interfering RNA molecules that may be used in conjunction with the compositions and methods described herein for the treatment of RNA dominance disorders, such as myotonic dystrophy type I and others, are siRNA molecules, miRNA molecules, and shRNA molecules, among others.
  • siRNA molecules the siRNA may be single stranded or double stranded.
  • miRNA molecules in contrast, are single-stranded molecules that form a hairpin, thereby adopting a hydrogen-bonded structure reminiscent of a nucleic acid duplex.
  • the interfering RNA may contain an antisense or“guide” strand that anneals (e.g., by way of complementarity) to the repeat-expanded mutant RNA target.
  • the interfering RNA may also contain a“passenger” strand that is complementary to the guide strand and, thus, may have the same nucleic acid sequence as the RNA target.
  • interfering RNA molecules that anneal to mutant DMPK containing expanded CUG repeat motifs and that may be used in conjunction with the compositions and methods described herein for the treatment of myotonic dystrophy type I are shown in Table 4, below.
  • Table 4 A graphical representation of the sites on a target DMPK RNA transcript to which the following interfering RNA molecules anneal by way of sequence complementarity is shown in FIG. 1 .
  • Exemplary miRNA constructs useful in conjunction with the compositions and methods described herein are those that have a combination of passenger and guide strands shown in Table 5, below. Table 5.
  • Exemplary anti-DMPK miRNA guide strand/passenger strand combinations are those that have a combination of passenger and guide strands shown in Table 5, below. Table 5.
  • Viral genomes provide a rich source of vectors that can be used for the efficient delivery of a gene of interest into the genome of a target cell in a patient (e.g., a mammalian cell, such as a human cell). Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes are typically incorporated into the genome of a target cell by generalized or specialized transduction. These processes occur as part of the natural viral replication cycle, and do not require added proteins or reagents in order to induce gene integration.
  • viral vectors examples include AAV, retrovirus, adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • RNA viruses such as picornavirus and alphavirus
  • double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox).
  • herpesvirus e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox
  • Other viruses that may be used in conjunction with the compositions and methods described herein include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example.
  • retroviruses examples include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al ., Eds., Lippincott-Raven Publishers, Philadelphia, 1996).
  • murine leukemia viruses include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses.
  • vectors are described, for example, in US Patent No. 5,801 ,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene therapy.
  • interfering RNA constructs described herein are incorporated into recombinant AAV (rAAV) vectors in order to facilitate their introduction into a cell, such as a target cardiac cell (e.g., a muscle cell) in a patient.
  • rAAV vectors useful in the conjunction with the compositions and methods described herein include recombinant nucleic acid constructs that contain (1 ) a transgene encoding an interfering RNA construct described herein (such as an siRNA, shRNA, or miRNA described herein) and (2) nucleic acids that facilitate and expression of the heterologous genes.
  • the viral nucleic acids may include those sequences of AAV that are required in cis for replication and packaging (e.g., functional ITRs) of the DNA into a virion.
  • Such rAAV vectors may also contain marker or reporter genes.
  • Useful rAAV vectors include those having one or more of the naturally-occurring AAV genes deleted in whole or in part, but retain functional flanking ITR sequences.
  • the AAV ITRs may be of any serotype (e.g., derived from serotype 2) suitable for a particular application. Methods for using rAAV vectors are described, for example, in Tal et al., J. Biomed. Sci.
  • AAV vectors for gene delivery The nucleic acids and vectors described herein can be incorporated into a rAAV virion in order to facilitate introduction of the nucleic acid or vector into a cell.
  • the capsid proteins of AAV compose the exterior, non-nucleic acid portion of the virion and are encoded by the AAV cap gene.
  • the cap gene encodes three viral coat proteins, VP1 , VP2 and VP3, which are required for virion assembly.
  • the construction of rAAV virions has been described, for example, in US Patent Nos.
  • rAAV virions useful in conjunction with the compositions and methods described herein include those derived from a variety of AAV serotypes including AAV 1 , 2, 3, 4, 5, 6, 7, 8 and 9. Construction and use of AAV vectors and AAV proteins of different serotypes are described, for example, in Chao et al.,
  • Pseudotyped vectors include AAV vectors of a given serotype (e.g., AAV2) pseudotyped with a capsid gene derived from a serotype other than the given serotype (e.g., AAV1 , AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9, among others).
  • AAV2 vector encoding a therapeutic protein pseudotyped with a capsid gene derived from AAV serotype 8 or AAV serotype 9.
  • AAV virions that have mutations within the virion capsid may be used to infect particular cell types more effectively than non-mutated capsid virions.
  • suitable AAV mutants may have ligand insertion mutations for the facilitation of targeting AAV to specific cell types.
  • the construction and characterization of AAV capsid mutants including insertion mutants, alanine screening mutants, and epitope tag mutants is described in Wu et al., J. Virol. 74:8635-45 (2000).
  • Other rAAV virions that can be used in methods of the invention include those capsid hybrids that are generated by molecular breeding of viruses as well as by exon shuffling. See, e.g., Soong et al., Nat. Genet., 25:436-439 (2000) and Kolman and Stemmer, Nat. Biotechnol. 19:423-428 (2001 ). Additional Methods for the Delivery of Interfering RNA
  • a transgene such as a transgene encoding an interfering RNA construct described herein
  • a target cell e.g., a target cell from or within a human patient suffering from RNA dominance
  • electroporation can be used to permeabilize mammalian cells (e.g., human target cells) by the application of an electrostatic potential to the cell of interest.
  • mammalian cells such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al.
  • NucleofectionTM utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. NucleofectionTM and protocols useful for performing this technique are described in detail, e.g., in Distler et al., Experimental Dermatology 14:315 (2005), as well as in US 2010/03171 14, the disclosures of each of which are incorporated herein by reference.
  • Additional techniques useful for the transfection of target cells include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human target cell. Squeeze-poration is described in detail, e.g., in Sharei et al., Journal of Visualized Experiments 81 :e50980 (2013), the disclosure of which is incorporated herein by reference.
  • Lipofection represents another technique useful for transfection of target cells. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for example, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for example, in US Patent No. 7,442,386, the disclosure of which is incorporated herein by reference.
  • Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex.
  • exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane are activated dendrimers (described, e.g., in Dennig, Topics in Current Chemistry
  • Magnetic beads are another tool that can be used to transfect target cells in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for example, in US 2010/0227406, the disclosure of which is incorporated herein by reference.
  • laserfection a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cells and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g., in Rhodes et al. , Methods in Cell Biology 82:309 (2007), the disclosure of which is incorporated herein by reference.
  • Microvesicles represent another potential vehicle that can be used to modify the genome of a target cell according to the methods described herein.
  • microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g., a genome-modifying protein, such as a nuclease can be used to efficiently deliver proteins into a cell that subsequently catalyze the site- specific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence.
  • vesicles also referred to as Gesicles
  • Gesicles for the genetic modification of eukaryotic cells is described in detail, e.g., in Quinn et al., Genetic Modification of Target Cells by Direct Delivery of Active Protein [abstract].
  • Methylation changes in early embryonic genes in cancer in: Proceedings of the 18th Annual Meeting of the American Society of Gene and Cell Therapy; 2015 May 13,
  • transposons are polynucleotides that encode transposase enzymes and contain a polynucleotide sequence or gene of interest flanked by 5’ and 3’ excision sites.
  • transposase gene commences and results in active enzymes that cleave the gene of interest from the transposon. This activity is mediated by the site-specific recognition of transposon excision sites by the transposase. In some instances, these excision sites may be terminal repeats or inverted terminal repeats.
  • the transgene of interest can be integrated into the genome of a mammalian cell by transposase-catalyzed cleavage of similar excision sites that exist within the nuclear genome of the cell.
  • the transposon may be a retrotransposon, such that the gene encoding the target gene is first transcribed to an RNA product and then reverse-transcribed to DNA before incorporation in the mammalian cell genome.
  • transposon systems are the piggybac transposon (described in detail in, e.g., WO 2010/085699) and the sleeping beauty transposon (described in detail in, e.g., US 2005/01 12764), the disclosures of each of which are incorporated herein by reference as they pertain to transposons for use in gene delivery to a cell of interest.
  • CRISPR clustered regularly interspaced short palindromic repeats
  • CRISPR/Cas system includes palindromic repeat sequences within plasmid DNA and an associated Cas9 nuclease. This ensemble of DNA and protein directs site specific DNA cleavage of a target sequence by first incorporating foreign DNA into CRISPR loci. Polynucleotides containing these foreign sequences and the repeat-spacer elements of the CRISPR locus are in turn transcribed in a host cell to create a guide RNA, which can subsequently anneal to a target sequence and localize the Cas9 nuclease to this site.
  • CRISPR/Cas to modulate gene expression has been described in, for example, US Patent No. 8,697,359, the disclosure of which is incorporated herein by reference as it pertains to the use of the CRISPR/Cas system for genome editing.
  • Alternative methods for site- specifically cleaving genomic DNA prior to the incorporation of a transgene of interest in a target cell include the use of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs).
  • ZFNs zinc finger nucleases
  • TALENs transcription activator-like effector nucleases
  • these enzymes do not contain a guiding polynucleotide to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes.
  • ZFNs and TALENs in genome editing applications are described, e.g., in Urnov et al., Nature Reviews Genetics 1 1 :636 (2010); and in Joung et al., Nature Reviews Molecular Cell Biology 14:49 (2013), the disclosure of each of which are incorporated herein by reference as they pertain to compositions and methods for genome editing.
  • Additional genome editing techniques that can be used to incorporate polynucleotides encoding target transgenes into the genome of a target cell include the use of ARCUSTM meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA.
  • the use of these enzymes for the incorporation of genes encoding target genes into the genome of a mammalian cell is advantageous in view of the defined structure-activity relationships that have been established for such enzymes.
  • Single chain meganucleases can be modified at certain amino acid positions in order to create nucleases that selectively cleave DNA at desired locations, enabling the site-specific incorporation of a target transgene into the nuclear DNA of a target cell.
  • RNA transcript expression level of a pathological RNA transcript such as a DMPK RNA transcript harboring an expanded CUG trinucleotide repeat or a C90RF72 RNA transcript harboring an expanded GGGGCC (SEQ ID NO: 162) hexanucleotide
  • RNA transcript expression can be inferred by evaluating the concentration or relative abundance of an encoded protein produced by translation of the RNA transcript. Protein concentrations can also be assessed, for example, using functional assays. Using these techniques, a reduction in the concentration of pathological RNA transcripts in response to the compositions and methods described herein can be observed, while monitoring the expression of the encoded protein.
  • RNA transcript expression can be evaluated by a number of methodologies known in the art, including, but not limited to, nucleic acid sequencing, microarray analysis, proteomics, in-situ hybridization (e.g., fluorescence in-situ hybridization (FISH)), amplification-based assays, in situ hybridization, fluorescence activated cell sorting (FACS), northern analysis and/or PCR analysis of RNAs.
  • FISH fluorescence in-situ hybridization
  • FACS fluorescence activated cell sorting
  • Nucleic acid-based methods for detection of RNA transcript expression include imaging-based techniques (e.g., Northern blotting or Southern blotting), which may be used in conjunction with cells obtained from a patient following administration of, for example, a vector encoding an interfering RNA described herein or a composition containing such an interfering RNA construct.
  • Northern blot analysis is a conventional technique well known in the art and is described, for example, in Molecular Cloning, a Laboratory Manual, second edition, 1989, Sambrook, Fritch, Maniatis, Cold Spring Harbor Press, 10 Skyline Drive, Plainview, NY 1 1803-2500. Typical protocols for evaluating the status of genes and gene products are found, for example in Ausubel et al.
  • RNA detection techniques that may be used in conjunction with the compositions and methods described herein to evaluate the suppression of RNA transcripts harboring expanded nucleotide repeat regions, such as DMPK RNA transcripts harboring expanded CUG trinucleotide repeats and C90RF72 RNA transcripts harboring expanded GGGGCC (SEQ ID NO: 162) hexanucleotide repeats, further include microarray sequencing experiments (e.g., Sanger sequencing and next-generation sequencing methods, also known as high-throughput sequencing or deep sequencing).
  • microarray sequencing experiments e.g., Sanger sequencing and next-generation sequencing methods, also known as high-throughput sequencing or deep sequencing.
  • next generation sequencing technologies include, without limitation, lllumina sequencing, Ion Torrent sequencing, 454 sequencing, SOLiD sequencing, and nanopore sequencing platforms. Additional methods of sequencing known in the art can also be used.
  • transgene expression at the mRNA level may be determined using RNA-Seq (e.g., as described in Mortazavi et al. , Nat. Methods 5:621 -628 (2008), the disclosure of which is incorporated herein by reference in their entirety).
  • RNA-Seq is a robust technology for monitoring expression by direct sequencing the RNA molecules in a sample.
  • this methodology may involve fragmentation of RNA to an average length of 200 nucleotides, conversion to cDNA by random priming, and synthesis of double-stranded cDNA (e.g., using the Just cDNA DoubleStranded cDNA Synthesis Kit from Agilent Technology®). Then, the cDNA is converted into a molecular library for sequencing by addition of sequence adapters for each library (e.g., from lllumina®/Solexa), and the resulting 50-100 nucleotide reads are mapped onto the genome.
  • sequence adapters for each library e.g., from lllumina®/Solexa
  • RNA expression levels may be determined using microarray-based platforms (e.g., single nucleotide polymorphism arrays), as microarray technology offers high resolution. Details of various microarray methods can be found in the literature. See, for example, U.S. Pat. No. 6,232,068 and Pollack et al., Nat. Genet. 23:41 -46 (1999), the disclosures of each of which are incorporated herein by reference in their entirety.
  • nucleic acid microarrays mRNA samples are reverse transcribed and labeled to generate cDNA. The probes can then hybridize to one or more complementary nucleic acids arrayed and immobilized on a solid support.
  • the array can be configured, for example, such that the sequence and position of each member of the array is known.
  • Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene.
  • Expression level may be quantified according to the amount of signal detected from hybridized probe-sample complexes.
  • a typical microarray experiment involves the following steps: 1 ) preparation of fluorescently labeled target from RNA isolated from the sample, 2) hybridization of the labeled target to the microarray, 3) washing, staining, and scanning of the array, 4) analysis of the scanned image and 5) generation of gene expression profiles.
  • Affymetrix GENECFIIP® system which is commercially available and comprises arrays fabricated by direct synthesis of oligonucleotides on a glass surface.
  • Other systems may be used as known to one skilled in the art.
  • Amplification-based assays also can be used to measure the expression level of a particular RNA transcript, such as a DMPK RNA transcript harboring an expanded CUG trinucleotide repeat or a C90RF72 RNA transcript harboring an expanded GGGGCC (SEQ ID NO: 162) hexanucleotide repeat.
  • the nucleic acid sequence of the transcript acts as a template in an amplification reaction (for example, PCR, such as qPCR).
  • an amplification reaction for example, PCR, such as qPCR.
  • the amount of amplification product is proportional to the amount of template in the original sample.
  • Comparison to appropriate controls provides a measure of the expression level of the transcript of interest, corresponding to the specific probe used, according to the principles described herein.
  • Methods of real-time qPCR using TaqMan probes are well known in the art. Detailed protocols for real-time qPCR are provided, for example, in Gibson et al., Genome Res. 6:995-1001 (1996), and in Heid et al. , Genome Res. 6:986-994 (1996), the disclosures of each of which are incorporated herein by reference in their entirety.
  • Levels of RNA transcript expression as described herein can be determined, for example, by RT-PCR technology.
  • Probes used for PCR may be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator, or enzyme.
  • a detectable marker such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator, or enzyme.
  • RNA construct may also be inferred by analyzing expression of the protein encoded by the construct. Protein levels can be assessed using standard detection techniques known in the art. Protein expression assays suitable for use with the compositions and methods described herein include proteomics approaches, immunohistochemical and/or western blot analysis, immunoprecipitation, molecular binding assays, ELISA, enzyme-linked immunofiltration assay (ELIFA), mass spectrometry, mass spectrometric immunoassay, and biochemical enzymatic activity assays. In particular, proteomics methods can be used to generate large-scale protein expression datasets in multiplex.
  • Proteomics methods may utilize mass spectrometry to detect and quantify polypeptides (e.g., proteins) and/or peptide microarrays utilizing capture reagents (e.g., antibodies) specific to a panel of target proteins to identify and measure expression levels of proteins expressed in a sample (e.g., a single cell sample or a multi cell population).
  • polypeptides e.g., proteins
  • capture reagents e.g., antibodies
  • Exemplary peptide microarrays have a substrate-bound plurality of polypeptides, the binding of an oligonucleotide, a peptide, or a protein to each of the plurality of bound polypeptides being separately detectable.
  • the peptide microarray may include a plurality of binders, including, but not limited to, monoclonal antibodies, polyclonal antibodies, phage display binders, yeast two-hybrid binders, aptamers, which can specifically detect the binding of specific oligonucleotides, peptides, or proteins. Examples of peptide arrays may be found in U.S. Patent Nos.
  • MS Mass spectrometry
  • LC-MS ESI-MS
  • ESI-MS/MS MALDI-TOF-MS
  • MALDI-TOF/TOF-MS MALDI-TOF/TOF-MS
  • tandem MS and the like.
  • Mass spectrometers generally contain an ion source and optics, mass analyzer, and data processing electronics. Mass analyzers include scanning and ion-beam mass spectrometers, such as time-of-flight (TOF) and quadruple (Q), and trapping mass spectrometers, such as ion trap (IT), Orbitrap, and Fourier transform ion cyclotron resonance (FT-ICR), may be used in the methods described herein. Details of various MS methods can be found in the literature. See, for example, Yates et al., Annu. Rev. Biomed. Eng. 1 1 :49-79, 2009, the disclosure of which is incorporated herein by reference in its entirety.
  • TOF time-of-flight
  • Q quadruple
  • trapping mass spectrometers such as ion trap (IT), Orbitrap, and Fourier transform ion cyclotron resonance (FT-ICR)
  • proteins in a sample obtained from the patient can be first digested into smaller peptides by chemical (e.g., via cyanogen bromide cleavage) or enzymatic (e.g., trypsin) digestion.
  • Complex peptide samples also benefit from the use of front-end separation techniques, e.g., 2D-PAGE, HPLC, RPLC, and affinity chromatography.
  • the digested, and optionally separated, sample is then ionized using an ion source to create charged molecules for further analysis.
  • Ionization of the sample may be performed, e.g., by electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), photoionization, electron ionization, fast atom bombardment (FAB)/liquid secondary ionization (LSIMS), matrix assisted laser desorption/ionization (MALDI), field ionization, field desorption, thermospray/plasmaspray ionization, and particle beam ionization. Additional information relating to the choice of ionization method is known to those of skill in the art.
  • Tandem MS also known as MS/MS
  • Tandem MS may be particularly useful for analyzing complex mixtures. Tandem MS involves multiple steps of MS selection, with some form of ion fragmentation occurring in between the stages, which may be accomplished with individual mass spectrometer elements separated in space or using a single mass spectrometer with the MS steps separated in time.
  • spatially separated tandem MS the elements are physically separated and distinct, with a physical connection between the elements to maintain high vacuum.
  • separation is accomplished with ions trapped in the same place, with multiple separation steps taking place over time.
  • Signature MS/MS spectra may then be compared against a peptide sequence database (e.g., SEQUEST).
  • Post- translational modifications to peptides may also be determined, for example, by searching spectra against a database while allowing for specific peptide modifications.
  • the interfering RNA constructs may be incorporated into a vehicle for administration into a patient, such as a human patient suffering from RNA dominance, as described herein.
  • Pharmaceutical compositions containing vectors, such as viral vectors, that encode an interfering RNA construct described herein can be prepared using methods known in the art.
  • such compositions can be prepared using, e.g., physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980); incorporated herein by reference), and in a desired form, e.g., in the form of lyophilized formulations or aqueous solutions.
  • nucleic acids and viral vectors described herein may be prepared in water suitably mixed with one or more excipients, carriers, or diluents. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions
  • the formulation may be sterile and may be fluid to the extent that easy syringability exists. Formulations may be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
  • Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • a coating such as lecithin
  • surfactants for example, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • a solution containing a pharmaceutical composition described herein may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intramuscular, subcutaneous, and intraperitoneal administration.
  • sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage may be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion.
  • compositions may meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biologies standards.
  • Viral vectors such as AAV vectors and others described herein, containing a transgene encoding an interfering RNA construct described herein may be administered to a patient (e.g., a human patient) by a variety of routes of administration.
  • the route of administration may vary, for example, with the onset and severity of disease, and may include, e.g., intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intradermal, transdermal, parenteral, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, and oral administration.
  • Intravascular administration includes delivery into the vasculature of a patient.
  • the administration is into a vessel considered to be a vein (intravenous), and in some administration, the administration is into a vessel considered to be an artery (intraarterial).
  • Veins include, but are not limited to, the internal jugular vein, a peripheral vein, a coronary vein, a hepatic vein, the portal vein, great saphenous vein, the pulmonary vein, superior vena cava, inferior vena cava, a gastric vein, a splenic vein, inferior mesenteric vein, superior mesenteric vein, cephalic vein, and/or femoral vein.
  • Arteries include, but are not limited to, coronary artery, pulmonary artery, brachial artery, internal carotid artery, aortic arch, femoral artery, peripheral artery, and/or ciliary artery. It is contemplated that delivery may be through or to an arteriole or capillary.
  • Treatment regimens may vary, and often depend on disease severity and the age, weight, and sex of the patient.
  • Treatment may include administration of vectors (e.g., viral vectors) or other agents described herein as useful for the introduction of a transgene into a target cell in various unit doses.
  • Each unit dose will ordinarily contain a predetermined-quantity of the therapeutic composition.
  • Example 1 Development and evaluation of adeno-associated viral vectors encoding miRNA constructs for the treatment of disorders associated with RNA dominance
  • This example describes a series of experiments conducted in order to characterize the development and evaluation of rAAV vectors encoding miRNA constructs against human DMPK and murine HSA LR , which is expressed in mouse models of the RNA dominance disorder, myotonic dystrophy.
  • Myotonic dystrophy (DM) is caused by expansion of a microsatellite repeat that leads to expression of a toxic expanded repeat mRNA.
  • Another RNA dominance disorder, facioscapulohumeral muscular dystrophy (FSHD) is caused by contraction of a D4Z4 macrosatellite repeat that leads to expression of DUX4, a toxic protein in adult muscle.
  • the goal of the experiments described in this example is to develop AAV vectors encoding miRNA constructs that target muscle DM and FSHD-related mRNAs, so as to prevent muscle dysfunction and loss in individuals with disease.
  • HSA human skeletal actin gene directed interfering RNA hairpin
  • the HSA LR mouse was produced with insertion of an expanded CTG repeat in the 3’ UTR of the HSA gene, a similar genetic context to the disease-causing repeat expansion in the DMPK gene in humans.
  • the HSA LR mouse displays many of the genetic and phenotypic changes associated with DM1 in skeletal muscle, including myotonia, splicing changes in a variety of mRNAs, and nuclear inclusions (foci).
  • DMPK myotonic dystrophy type 1
  • RNAi expression cassettes with 19-22 bp target recognition sequences were tested for a variety of applications.
  • the RNAi hairpins were based on miR30a endogenous sequence.
  • the single-stranded rAAV genomes were packaged in an rAAV6 capsid for targeting muscle.
  • the rAAV plasmid pARAP4 includes the human alkaline phosphatase reporter gene (Hu Aik Phos) reporter gene, expressed from the Rous
  • SSV Sarcoma Virus
  • pA SV40 polyadenylation sequence
  • ITRs inverted terminal repeats
  • the newest vector modification removes the RSV promoter sequence to prevent Hu Aik Phos expression that limited rAAV- RNAi efficacy at higher doses due muscle cell toxicity.
  • HSA LR mice show characteristics of muscular dystrophy resembling DM in humans.
  • the HSA LR transgene is derived from insertion of a (CTG)2so repeat in the 3’ UTR of the HSA gene.
  • CCG CCG2so repeat
  • splicing alterations occur in a variety of mRNAs, and nuclear foci containing the expanded transgenic mRNA and splicing factors are present.
  • HSA LR mice were transduced with rAAV6 HSA miR DM10.
  • Human placental alkaline phosphatase (AP) staining indicates presence of the viral genome with active reporter gene expression, and H&E staining of cryosections from treated mice is also shown.
  • Timepoint 8 weeks post injection, 4 week-old HSA LR mice.
  • rAAV-RNAi vectors encoding miRNA constructs complimentary to HSA LR transcripts reduced the expression of pathologic HSA LR RNA and effectuated the release of RNA-binding splicing factors that would otherwise be sequestered by the CUG repeat expansion, as evidenced by the restoration of correct splicing of SERCA1 mRNA (FIGS. 6C and 6D).
  • rAAV6 HSA miR DM10 systemic injection improves splicing of SERCA1 and CLCN1 in the tibialis anterior (TA) muscle.
  • TA tibialis anterior
  • miR DM4 was not as effective at reversing these splicing defects.
  • RNA target sequences for incorporation into miRNA-based hairpins were done using guidelines for siRNA design. Candidate target sequences were eliminated based on predicted seed sequence matches at other loci or in alternatively spliced regions. Additional screening included analysis using Bowtie for short sequence alignment to the human genome and extensive BLAST searches. Exemplary interfering RNA constructs against human DMPK are shown in Table 4, above, and are represented graphically in FIG. 1 .
  • rAAV6-mediated delivery of the HSA hairpins improves many molecular and phenotypic characteristics of DM1 modeled in the HSA LR mouse, including myotonia, disease-related splicing changes, and sequestration of splicing factors.
  • vectors carrying U6-expressed DMPK miRNAs can reduce endogenous DMPK mRNA in HEK293 cells following transfection.
  • rAAV-mediated therapy is effective for spinal muscular atrophy and is progressing in clinical trials for Duchenne muscular dystrophy.
  • Studies in non-human primates demonstrate that AAV can transduce muscle efficiently with regional limb delivery and persist for as long as 10 years. These studies support development of rAAV-mediated RNAi gene therapy for the treatment of dominant muscle diseases in humans, such as myotonic dystrophy type I, among others described herein.
  • Example 2 Treatment of myotonic dystrophy in a human patient by administration of a viral vector encoding a miRNA against DMPK
  • a physician of skill in the art may administer to a patient having myotonic dystrophy type I a viral vector encoding a miRNA that anneals to, and reduces the expression of, mutant DMPK RNA transcripts containing expanded CUG repeat regions.
  • the vector may be an AAV vector, such as a pseudotyped AAV2/8 or AAV2/9 vector.
  • the vector may be administered by way of one or more routes of administration described herein, such as by intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intramuscular, or subcutaneous injection.
  • the encoded miRNA may be a miRNA characterized herein, such as a miRNA having the nucleic acid sequence of any one of SEQ ID Nos: 40-161 .
  • the physician may monitor the progression of the disorder and the efficacy of the treatment by assessing, for example, the concentration of correctly spliced mRNA transcripts encoding SERCA1 , CLCN1 , and/or ZASP, using an RNA detection technique described herein.
  • the physician may also monitor the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein product resulting from the correctly spliced transcripts. Additionally or alternatively, the physician may monitor the concentration of mutant DMPK RNA transcripts expressed by the patient, particularly,
  • DMPK transcripts having from about 50 to about 4,000, or more, CUG trinucleotide repeats.
  • the physician may also monitor the progression of one or more symptoms of the disease, such as myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids
  • symptoms may also include
  • a finding that one or more, or all, of the foregoing symptoms has been ameliorated may also serve as a clinical indicator of successful treatment.
  • Example 3 Treatment of myotonic dystrophy in a human patient by administration of an siRNA oligonucleotide against DMPK
  • a physician of skill in the art may administer to a patient having myotonic dystrophy type I an siRNA oligonucleotide that anneals to, and reduces the expression of, mutant DMPK RNA transcripts containing expanded CUG repeat regions.
  • the oligonucleotide may have, for example, the nucleic acid sequence of any one of SEQ ID NOs: 3-39.
  • the physician may monitor the progression of the disorder and the efficacy of the treatment by assessing, for example, the concentration of correctly spliced mRNA transcripts encoding SERCA1 , CLCN1 , and/or ZASP, using an RNA detection technique described herein.
  • the physician may also monitor the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein product resulting from the correctly spliced transcripts.
  • the physician may monitor the concentration of mutant DMPK RNA transcripts expressed by the patient, particularly, DMPK transcripts having from about 50 to about 4,000, or more, CUG trinucleotide repeats.
  • a finding that (i) the concentration of correctly spliced SERCA1 , CLCN1 , and/or ZASP mRNA transcripts has increased, (ii) the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein products resulting from translation of the correctly spliced mRNA transcripts has increased, and/or (iii) the concentration of mutant DMPK RNA transcripts harboring expanded CUG trinucleotide repeat regions has decrease may serve as an indicator that the patient has been successfully treated.
  • the physician may also monitor the progression of one or more symptoms of the disease, such as myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids (ptosis), weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts.
  • symptoms may also include developmental delays, learning problems, language and speech difficulties, and personality development challenges. A finding that one or more, or all, of the foregoing symptoms has been ameliorated may also serve as a clinical indicator of successful treatment.
  • Example 4 Ability of anti-DMPK siRNA molecules to suppress DMPK1 expression in cultured HEK293 cells
  • This example describes the results of experiments conducted in order to evaluate the ability of anti-DMPK siRNA molecules, such as various siRNA molecules described in Table 4 herein, to attenuate the expression of DMPK1 mRNA in cultured human cells.
  • anti-DMPK siRNA molecules such as various siRNA molecules described in Table 4 herein
  • a scrambled siRNA molecule and commercially available anti-DMPK siRNA molecules were tested as well.
  • HEK293 cells (2 x 10 5 cells/well) were transfected in triplicate with either 5 pM of a candidate anti-DMPK siRNA molecule (such as an siRNA molecule described in Table 4, above) or 5 pM scrambled negative siRNA control (Silencer® Select siRNA, Ambion by Life
  • RNAiMAX LipofectamineTM RNAiMAX
  • Thermo Fisher Scientific Mock transfections of cells treated only with 1 pL LipofectamineTM RNAiMAX were included for normalization.
  • cDNA generated was subsequently generated using SuperscriptTM III Reverse Transcriptase (Thermo Fisher Scientific) using 150ng of RNA per sample.
  • qPCR was performed to detect DMPK1 knockdown. qPCR experiments were set up in triplicate using the TaqManTM Fast Advanced Master Mix, and reactions were performed using a
  • DMPK1 expression values were normalized to GAPDH (TaqManTM Gene expression assay ID Hs02786624_g1 ) using QuantStudio 3 software.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The disclosure features compositions and methods for the treatment of disorders associated with improper ribonucleic acid (RNA) splicing, including disorders characterized by nuclear retention of RNA transcripts containing aberrantly expanded repeat regions that bind and sequester splicing factor proteins. Disclosed herein are interfering RNA constructs that suppress the expression of RNA transcripts containing expanded repeat regions, as well as viral vectors, such as adeno-associated viral vectors, encoding such interfering RNA molecules. For example, the disclosure features interfering RNA molecules, such as siRNA, miRNA, and shRNA constructs, that anneal to dystrophia myotonica protein kinase (DMPK) RNA transcripts and attenuate the expression of DMPK RNA containing expanded CUG trinucleotide repeats. Using the compositions and methods described herein, a patient having an RNA dominance disorder, such as a human patient having myotonic dystrophy, among other conditions described herein, may be administered an interfering RNA construct or vector containing the same so as to reduce the occurrence of spliceopathy in the patient, thereby treating an underlying etiology of the disease.

Description

COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY
AND TREATING RNA DOMINANCE DISORDERS
Government License Rights
This invention was made with government support under Grant No. R03 AR056107, awarded by the National Institutes of Health. The government has certain rights in the invention.
Field of the Invention
The invention relates to the field of nucleic acid biotechnology and provides compositions and methods for treating genetic disorders associated with improper ribonucleic acid splicing.
Background of the Invention
The expression and nuclear retention of endogenous ribonucleic acid (RNA) transcripts containing aberrantly expanded repeat regions leads to the onset of RNA dominance, a pathology that underlies various heritable genetic disorders, including myotonic dystrophy type 1 , among others.
Myotonic dystrophy is the most common form of muscular dystrophy, and occurs with an estimate frequency of about 1 in 7,500 human adults. RNA dominance results from a gain-of-function mutation in RNA transcripts that imparts these molecules with undesired biological activity. In myotonic dystrophy, RNA dominance is effectuated by the presence of expanded CUG trinucleotide repeats in RNA transcript that encode dystrophia myotonica protein kinase (DMPK), which sequester RNA proteins that control RNA splicing, such as muscleblind-like protein, by virtue of the elevated avidity of these expansion regions for such splicing factor proteins. There is a paucity of strategies available for successfully treating and ameliorating the symptoms of myotonic dystrophy, among other disorders associated with RNA dominance, and there remains a need for effective therapeutics for these diseases.
Summary of the Invention
Described herein are compositions and methods useful for reducing the occurrence of spliceopathy and for treating disorders associated with ribonucleic acid (RNA) dominance, a pathology that is induced by the expression and nuclear retention of messenger RNA (mRNA) transcripts containing expanded repeat regions that bind and sequester splicing factor proteins, thereby interfering with the proper splicing of various mRNA transcripts. The compositions described herein that may be used to treat such disorders include nucleic acids containing interfering RNA constructs that suppress the expression of RNA transcripts containing aberrantly expanded repeat regions, such as siRNA, miRNA, and shRNA constructs that anneal to portions of nuclear-retained, repeat-expanded RNA transcripts and promote the degradation of these pathological transcripts by way of various cellular processes. The present disclosure additionally features vectors, such as viral vectors, encoding such interfering RNA constructs. Exemplary viral vectors described herein that encode interfering RNA constructs (e.g., siRNA, miRNA, or shRNA) for suppressing the expression of RNA transcripts containing aberrantly expanded repeat regions are adeno-associated viral (AAV) vectors, such as pseudotyped AAV2/8 and AAV2/9 vectors.
Using the compositions and methods described herein, a patient experiencing a spliceopathy and/or having a disease associated with RNA dominance, such as myotonic dystrophy, among others, can be administered a nucleic acid containing an interfering RNA construct, or a vector encoding the same, so as to reduce the expression of RNA transcripts containing expanded repeat regions and release splicing factor proteins that are sequestered by repeat-expanded RNA. For example, the compositions and methods described herein can be used to treat patients having myotonic dystrophy, as such patients may be administered an interfering RNA construct or a viral vector, such as an AAV vector, encoding such a construct, thereby reducing the expression of RNA transcripts encoding dystrophia myotonica protein kinase (DMPK). Wild-type DMPK RNA constructs typically contain from about 5 to about 37 CUG trinucleotide repeats in the 3’ untranslated region (UTR) of such transcripts. Patients having myotonic dystrophy, however, express DMPK RNA transcripts that contain 50 or more CUG repeats. The compositions and methods described herein can be used to treat patients expressing this mutant DMPK RNA, thereby releasing splicing factors to orchestrate the proper splicing of proteins associated with muscle function and treating an underlying cause of myotonic dystrophy. Similarly, the compositions and methods described herein can be used to reduce spliceopathy in, and treat one or more underlying causes of, various other disorders associated with RNA dominance and the expression of repeat- expanded RNA transcripts.
The present disclosure is based, in part, on the surprising discovery that interfering RNA constructs that anneal to repeat-expanded RNA targets at sites distal from the expanded repeat region can be used to suppress the expression of such RNA transcripts and effectively release splicing factor proteins that would otherwise be sequestered by these molecules. The compositions and methods described herein can thus attenuate the expression and nuclear retention of pathological RNA transcripts without the need to contain complementary nucleotide repeat motifs. This property provides an important clinical benefit. Nucleotide repeats are ubiquitous in mammalian genomes, such as in the genomes of human patients. The use of interfering RNA constructs that do not have nucleotide repeats, but rather anneal to other regions of a target RNA transcript, enables the selective suppression of transcripts that give rise to RNA dominance disorders without disrupting the expression of other transcripts, such as those encoding other genes that happen to contain nucleotide repeat regions but that do not aberrantly sequester splicing factor proteins. Using the compositions and methods described herein, the expression of RNA transcripts that contain pathological nucleotide repeat expansions can be diminished, while preserving the expression of important healthy RNA transcripts (for example, an RNA transcript encoding a non-target gene that happens to contain a nucleotide repeat), as well as their downstream protein products.
In a first aspect, the invention features a viral vector containing one or more transgenes encoding an interfering RNA. For example, the viral vector may contain from one to five such transgenes, from one to 10 such transgenes, from one to 15 such transgenes, from one to 20 such transgenes, from one to 50 such transgenes, from one to 100 such transgenes, from one to 1 ,000 such transgenes, or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 1 00, 1 ,000, or more, such transgenes). The interfering RNA(s) may be at least 5, at least 10, at least 17, at least 19, or more, nucleotides in length, (e.g., at least 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 1 7, 18, 1 9, or more, nucleotides in length, such as from 17 to 24, 18 to 23, or 19 to 22 nucleotides in length).
The interfering RNA(s) may, e.g., each be, independently, from 10-35 nucleotides in length. In some embodiments, the interfering RNA(s) are 10 nucleotides in length. In some embodiments, the interfering RNA(s) are 1 1 nucleotides in length. In some embodiments, the interfering RNA(s) are 12 nucleotides in length. In some embodiments, the interfering RNA(s) are 13 nucleotides in length. In some embodiments, the interfering RNA(s) are 14 nucleotides in length. In some embodiments, the interfering RNA(s) are 15 nucleotides in length. In some embodiments, the interfering RNA(s) are 16 nucleotides in length. In some embodiments, the interfering RNA(s) are 17 nucleotides in length. In some embodiments, the interfering RNA(s) are 18 nucleotides in length. In some embodiments, the interfering RNA(s) are 19 nucleotides in length. In some embodiments, the interfering RNA(s) are 20 nucleotides in length. In some embodiments, the interfering RNA(s) are 21 nucleotides in length. In some embodiments, the interfering RNA(s) are 22 nucleotides in length. In some embodiments, the interfering RNA(s) are 23 nucleotides in length. In some embodiments, the interfering RNA(s) are 24 nucleotides in length. In some embodiments, the interfering RNA(s) are 25 nucleotides in length. In some embodiments, the interfering RNA(s) are 26 nucleotides in length. In some embodiments, the interfering RNA(s) are 27 nucleotides in length. In some embodiments, the interfering RNA(s) are 28 nucleotides in length. In some embodiments, the interfering RNA(s) are 29 nucleotides in length. In some embodiments, the interfering RNA(s) are 30 nucleotides in length. In some embodiments, the interfering RNA(s) are 31 nucleotides in length. In some embodiments, the interfering RNA(s) are 32 nucleotides in length. In some embodiments, the interfering RNA(s) are 33 nucleotides in length. In some embodiments, the interfering RNA(s) are 34 nucleotides in length. In some embodiments, the interfering RNA(s) are 35 nucleotides in length.
In some embodiments, the interfering RNA(s) contain a portion that anneals to an endogenous RNA transcript containing an expanded repeat region. The portion of each interfering RNA(s) may anneal to a segment of the endogenous RNA transcript that does not overlap with the expanded repeat region. In some embodiments, the endogenous RNA transcript encodes human DMPK and contains an expanded repeat region. The expanded repeat region may contain, for example, 50 or more CUG trinucleotide repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinucleotide repeats, 210 trinucleotide repeats, 220 trinucleotide repeats, 230 trinucleotide repeats, 240 trinucleotide repeats, 250 trinucleotide repeats, 260 trinucleotide repeats, 270 trinucleotide repeats, 280 trinucleotide repeats, 290 trinucleotide repeats, 300 trinucleotide repeats, 310 trinucleotide repeats, 320 trinucleotide repeats, 330 trinucleotide repeats, 340 trinucleotide repeats, 350 trinucleotide repeats, 360 trinucleotide repeats, 370 trinucleotide repeats, 380 trinucleotide repeats, 390 trinucleotide repeats, 400 trinucleotide repeats, 410 trinucleotide repeats, 420 trinucleotide repeats, 430 trinucleotide repeats, 440 trinucleotide repeats, 450 trinucleotide repeats, 460 trinucleotide repeats, 470 trinucleotide repeats, 480 trinucleotide repeats, 490 trinucleotide repeats, 500 trinucleotide repeats, 510 trinucleotide repeats, 520 trinucleotide repeats, 530 trinucleotide repeats, 540 trinucleotide repeats, 550 trinucleotide repeats, 560 trinucleotide repeats, 570 trinucleotide repeats, 580 trinucleotide repeats, 590 trinucleotide repeats, 600 trinucleotide repeats, 610 trinucleotide repeats, 620 trinucleotide repeats, 630 trinucleotide repeats, 640 trinucleotide repeats, 650 trinucleotide repeats, 660 trinucleotide repeats, 670 trinucleotide repeats, 680 trinucleotide repeats, 690 trinucleotide repeats, 700 trinucleotide repeats, 710 trinucleotide repeats, 720 trinucleotide repeats, 730 trinucleotide repeats, 740 trinucleotide repeats, 750 trinucleotide repeats, 760 trinucleotide repeats, 770 trinucleotide repeats, 780 trinucleotide repeats, 790 trinucleotide repeats, 800 trinucleotide repeats, 810 trinucleotide repeats, 820 trinucleotide repeats, 830 trinucleotide repeats, 840 trinucleotide repeats, 850 trinucleotide repeats, 860 trinucleotide repeats, 870 trinucleotide repeats, 880 trinucleotide repeats, 890 trinucleotide repeats, 900 trinucleotide repeats, 910 trinucleotide repeats, 920 trinucleotide repeats, 930 trinucleotide repeats, 940 trinucleotide repeats, 950 trinucleotide repeats, 960 trinucleotide repeats, 970 trinucleotide repeats, 980 trinucleotide repeats, 990 trinucleotide repeats, 1 ,000 trinucleotide repeats, 1 ,100 trinucleotide repeats, 1 ,200 trinucleotide repeats, 1 ,300 trinucleotide repeats,
1 ,400 trinucleotide repeats, 1 ,500 trinucleotide repeats, 1 ,600 trinucleotide repeats, 1 ,700 trinucleotide repeats, 1 ,800 trinucleotide repeats, 1 ,900 trinucleotide repeats, 2,000 trinucleotide repeats, 2,100 trinucleotide repeats, 2,200 trinucleotide repeats, 2,300 trinucleotide repeats, 2,400 trinucleotide repeats, 2,500 trinucleotide repeats, 2,600 trinucleotide repeats, 2,700 trinucleotide repeats, 2,800 trinucleotide repeats, 2,900 trinucleotide repeats, 3,000 trinucleotide repeats, 3,100 trinucleotide repeats, 3,200 trinucleotide repeats, 3,300 trinucleotide repeats, 3,400 trinucleotide repeats, 3,500 trinucleotide repeats,
3,600 trinucleotide repeats, 3,700 trinucleotide repeats, 3,800 trinucleotide repeats, 3,900 trinucleotide repeats, or 4,000 trinucleotide repeats, among others). In some embodiments, the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, the endogenous RNA transcript contains a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The endogenous RNA transcript may contain, for example, a portion having the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
In some embodiments, the viral vector further comprises a transgene encoding human DMPK, such as a codon-optimized human DMPK that, upon transcription, does not anneal to the interfering RNA. For example, the DMPK transcript expressed by the transgene encoding human DMPK may be less than 85% complementary to the interfering RNA (e.g., less than 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1 % complementary, or less). The transgene encoding human DMPK may be operably linked to the transgene(s) encoding the interfering RNA, for example, such that the interfering RNA(s) and the DMPK are expressed from the same promoter. This may be effectuated, for instance, by the placement of an internal ribosomal entry site (IRES) between the transgene(s) encoding the interfering RNA(s) and the transgene encoding human DMPK. In some embodiments, the transgene(s) encoding the interfering RNA(s) and the transgene encoding human DMPK are each operably linked to separate promoters.
In some embodiments, the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript having the nucleic acid sequence of any one of SEQ ID NOs: 3-39.
In some embodiments, the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of exons 1 -15 of human DMPK RNA (e.g., to a segment within exon 1 , exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 9, exon 10, exon 1 1 , exon 12, exon
13, exon 14, or exon 15 of human DMPK RNA). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%,
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g.,
90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -1 5 of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
In some embodiments, the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of introns 1 -14 of human DMPK RNA (e.g., to a segment within intron 1 , intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 10, intron 1 1 , intron 12, intron 13, or intron 14 of human DMPK RNA). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
In some embodiments, the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript containing an exon-intron boundary within human DMPK (e.g., to a segment containing the boundary between exon 1 and intron 1 , between intron 1 and exon 2, between exon 2 and intron 2, between intron 2 and exon 3, between exon 3 and intron 3, between intron 3 and exon 4, between exon 4 and intron 4, between intron 4 and exon 5, between exon 5 and intron 5, between intron
5 and exon 6, between exon 6 and intron 6, between intron 6 and exon 7, between exon 7 and intron 7, between intron 7 and exon 8, between exon 8 and intron 8, between intron 8 and exon 9, between exon 9 and intron 9, between intron 9 and exon 1 0, between exon 10 and intron 10, between intron 10 and exon
1 1 , between exon 1 1 and intron 1 1 , between intron 1 1 and exon 12, between exon 12 and intron 12, between intron 12 and exon 13, between exon 13 and intron 13, between intron 13 and exon 14, between exon 14 and intron 14, or between intron 14 and exon 15). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%,
89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
In some embodiments, the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within the 5’ UTR or 3’ UTR of human DMPK. The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100%
complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
In some embodiments, the segment within human DMPK is from about 10 to about 80 nucleotides in length. For example, the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, 50 nucleotides, 51 nucleotides, 52 nucleotides, 53 nucleotides, 54 nucleotides, 55 nucleotides, 56 nucleotides, 57 nucleotides, 58 nucleotides, 59 nucleotides, 60 nucleotides, 61 nucleotides, 62 nucleotides, 63 nucleotides, 64 nucleotides, 65 nucleotides, 66 nucleotides, 67 nucleotides, 68 nucleotides, 69 nucleotides, 70 nucleotides, 71 nucleotides, 72 nucleotides, 73 nucleotides, 74 nucleotides, 75 nucleotides, 76 nucleotides, 77 nucleotides, 78 nucleotides, 79 nucleotides, or 80 nucleotides in length. In some embodiments, the segment within human DMPK is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, or 50 nucleotides in length. In some embodiments, the segment within human DMPK is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length. In some embodiments, the segment is 18 nucleotides in length. In some embodiments, the segment is 19 nucleotides in length. In some embodiments, the segment is 20 nucleotides in length. In some embodiments, the segment is 21 nucleotides in length.
In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches). In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches. For example, interfering RNA may anneal to the endogenous RNA transcript encoding human DMKPK with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
In some embodiments, the interfering RNA contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 . The interfering RNA may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of ay one of SEQ ID NOs: 3-161 . In some embodiments, the interfering RNA contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of ay one of SEQ ID NOs: 3-161 . In some embodiments, the interfering RNA contains a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3- 161 . In some embodiments, the interfering RNA is a miRNA having a combination of passenger and guide strands shown in Table 5, herein.
In some embodiments, the endogenous RNA transcript contains human chromosome 9 open reading frame 72 (C90RF72) and an expanded repeat region. The expanded repeat region may contain, for example, greater than 25 GGGGCC (SEQ ID NO: 1 62) hexanucleotide repeats, such as from about
700 to about 1 ,600 GGGGCC (SEQ ID NO: 162) hexanucleotide repeats, For example, the expanded repeat region may contain 700 hexanucleotide repeats, 710 hexanucleotide repeats, 720 hexanucleotide repeats, 730 hexanucleotide repeats, 740 hexanucleotide repeats, 750 hexanucleotide repeats, 760 hexanucleotide repeats, 770 hexanucleotide repeats, 780 hexanucleotide repeats, 790 hexanucleotide repeats, 800 hexanucleotide repeats, 810 hexanucleotide repeats, 820 hexanucleotide repeats, 830 hexanucleotide repeats, 840 hexanucleotide repeats, 850 hexanucleotide repeats, 860 hexanucleotide repeats, 870 hexanucleotide repeats, 880 hexanucleotide repeats, 890 hexanucleotide repeats, 900 hexanucleotide repeats, 910 hexanucleotide repeats, 920 hexanucleotide repeats, 930 hexanucleotide repeats, 940 hexanucleotide repeats, 950 hexanucleotide repeats, 960 hexanucleotide repeats, 970 hexanucleotide repeats, 980 hexanucleotide repeats, 990 hexanucleotide repeats, or 1 ,000
hexanucleotide repeats, among others. The expanded repeat region may contain greater than 30 hexanucleotide repeats, such as 30 hexanucleotide repeats, 40 hexanucleotide repeats, 50
hexanucleotide repeats, 60 CUG hexanucleotide repeats, 70 hexanucleotide repeats, 80 hexanucleotide repeats, 90 hexanucleotide repeats, 100 hexanucleotide repeats, 1 10 hexanucleotide repeats, 120 hexanucleotide repeats, 130 hexanucleotide repeats, 140 hexanucleotide repeats, 150 hexanucleotide repeats, 160 hexanucleotide repeats, 170 hexanucleotide repeats, 180 hexanucleotide repeats, 190 hexanucleotide repeats, 200 hexanucleotide repeats, 210 hexanucleotide repeats, 220 hexanucleotide repeats, 230 hexanucleotide repeats, 240 hexanucleotide repeats, 250 hexanucleotide repeats, 260 hexanucleotide repeats, 270 hexanucleotide repeats, 280 hexanucleotide repeats, 290 hexanucleotide repeats, 300 hexanucleotide repeats, 310 hexanucleotide repeats, 320 hexanucleotide repeats, 330 hexanucleotide repeats, 340 hexanucleotide repeats, 350 hexanucleotide repeats, 360 hexanucleotide repeats, 370 hexanucleotide repeats, 380 hexanucleotide repeats, 390 hexanucleotide repeats, 400 hexanucleotide repeats, 410 hexanucleotide repeats, 420 hexanucleotide repeats, 430 hexanucleotide repeats, 440 hexanucleotide repeats, 450 hexanucleotide repeats, 460 hexanucleotide repeats, 470 hexanucleotide repeats, 480 hexanucleotide repeats, 490 hexanucleotide repeats, 500 hexanucleotide repeats, 510 hexanucleotide repeats, 520 hexanucleotide repeats, 530 hexanucleotide repeats, 540 hexanucleotide repeats, 550 hexanucleotide repeats, 560 hexanucleotide repeats, 570 hexanucleotide repeats, 580 hexanucleotide repeats, 590 hexanucleotide repeats, 600 hexanucleotide repeats, 610 hexanucleotide repeats, 620 hexanucleotide repeats, 630 hexanucleotide repeats, 640 hexanucleotide repeats, 650 hexanucleotide repeats, 660 hexanucleotide repeats, 670 hexanucleotide repeats, 680 hexanucleotide repeats, 690 hexanucleotide repeats, 700 hexanucleotide repeats, 710 hexanucleotide repeats, 720 hexanucleotide repeats, 730 hexanucleotide repeats, 740 hexanucleotide repeats, 750 hexanucleotide repeats, 760 hexanucleotide repeats, 770 hexanucleotide repeats, 780 hexanucleotide repeats, 790 hexanucleotide repeats, 800 hexanucleotide repeats, 810 hexanucleotide repeats, 820 hexanucleotide repeats, 830 hexanucleotide repeats, 840 hexanucleotide repeats, 850 hexanucleotide repeats, 860 hexanucleotide repeats, 870 hexanucleotide repeats, 880 hexanucleotide repeats, 890 hexanucleotide repeats, 900 hexanucleotide repeats, 910 hexanucleotide repeats, 920 hexanucleotide repeats, 930 hexanucleotide repeats, 940 hexanucleotide repeats, 950 hexanucleotide repeats, 960 hexanucleotide repeats, 970 hexanucleotide repeats, 980 hexanucleotide repeats, 990 hexanucleotide repeats, 1 ,000 hexanucleotide repeats, 1 ,100 hexanucleotide repeats, 1 ,200 hexanucleotide repeats, 1 ,300 hexanucleotide repeats, 1 ,400 hexanucleotide repeats, 1 ,500 hexanucleotide repeats, 1 ,600 hexanucleotide repeats, or more.
In some embodiments, the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163. The endogenous RNA transcript may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163. In some embodiments, the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 163. In some embodiments, the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 163.
In some embodiments, the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165. The endogenous RNA transcript may contain, for example, a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165. In some embodiments, the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 165. In some embodiments, the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 165.
In some embodiments, the endogenous RNA transcript contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 166. The endogenous RNA transcript may contain, for example, a portion having at least 90% sequence identity
(e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 166. In some embodiments, the endogenous RNA transcript contains a portion having at least 95% sequence identity (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of SEQ ID NO: 166. In some embodiments, the RNA transcript contains a portion having the nucleic acid sequence of SEQ ID NO: 166.
In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within human C90RF72, such as to the nucleic acid sequence of a segment within SEQ ID NO: 163, 165, or 166.
In some embodiments, the segment within human C90RF72 is from about 10 to about 80 nucleotides in length. For example, the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, 50 nucleotides, 51 nucleotides, 52 nucleotides, 53 nucleotides, 54 nucleotides, 55 nucleotides, 56 nucleotides, 57 nucleotides, 58 nucleotides, 59 nucleotides, 60 nucleotides, 61 nucleotides, 62 nucleotides, 63 nucleotides, 64 nucleotides, 65 nucleotides, 66 nucleotides, 67 nucleotides, 68 nucleotides, 69 nucleotides, 70 nucleotides, 71 nucleotides, 72 nucleotides, 73 nucleotides, 74 nucleotides, 75 nucleotides, 76 nucleotides, 77 nucleotides, 78 nucleotides, 79 nucleotides, or 80 nucleotides in length. In some embodiments, the segment within human C90RF72is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, or 50 nucleotides in length. In some embodiments, the segment within human C90RF72 is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length. In some embodiments, the segment is 18 nucleotides in length. In some embodiments, the segment is 19 nucleotides in length. In some embodiments, the segment is 20 nucleotides in length. In some embodiments, the segment is 21 nucleotides in length.
In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches). In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches. In some embodiments, the interfering RNA anneals to the endogenous RNA transcript encoding human C90RF72 with no more than two nucleotide mismatches. For example, interfering RNA may anneal to the endogenous RNA transcript encoding human C90RF72 with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
In some embodiments, the interfering RNA is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA), such as a U6 miRNA. The miRNA may be based, for example, on the endogenous human miR30a nucleic acid sequence, having one or more nucleic acid substitutions as needed for complementarity to a target mRNA (e.g., a target mRNA described herein). In the case of a miRNA, the viral vector may contain, for example, a primary miRNA (pri-miRNA) transcript encoding a mature miRNA. In some embodiments, the viral vector contains a pre-miRNA transcript encoding a mature miRNA.
In some embodiments, the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron. The promoter may be, for example, a desmin promoter, a phosphoglycerate kinase (PGK) promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a promoter within intron 1 of ocular paired like homeodomain 3 (PITX3).
In some embodiments, the viral vector is an AAV, adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus. The viral vector may be, for example, an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhI O, or AAVrh74 serotype. In some embodiments, the viral vector is a pseudotyped AAV, such as an AAV2/8 or AAV/29 vector. The viral vector may contain a recombinant capsid protein. In some embodiments, the viral vector is a synthetic virus, such as a chimeric virus, mosaic virus, or pseudotyped virus, and/or a synthetic virus that contains a foreign protein, synthetic polymer, nanoparticle, or small molecule.
In another aspect, the invention features a nucleic acid encoding or containing an interfering RNA that contains a portion having at least 85% sequence identity (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 1 00% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-1 61 . In some embodiments, the interfering RNA contains a portion having at least 90% sequence identity (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 . The interfering RNA may contain, for example, a portion having at least 95% sequence identity (e.g.,
95%, 96%, 97%, 98%, 99%, 99.9%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 . In some embodiments, the interfering RNA contains a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3-1 61 . In some embodiments, the interfering RNA is a miRNA having a combination of passenger and guide strands shown in Table 5, herein.
In some embodiments, the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of exons 1 -15 of human DMPK RNA (e.g., to a segment within exon 1 , exon 2, exon 3, exon 4, exon 5, exon 6, exon 7, exon 8, exon 9, exon 10, exon 1 1 , exon 12, exon 13, exon 14, or exon 15 of human DMPK RNA). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. In some
embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK. In some embodiments, the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of introns 1 -14 of human DMPK RNA (e.g., to a segment within intron 1 , intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 10, intron 1 1 , intron 12, intron 13, or intron 14 of human DMPK RNA). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
In some embodiments, the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK containing an exon-intron boundary within human
DMPK (e.g., to a segment containing the boundary between exon 1 and intron 1 , between intron 1 and exon 2, between exon 2 and intron 2, between intron 2 and exon 3, between exon 3 and intron 3, between intron 3 and exon 4, between exon 4 and intron 4, between intron 4 and exon 5, between exon 5 and intron 5, between intron 5 and exon 6, between exon 6 and intron 6, between intron 6 and exon 7, between exon 7 and intron 7, between intron 7 and exon 8, between exon 8 and intron 8, between intron
8 and exon 9, between exon 9 and intron 9, between intron 9 and exon 10, between exon 10 and intron
10, between intron 10 and exon 1 1 , between exon 1 1 and intron 1 1 , between intron 1 1 and exon 12, between exon 12 and intron 12, between intron 12 and exon 13, between exon 13 and intron 13, between intron 13 and exon 14, between exon 14 and intron 14, or between intron 14 and exon 1 5). The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary
(e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or
100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon- intron boundary within human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment containing an exon-intron boundary within human DMPK.
In some embodiments, the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within the 5’ UTR or 3’ UTR of human DMPK. The portion of each interfering RNA may have, for example, a nucleic acid sequence that is least 85% complementary (e.g., 85%, 85%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary (e.g., 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. For example, the portion of each interfering RNA may have a nucleic acid sequence that is at least 95% complementary (e.g., 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK. In some embodiments, the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
In some embodiments, the segment within human DMPK is from about 10 to about 80 nucleotides in length. For example, the segment may be 10 nucleotides, 1 1 nucleotides, 12 nucleotides,
13 nucleotides, 14 nucleotides, 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, 50 nucleotides, 51 nucleotides, 52 nucleotides, 53 nucleotides, 54 nucleotides, 55 nucleotides, 56 nucleotides, 57 nucleotides, 58 nucleotides, 59 nucleotides, 60 nucleotides, 61 nucleotides, 62 nucleotides, 63 nucleotides, 64 nucleotides, 65 nucleotides, 66 nucleotides, 67 nucleotides, 68 nucleotides, 69 nucleotides, 70 nucleotides, 71 nucleotides, 72 nucleotides, 73 nucleotides, 74 nucleotides, 75 nucleotides, 76 nucleotides, 77 nucleotides, 78 nucleotides, 79 nucleotides, or 80 nucleotides in length. In some embodiments, the segment within human DMPK is from about 15 to about 50 nucleotides in length, such as a segment of 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides, or 50 nucleotides in length. In some embodiments, the segment within human DMPK is from about 17 to about 23 nucleotides in length, such as 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, or 23 nucleotides in length. In some embodiments, the segment is 18 nucleotides in length. In some embodiments, the segment is 19 nucleotides in length. In some embodiments, the segment is 20 nucleotides in length. In some embodiments, the segment is 21 nucleotides in length.
In some embodiments, the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches (e.g., with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, five nucleotide mismatches, six nucleotide mismatches, seven nucleotide mismatches, or eight nucleotide mismatches). In some embodiments, the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, three nucleotide mismatches, four nucleotide mismatches, or five nucleotide mismatches. In some embodiments, the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches, such as with one nucleotide mismatch, two nucleotide mismatches, or three nucleotide mismatches. In some embodiments, the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches. For example, interfering RNA may anneal to the endogenous RNA transcript encoding human DMKPK with no nucleotide mismatches, one nucleotide mismatch, or two nucleotide mismatches.
In some embodiments, the interfering RNA is a siRNA, a shRNA, or a miRNA, such as a U6 miRNA. The miRNA may be based, for example, on the endogenous human miR30a nucleic acid sequence, having one or more nucleic acid substitutions as needed for complementarity to a target mRNA (e.g., a target mRNA described herein). In the case of a miRNA, the nucleic acid may contain, for example, a pri-miRNA transcript encoding a mature miRNA. In some embodiments, the viral vector contains a pre-miRNA transcript encoding a mature miRNA.
In some embodiments, the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron. The promoter may be, for example, a desmin promoter, a PGK promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a promoter within intron 1 of ocular PITX3. In an additional aspect, the invention features a vector containing the nucleic acid of any of the above aspects or embodiments. The vector may be, for example, an AAV (e.g., an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhl 0, or AAVrh74 serotype, or a pseudotyped AAV, such as an AAV2/8 or AAV/29 vector), adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, or a synthetic virus (e.g., a chimeric virus, mosaic virus, or pseudotyped virus, and/or a synthetic virus that contains a foreign protein, synthetic polymer, nanoparticle, or small molecule), and may contain one or more recombinant capsid proteins.
In yet another aspect, the invention features a composition containing the nucleic acid of any of the above aspects or embodiments. The composition may be, for example, a liposome, vesicle, synthetic vesicle, exosome, synthetic exosome, dendrimer, or nanoparticle.
In another aspect, the invention features a pharmaceutical composition containing the nucleic acid of any of the above aspects or embodiments. The pharmaceutical composition may further contain a pharmaceutically acceptable carrier, diluent, or excipient.
In an additional aspect, the invention features a method of reducing the occurrence of spliceopathy (e.g., of an mRNA transcript for which splicing is regulated, in part, by the activity of muscleblind-like protein) in a patient, such as a human patient, in need thereof. The method may include administering to the patient a therapeutically effective amount of the vector or composition of any of the above aspects or embodiments. In some embodiments, the patient has myotonic dystrophy. Upon administration of the vector or composition to the patient, the patient may exhibit an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein.
In another aspect, the invention features a method of treating a disorder characterized by nuclear retention of RNA containing an expanded repeat region in a patient, such as a human patient, in need thereof by administering to the patient a therapeutically effective amount of the vector or composition of any of the above aspects or embodiments. The disorder may be, for example, myotonic dystrophy, and the nuclear-retained RNA may be DMPK RNA. In some embodiments, the disorder is amyotrophic lateral sclerosis and the nuclear-retrained RNA is C90RF72 RNA.
Upon administration of the vector or composition to the patient, the patient may exhibit an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein. For example, upon administration of the vector or composition to the patient, the patient may exhibit an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold,
1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold,
2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4- fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5-fold, 5.1 -fold, 5.2- fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6-fold, 6.1 -fold, 6.2-fold, 6.3-fold, 6.4- fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7-fold, 7.1 -fold, 7.2-fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6- fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2-fold, 8.3-fold, 8.4-fold, 8.5-fold, 8.6-fold, 8.7-fold, 8.8- fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5-fold, 9.6-fold, 9.7-fold, 9.8-fold, 9.9-fold, 10- fold, or more), as assessed, for example, using an RNA or protein detection assay described herein.
In some embodiments, upon administration of the vector or composition to the patient, the patient may exhibit a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%,
51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), as assessed, for example, using an RNA or protein detection assay described herein.
For example, upon administration of the vector or composition to the patient, the patient may exhibit a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 1 0%, 1 1 %, 12%, 13%, 14%, 15%, 1 6%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%,
37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51 %, 52%, 53%, 54%,
55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%,
73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), as assessed, for example, using an RNA or protein detection assay described herein.
In some embodiments, upon administration of the vector or composition to the patient, the patient exhibits an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor, RYR1 , cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2- fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4- fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6- fold, 4.7-fold, 4.8-fold, 4.9-fold, 5-fold, 5.1 -fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8- fold, 5.9-fold, 6-fold, 6.1 -fold, 6.2-fold, 6.3-fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7- fold, 7.1 -fold, 7.2-fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6-fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2- fold, 8.3-fold, 8.4-fold, 8.5-fold, 8.6-fold, 8.7-fold, 8.8-fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4- fold, 9.5-fold, 9.6-fold, 9.7-fold, 9.8-fold, 9.9-fold, 1 0-fold, or more), as assessed, for example, using an
RNA or protein detection assay described herein.
In some embodiments of either of the preceding two preceding aspects, the vector or composition is administered to the patient by way of intravenous, intrathecal, intracerebroventricular,
intraparenchymal, intracisternal, intradermal, transdermal, parenteral, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, or oral administration.
In another aspect, the invention features a kit containing the vector or composition of any of the above aspects or embodiments. The kit may further contain a package insert instructing a user of the kit to administer the vector or composition to the patient to reduce the occurrence of a spliceopathy in the patient, such as spliceopathy of an mRNA transcript for which splicing is regulated, in part, by the activity of muscleblind-like protein.
In an additional aspect, the invention features a kit containing the vector or composition of any of the above aspects or embodiments and a package insert that instructs a user of the kit to administer the vector or composition to the patient to reduce the occurrence of a spliceopathy in the patient to treat a disorder characterized by nuclear retention of RNA containing an expanded repeat region. The disorder may be, for example, myotonic dystrophy, and the nuclear-retained RNA may be DMPK RNA. In some embodiments, the disorder is amyotrophic lateral sclerosis and the nuclear-retrained RNA is C90RF72 RNA.
Definitions
As used herein, the term“about” refers to a value that is within 10% above or below the value being described. For example, the phrase“about 1 00 nucleic acid residues” refers to a value of from 90 to 1 10 nucleic acid residues.
As used herein, the term "anneal" refers to the formation of a stable duplex of nucleic acids by way of hybridization mediated by inter-strand hydrogen bonding, for example, according to Watson-Crick base pairing. The nucleic acids of the duplex may be, for example, at least 50% complementary to one another (e.g., about 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%,
64%, 65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 80%, 81 %, 82%, 83%, 84%, 85%,
86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary to one another. The "stable duplex" formed upon the annealing of one nucleic acid to another is a duplex structure that is not denatured by a stringent wash. Exemplary stringent wash conditions are known in the art and include temperatures of about 5° C less than the melting temperature of an individual strand of the duplex and low concentrations of monovalent salts, such as monovalent salt concentrations (e.g., NaCI concentrations) of less than 0.2 M (e.g., 0.2 M, 0.19 M, 0.18 M, 0.17 M, 0.16 M, 0.15 M, 0.14 M, 0.13 M, 0.12 M, 0.1 1 M, 0.1 M, 0.09 M, 0.08 M, 0.07 M, 0.06 M, 0.05 M, 0.04 M, 0.03 M, 0.02 M, 0.01 M, or less).
As used herein, the terms“conservative mutation,”“conservative substitution,” or“conservative amino acid substitution” refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally-occurring amino acids in Table 1 below.
Table 1 . Representative physicochemical properties of naturally-occurring amino acids
Figure imgf000022_0001
Figure imgf000023_0001
†based on volume in A3: 50-100 is small, 1 00-150 is intermediate,
150-200 is large, and >200 is bulky
From this table it is appreciated that the conservative amino acid families include, e.g., (i) G, A, V, L, I, P, and M; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W. A conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family (e.g., a substitution of Ser for Thr or Lys for Arg).
As used herein, the terms“dystrophia myotonica protein kinase” and its abbreviation,“DMPK,” refer to the serine/threonine kinase protein involved in the regulation of skeletal muscle structure and function, for example, in human subjects. The terms“dystrophia myotonica protein kinase” and“DMPK” are used interchangeably herein and refer not only to wild-type forms of the DMPK gene, but also to variants of wild-type DMPK proteins and nucleic acids encoding the same. The nucleic acid sequences of two isoforms of human DMPK mRNA are provided herein as SEQ ID NOs: 1 and 2, which correspond to GenBank Accession Nos. BC026328.1 and BC062553.1 , respectively (3’ UTRs not included). These nucleic acid sequences are provided in Table 2, below.
Table 2. Nucleic acid sequences of exemplary human DMPK isoforms
Figure imgf000023_0002
Figure imgf000024_0001
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
The terms“dystrophia myotonica protein kinase” and“DMPK” as used herein include, for example, forms of the human DMPK gene that have a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% identical to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2) and/or forms of the human DMPK gene that encode a DMPK protein having one or more (e.g., up to 25) conservative amino acid substitutions relative to a wild- type DMPK protein. The terms“dystrophia myotonica protein kinase” and“DMPK” as used herein additionally include DMPK RNA transcripts containing expanded CUG trinucleotide repeat regions relative to the length of the CUG trinucleotide repeat region of a wild-type DMPK mRNA transcript. The expanded repeat region may contain, for example, 50 or more CUG trinucleotide repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinucleotide repeats, 210 trinucleotide repeats, 220 trinucleotide repeats, 230 trinucleotide repeats, 240 trinucleotide repeats, 250 trinucleotide repeats, 260 trinucleotide repeats, 270 trinucleotide repeats, 280 trinucleotide repeats, 290 trinucleotide repeats, 300 trinucleotide repeats, 31 0 trinucleotide repeats, 320 trinucleotide repeats, 330 trinucleotide repeats, 340 trinucleotide repeats, 350 trinucleotide repeats, 360 trinucleotide repeats, 370 trinucleotide repeats, 380 trinucleotide repeats, 390 trinucleotide repeats, 400 trinucleotide repeats, 410 trinucleotide repeats, 420 trinucleotide repeats, 430 trinucleotide repeats, 440 trinucleotide repeats, 450 trinucleotide repeats, 460 trinucleotide repeats, 470 trinucleotide repeats, 480 trinucleotide repeats, 490 trinucleotide repeats, 500 trinucleotide repeats, 51 0 trinucleotide repeats, 520 trinucleotide repeats, 530 trinucleotide repeats, 540 trinucleotide repeats, 550 trinucleotide repeats, 560 trinucleotide repeats, 570 trinucleotide repeats, 580 trinucleotide repeats, 590 trinucleotide repeats, 600 trinucleotide repeats, 610 trinucleotide repeats, 620 trinucleotide repeats, 630 trinucleotide repeats, 640 trinucleotide repeats, 650 trinucleotide repeats, 660 trinucleotide repeats, 670 trinucleotide repeats, 680 trinucleotide repeats, 690 trinucleotide repeats, 700 trinucleotide repeats, 71 0 trinucleotide repeats, 720 trinucleotide repeats, 730 trinucleotide repeats, 740 trinucleotide repeats, 750 trinucleotide repeats, 760 trinucleotide repeats, 770 trinucleotide repeats, 780 trinucleotide repeats, 790 trinucleotide repeats, 800 trinucleotide repeats, 810 trinucleotide repeats, 820 trinucleotide repeats, 830 trinucleotide repeats, 840 trinucleotide repeats, 850 trinucleotide repeats, 860 trinucleotide repeats, 870 trinucleotide repeats, 880 trinucleotide repeats, 890 trinucleotide repeats, 900 trinucleotide repeats, 91 0 trinucleotide repeats, 920 trinucleotide repeats, 930 trinucleotide repeats, 940 trinucleotide repeats, 950 trinucleotide repeats, 960 trinucleotide repeats, 970 trinucleotide repeats, 980 trinucleotide repeats, 990 trinucleotide repeats, 1 ,000 trinucleotide repeats, 1 ,1 00 trinucleotide repeats, 1 ,200 trinucleotide repeats, 1 ,300 trinucleotide repeats, 1 ,400 trinucleotide repeats, 1 ,500 trinucleotide repeats, 1 ,600 trinucleotide repeats, 1 ,700 trinucleotide repeats, 1 ,800 trinucleotide repeats, 1 ,900 trinucleotide repeats, 2,000 trinucleotide repeats, 2,100 trinucleotide repeats, 2,200 trinucleotide repeats, 2,300 trinucleotide repeats, 2,400 trinucleotide repeats, 2,500 trinucleotide repeats, 2,600 trinucleotide repeats, 2,700 trinucleotide repeats, 2,800 trinucleotide repeats, 2,900 trinucleotide repeats, 3,000 trinucleotide repeats, 3,1 00 trinucleotide repeats, 3,200 trinucleotide repeats, 3,300 trinucleotide repeats, 3,400 trinucleotide repeats, 3,500 trinucleotide repeats, 3,600 trinucleotide repeats, 3,700 trinucleotide repeats, 3,800 trinucleotide repeats, 3,900 trinucleotide repeats, or 4,000 trinucleotide repeats, among others).
As used herein, the term“interfering RNA” refers to a RNA, such as a short interfering RNA
(siRNA), micro RNA (miRNA), or short hairpin RNA (shRNA) that suppresses the expression of a target
RNA transcript by way of (i) annealing to the target RNA transcript, thereby forming a nucleic acid duplex; and (ii) promoting the nuclease-mediated degradation of the RNA transcript and/or (iii) slowing, inhibiting, or preventing the translation of the RNA transcript, such as by sterically precluding the formation of a functional ribosome-RNA transcript complex or otherwise attenuating formation of a functional protein product from the target RNA transcript. Interfering RNAs as described herein may be provided to a patient, such as a human patient having myotonic dystrophy, in the form of, for example, a single- or double-stranded oligonucleotide, or in the form of a vector (e.g., a viral vector, such as an adeno- associated viral vector described herein) containing a transgene encoding the interfering RNA.
Exemplary interfering RNA platforms are described, for example, in Lam et al. , Molecular Therapy - Nucleic Acids 4:e252 (2015); Rao et al., Advanced Drug Delivery Reviews 61 :746-769 (2009); and Borel et al., Molecular Therapy 22:692-701 (2014), the disclosures of each of which are incorporated herein by reference in their entirety.
As used herein, the“length” of a nucleic acid refers to the linear size of the nucleic acid as assessed by measuring the quantity of nucleotides from the 5’ to the 3’ end of the nucleic acid.
Exemplary molecular biology techniques that may be used to determine the length of a nucleic acid of interest are known in the art.
As used herein, the term“myotonic dystrophy” refers to an inherited muscle wasting disorder characterized by the nuclear retention of RNA transcripts encoding DMPK and containing an expanded CUG trinucleotide repeat region in the 3’ untranslated region (UTR), such as an expanded CUG trinucleotide repeat region having from 50 to 4,000 CUG repeats. Wild-type RMPK RNA transcripts, by comparison, typically contain from 5 to 37 CUG repeats in the 3' UTR. In patients having myotonic dystrophy, the expanded CUG repeat region interacts with RNA-binding splicing factors, such as muscleblind-like protein. This interaction causes the mutant transcript to be retained in nuclear foci and leads to sequestration of RNA-binding proteins away from other pre-mRNA substrates, which, in turn, promotes spliceopathy of proteins involved in modulating muscle structure and function. In type I myotonic dystrophy (DM1 ), skeletal muscle is often the most severely affected tissue, but the disease also imparts toxic effects on cardiac and smooth muscle, the ocular lens, and the brain. The cranial, distal limb, and diaphragm muscles are preferentially affected. Manual dexterity is compromised early, which causes several decades of severe disability. The median age at death of myotonic dystrophy patients is 55 years, which is usually caused by respiratory failure (de Die-Smulders C E, et al., Brain 121 :1557-1563 (1998)).
As used herein, the term“operably linked” refers to a first molecule (e.g., a first nucleic acid) joined to a second molecule (e.g., a second nucleic acid), wherein the molecules are so arranged that the first molecule affects the function of the second molecule. The two molecules may or may not be part of a single contiguous molecule and may or may not be adjacent to one another. For example, a promoter is operably linked to a transcribable polynucleotide molecule if the promoter modulates transcription of the transcribable polynucleotide molecule of interest in a cell. Additionally, two portions of a transcription regulatory element are operably linked to one another if they are joined such that the transcription activating functionality of one portion is not adversely affected by the presence of the other portion. Two transcription regulatory elements may be operably linked to one another by way of a linker nucleic acid (e.g., an intervening non-coding nucleic acid) or may be operably linked to one another with no intervening nucleotides present.
As used herein, one segment of a nucleic acid molecule is considered to“overlap with” another segment of the same nucleic acid molecule if the two segments share one or more constituent nucleotides. For example, two segments of the same nucleic acid molecule are considered to“overlap with” one another if the two segments share 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or more, constituent nucleotides. The two segments are not considered to“overlap with” one another if the two segments have zero constituent nucleotides in common.
“Percent (%) sequence complementarity” with respect to a reference polynucleotide sequence is defined as the percentage of nucleic acids in a candidate sequence that are complementary to the nucleic acids in the reference polynucleotide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence complementarity. A given nucleotide is considered to be“complementary” to a reference nucleotide as described herein if the two nucleotides form canonical Watson-Crick base pairs. For the avoidance of doubt, Watson-Crick base pairs in the context of the present disclosure include adenine-thymine, adenine-uracil, and cytosine-guanine base pairs. A proper Watson-Crick base pair is referred to in this context as a“match,” while each unpaired nucleotide, and each incorrectly paired nucleotide, is referred to as a“mismatch.” Alignment for purposes of determining percent nucleic acid sequence complementarity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal complementarity over the full length of the sequences being compared. As an illustration, the percent sequence complementarity of a given nucleic acid sequence, A, to a given nucleic acid sequence, B, (which can alternatively be phrased as a given nucleic acid sequence, A that has a certain percent complementarity to a given nucleic acid sequence, B) is calculated as follows:
100 multiplied by (the fraction X/Y)
where X is the number of complementary base pairs in an alignment (e.g., as executed by computer software, such as BLAST) in that program’s alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid sequence A is not equal to the length of nucleic acid sequence B, the percent sequence complementarity of A to B will not equal the percent sequence complementarity of B to A. As used herein, a query nucleic acid sequence is considered to be“completely complementary” to a reference nucleic acid sequence if the query nucleic acid sequence has 100% sequence complementarity to the reference nucleic acid sequence.
“Percent (%) sequence identity” with respect to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acids or amino acids in a candidate sequence that are identical to the nucleic acids or amino acids in the reference polynucleotide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid or amino acid sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, or Megalign software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, percent sequence identity values may be generated using the sequence comparison computer program BLAST. As an illustration, the percent sequence identity of a given nucleic acid or amino acid sequence, A, to, with, or against a given nucleic acid or amino acid sequence, B, (which can alternatively be phrased as a given nucleic acid or amino acid sequence, A that has a certain percent sequence identity to, with, or against a given nucleic acid or amino acid sequence, B) is calculated as follows:
100 multiplied by (the fraction X/Y)
where X is the number of nucleotides or amino acids scored as identical matches by a sequence alignment program (e.g., BLAST) in that program’s alignment of A and B, and where Y is the total number of nucleic acids in B. It will be appreciated that where the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the percent sequence identity of A to B will not equal the percent sequence identity of B to A.
As used herein, the term“pharmaceutical composition” refers to a mixture containing a therapeutic agent, such as a nucleic acid or vector described herein, optionally in combination with one or more pharmaceutically acceptable excipients, diluents, and/or carriers, to be administered to a subject, such as a mammal, e.g., a human, in order to prevent, treat or control a particular disease or condition affecting or that may affect the subject.
As used herein, the term“pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms, which are suitable for contact with the tissues of a subject, such as a mammal (e.g., a human) without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.
As used herein, the term“repeat region” refers to segments within a gene of interest or an RNA transcript thereof containing nucleic acid repeats, such as the poly CTG sequence in the 3” UTR of the human DMPK gene (or the poly CUG sequence in the 3’ UTR of the RNA transcript thereof). A repeat region is considered to be an“expanded repeat region,” a“repeat expansion,” or the like, if the number of nucleotide repeats in the repeat region exceeds the quantity of repeats ordinarily found in the repeat region of a wild-type form of the gene or RNA transcript thereof. For example, the 3’ UTRs of wild-type human DMPK genes typically contain from 5 to 37 CTG or CUG repeats. “Expanded repeat regions” and “repeat expansions” in the context of the DMPK gene or an RNA transcript thereof thus refer to repeat regions containing greater than 37 CTG or CUG repeats, such as from about 50 to about 4,000 CUG trinucleotide repeats (e.g., about 50 CUG trinucleotide repeats, about 60 CUG trinucleotide repeats, about 70 trinucleotide repeats, 80 trinucleotide repeats, 90 trinucleotide repeats, 100 trinucleotide repeats, 1 10 trinucleotide repeats, 120 trinucleotide repeats, 130 trinucleotide repeats, 140 trinucleotide repeats, 150 trinucleotide repeats, 160 trinucleotide repeats, 170 trinucleotide repeats, 180 trinucleotide repeats, 190 trinucleotide repeats, 200 trinucleotide repeats, 210 trinucleotide repeats, 220 trinucleotide repeats, 230 trinucleotide repeats, 240 trinucleotide repeats, 250 trinucleotide repeats, 260 trinucleotide repeats, 270 trinucleotide repeats, 280 trinucleotide repeats, 290 trinucleotide repeats, 300 trinucleotide repeats, 310 trinucleotide repeats, 320 trinucleotide repeats, 330 trinucleotide repeats, 340 trinucleotide repeats, 350 trinucleotide repeats, 360 trinucleotide repeats, 370 trinucleotide repeats, 380 trinucleotide repeats, 390 trinucleotide repeats, 400 trinucleotide repeats, 410 trinucleotide repeats, 420 trinucleotide repeats, 430 trinucleotide repeats, 440 trinucleotide repeats, 450 trinucleotide repeats, 460 trinucleotide repeats, 470 trinucleotide repeats, 480 trinucleotide repeats, 490 trinucleotide repeats, 500 trinucleotide repeats, 510 trinucleotide repeats, 520 trinucleotide repeats, 530 trinucleotide repeats, 540 trinucleotide repeats, 550 trinucleotide repeats, 560 trinucleotide repeats, 570 trinucleotide repeats, 580 trinucleotide repeats, 590 trinucleotide repeats, 600 trinucleotide repeats, 610 trinucleotide repeats, 620 trinucleotide repeats, 630 trinucleotide repeats, 640 trinucleotide repeats, 650 trinucleotide repeats, 660 trinucleotide repeats, 670 trinucleotide repeats, 680 trinucleotide repeats, 690 trinucleotide repeats, 700 trinucleotide repeats, 710 trinucleotide repeats, 720 trinucleotide repeats, 730 trinucleotide repeats, 740 trinucleotide repeats, 750 trinucleotide repeats, 760 trinucleotide repeats, 770 trinucleotide repeats, 780 trinucleotide repeats, 790 trinucleotide repeats, 800 trinucleotide repeats, 810 trinucleotide repeats, 820 trinucleotide repeats, 830 trinucleotide repeats, 840 trinucleotide repeats, 850 trinucleotide repeats, 860 trinucleotide repeats, 870 trinucleotide repeats, 880 trinucleotide repeats, 890 trinucleotide repeats, 900 trinucleotide repeats, 910 trinucleotide repeats, 920 trinucleotide repeats, 930 trinucleotide repeats, 940 trinucleotide repeats, 950 trinucleotide repeats, 960 trinucleotide repeats, 970 trinucleotide repeats, 980 trinucleotide repeats, 990 trinucleotide repeats, 1 ,000 trinucleotide repeats, 1 ,100 trinucleotide repeats, 1 ,200 trinucleotide repeats, 1 ,300 trinucleotide repeats, 1 ,400 trinucleotide repeats, 1 ,500 trinucleotide repeats, 1 ,600 trinucleotide repeats, 1 ,700 trinucleotide repeats, 1 ,800 trinucleotide repeats, 1 ,900 trinucleotide repeats, 2,000 trinucleotide repeats, 2,100 trinucleotide repeats, 2,200 trinucleotide repeats, 2,300 trinucleotide repeats, 2,400 trinucleotide repeats, 2,500 trinucleotide repeats, 2,600 trinucleotide repeats,
2,700 trinucleotide repeats, 2,800 trinucleotide repeats, 2,900 trinucleotide repeats, 3,000 trinucleotide repeats, 3,100 trinucleotide repeats, 3,200 trinucleotide repeats, 3,300 trinucleotide repeats, 3,400 trinucleotide repeats, 3,500 trinucleotide repeats, 3,600 trinucleotide repeats, 3,700 trinucleotide repeats,
3,800 trinucleotide repeats 3,900 trinucleotide repeats, or 4,000 trinucleotide repeats, among others). As used herein, the term“RNA dominance” refers to a pathology that is induced by the expression and nuclear retention of RNA transcripts containing expanded repeat regions relative to the quantity of repeat regions, if any, contained by a wild-type form of the RNA transcript of interest. The toxic effects of RNA dominance are a manifestation, for example, of the binding interaction between the expanded repeat regions of the pathologic, mutant RNA transcripts with splicing factor proteins, which promotes the sequestration of splicing factors away from pre-mRNA transcripts, thereby engendering spliceopathy among such substrates. Exemplary disorders associated with RNA dominance are myotonic dystrophy and amyotrophic lateral sclerosis, as described herein, among others.
As used herein, the term“sample” refers to a specimen (e.g., blood, blood component (e.g., serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g., placental or dermal), pancreatic fluid, chorionic villus sample, or cells) isolated from a subject. The subject may be, for example, a patient suffering from a disease described herein, such as a heritable muscle wasting disorder (e.g., muscular dystrophy, such as myotonic dystrophy (e.g., myotonic dystrophy type I).
As used herein, the phrases“specifically binds” and“binds” refer to a binding reaction which is determinative of the presence of a particular molecule, such as an RNA transcript, in a heterogeneous population of ions, salts, small molecules, and/or proteins that is recognized, e.g., by a ligand or receptor, such as an RNA-binding splicing factor protein, with particularity. A ligand (e.g., an RNA-binding protein described herein) that specifically binds to a species (e.g., an RNA transcript) may bind to the species, e.g., with a KD of less than 1 mM. For example, a ligand that specifically binds to a species may bind to the species with a KD of up to 100 mM (e.g., between 1 pM and 100 mM). A ligand that does not exhibit specific binding to another molecule may exhibit a KD of greater than 1 mM (e.g., 1 pM, 100 pM, 500 pM,
1 mM, or greater) for that particular molecule or ion. A variety of assay formats may be used to determine the affinity of a ligand for a specific protein. For example, solid-phase ELISA assays are routinely used to identify ligands that specifically bind a target protein. See, e.g., Harlow & Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1988) and Harlow & Lane, Using Antibodies, A Laboratory Manual, Cold Spring Harbor Press, New York (1999), for a description of assay formats and conditions that can be used to determine specific protein binding.
As used herein, the term“spliceopathy” refers to a change in the splicing pattern of an mRNA transcript that leads to the expression of one or more alternative splice products relative to a wild-type form of the mRNA transcript of interest. Spliceopathy can lead to a toxic loss of function if, for example, the mRNA transcript is spliced in such a way that one or more exons necessary for the activity of the encoded protein are no longer present in the mRNA transcript upon translation. Additionally or alternatively, toxic loss of function may occur due to the aberrant inclusion of one or more introns, for example, in a manner that precludes the proper folding of the encoded protein. As used herein, the terms“subject” and“patient” refer to an organism that receives treatment for a particular disease or condition as described herein (such as a heritable muscle-wasting disorder, e.g., myotonic dystrophy). Examples of subjects and patients include mammals, such as humans, receiving treatment for a disease or condition described herein.
As used herein, the term“transcription regulatory element” refers to a nucleic acid that controls, at least in part, the transcription of a gene of interest. Transcription regulatory elements may include promoters, enhancers, and other nucleic acids (e.g., polyadenylation signals) that control or help to control gene transcription. Examples of transcription regulatory elements are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185 (Academic Press, San Diego, CA, 1990).
As used herein, the terms“treat” or“treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of a heritable muscle-wasting disorder, for example, myotonic dystrophy, and particularly, type I myotonic dystrophy. In the context of myotonic dystrophy treatment, beneficial or desired clinical results that are indicative of successful treatment include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e. , not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. Treatment of a patient having myotonic dystrophy (e.g., type I myotonic dystrophy may manifest in one or more detectable changes, such as a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions (e.g., a decrease in the expression of DMPK RNA transcripts that contain expanded CUG trinucleotide repeat regions of 1 % or more, such as a decrease of 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%,
25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, relative to the expression of DMPK RNA transcripts containing expanded CUG trinucleotide repeat regions by the patient prior to administration of a therapeutic agent, such as a vector or nucleic acid described herein.
Methods that can be used to assess RNA expression levels are known in the art and include RNA-seq assays and polymerase chain reaction techniques described herein. Additional clinical indications of successful treatment of a CPVT patient include alleviation of spliceopathy, for example, of an RNA transcript that is spliced in a manner that is dependent upon muscleblind-like protein. For example, observations that signal successful treatment of a patient having myotonic dystrophy include a finding that the patient exhibits an increase in corrective splicing of one or more RNA transcript substrates of muscleblind-like protein following administration of a therapeutic agent, such as a therapeutic agent described herein. For example, indicators that signal successful treatment of myotonic dystrophy include a determination that the patient exhibits an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold,
1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold,
2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold,
3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold,
4.8-fold, 4.9-fold, 5-fold, 5.1 -fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6- fold, 6.1 -fold, 6.2-fold, 6.3-fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7-fold, 7.1 -fold, 7.2- fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6-fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2-fold, 8.3-fold, 8.4- fold, 8.5-fold, 8.6-fold, 8.7-fold, 8.8-fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5-fold, 9.6- fold, 9.7-fold, 9.8-fold, 9.9-fold, 10-fold, or more), as assessed, for example, using an RNA or protein detection assay described herein. Treatment of myotonic dystrophy may also manifest as a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about
1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,
21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%,
39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51 %, 52%, 53%, 54%, 55%, 56%,
57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%,
75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), as assessed, for example, using an RNA or protein detection assay described herein. Additionally, successful treatment may be signaled by a determination that the patient exhibits a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , such as a decrease of about 1 % to about 100% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%,
16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31 %, 32%, 33%,
34%, 35%, 36%, 37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51 %,
52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%,
70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%,
88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), as assessed, for example, using an RNA or protein detection assay described herein. Successful treatment of myotonic dystrophy may also be signaled by a finding that, following the therapy, the patient exhibits an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor,
RYR1 , cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1.4- fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6- fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8- fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5- fold, 5.1 -fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6-fold, 6.1 -fold, 6.2- fold, 6.3-fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7-fold, 7.1 -fold, 7.2-fold, 7.3-fold, 7.4- fold, 7.5-fold, 7.6-fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2-fold, 8.3-fold, 8.4-fold, 8.5-fold, 8.6- fold, 8.7-fold, 8.8-fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5-fold, 9.6-fold, 9.7-fold, 9.8- fold, 9.9-fold, 10-fold, or more), as assessed, for example, using an RNA or protein detection assay described herein. Additional clinical indications of successful treatment of myotonic dystrophy include improvements in muscle function, such as in the cranial, distal limb, and diaphragm muscles.
As used herein, the term“vector” refers to a nucleic acid, e.g., DNA or RNA, that may function as a vehicle for the delivery of a gene of interest into a cell (e.g., a mammalian cell, such as a human cell), tissue, organ, or organism, such as a patient undergoing treatment for a disease or condition described herein, for purposes of expressing an encoded transgene. Exemplary vectors useful in conjunction with the compositions and methods described herein are plasmids, DNA vectors, RNA vectors, virions, or other suitable replicon (e.g., viral vector). A variety of vectors have been developed for the delivery of polynucleotides encoding exogenous proteins into a prokaryotic or eukaryotic cell. Examples of such expression vectors are disclosed in, e.g., WO 1994/1 1026, the disclosure of which is incorporated herein by reference. Expression vectors described herein contain a polynucleotide sequence as well as, e.g., additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell. Certain vectors that can be used for the expression of transgenes described herein include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription. Other useful vectors for expression of transgenes contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements include, e.g., 5’ and 3’ untranslated regions, an internal ribosomal entry site (IRES), and polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector. The expression vectors described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, or nourseothricin.
Brief Description of the Figures
FIG. 1 is a diagram showing the structure of human dystrophia myotonica protein kinase (DMPK) RNA, including the configuration of exons (represented by shaded rectangular boxes) and the site of the CUG trinucleotide repeat region. Numerical values from 600 to 12,600 along the bottom of the figure indicate nucleotide position along the length of the DMPK RNA transcript. The diagram shows the regions within the DMPK RNA transcript to which various exemplary interfering RNA constructs described herein anneal by way of sequence complementarity.
FIGS. 2A - 2C are diagrams showing the schematics of three generations of rAAV vectors encoding interfering RNA molecules (rAAV-RNAi vectors) targeting several genes of interest, such as those associated with RNA dominance. The rAAV plasmid pARAP4 includes the human alkaline phosphatase reporter gene (Hu Aik Phos) reporter gene, expressed from the Rous Sarcoma Virus (RSV) promoter, and the SV40 polyadenylation sequence, pA. The inverted terminal repeats (ITRs) originate from rAAV2, and the genomes are packaged in rAAV6 capsids. The newest vector modification removes the RSV promoter sequence to prevent Hu Aik Phos expression that limited rAAV-RNAi efficacy at higher doses due muscle cell toxicity.
FIG. 3A is a diagram showing exemplary routes of administration of rAAV-RNAi vectors into murine models of RNA dominance disorders, such as myotonic dystrophy.
FIGS. 3B and 3C are diagrams comparing various characteristics of myotonic dystrophy type I (DM1 ) and the murine HSALR model of this disease. HSALR mice show characteristics of myotonic dystrophy resembling DM in humans. The HSALR transgene is derived from insertion of a (CTG)2so repeat in the 3’ UTR of the human skeletal actin (HSA) gene. When the transgene is expressed in mouse skeletal muscle, myotonic discharges are evident, splicing alterations occur in a variety of mRNAs, and nuclear foci containing the expanded transgenic mRNA and splicing factors are present.
FIG. 4 is a diagram showing the characteristics of HSALR mice transduced with rAAV6 HSA miR DM10, as described in Example 1 , below. Human placental alkaline phosphatase (AP) staining indicates presence of the viral genome with active reporter gene expression. H&E staining of cryosections from treated mice. Timepoint, 8 weeks post-injection, 4 week-old HSALR mice.
FIGS. 5A and 5B are graphs quantifying HSA mRNA and expression of the HSA miRDMI 0 in seven individual HSALR mice transduced as described in Example 1 , below. mRNA expression shown was assessed by qPCR at 8 weeks post-rAAV injection.
FIGS. 6A - 6E are diagrams demonstrating that rAAV6 HSA miR DM10 systemic injection improves splicing of Atp2a (SERCA1 ) and CLCN1 in the tibialis anterior (TA) muscle, as described in Example 1 , below. In contrast, a different RNAi hairpin, miR DM4, is not as effective at reversing these splicing defects.
FIGS. 7A - 7C are diagrams showing the structure and activity of re-engineered rAAV-miR DM10 and -miR DM4 evaluated in vivo. Intramuscular injection of vectors without the RSV promoter to prevent
Hu Aik Phos expression to assess the efficacy of gene silencing compared to the previously tested Aik
Phos expressing vectors. FIG. 7A shows a schematic diagram of the rAAV genome lacking the RSV promoter sequence as the‘new DM10’ and‘new DM4’ labeled on the gels in FIG. 7B. FIG. 7B shows analysis of splicing patterns for Atp2a1/Serca1 following IM injection of ‘new DM10’ and‘new DM4’ into the TA muscle compared to Aik Phos expressing‘old DM10.’ L= low dose of 5x109 vector genomes; H= high dose of 5x1010 vector genomes. no RSV promoter; +, RSV present in vector genome. The high dose was chosen because it elicited some muscle regeneration as marked by the presence of central nuclei (CN) with IM injection of Hu Aik Phos expressing vectors. However, no evidence of muscle turnover was observed at this high dose of rAAV DM10 lacking RSV, new DM10 and new DM4.
FIG. 8A is a diagram showing how purified plasmids expressing the DMPK-targeting miRNAs were transfected into HEK293 cells and RNA was isolated and subjected to RT-qPCR to evaluate DMPK transcript engagement by the RISC complex and Dicer cleavage.
FIG. 8B is a graph showing the evaluation of the gene silencing activity of U6 DMPK miRNAs. Candidate therapeutic miRNA expression cassettes a and b showed reduction of the endogenous DMPK mRNA 48hrs after transfection of HEK293 cells with 1.5 pg of plasmid DNA compared to a plasmid with no miRNA expression cassette. Eight biological replicates were assayed per plasmid and control. Along the x-axis,“a” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 42 and a guide strand having the nucleic acid sequence of SEQ ID NO: 79;“b” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 44 and a guide strand having the nucleic acid sequence of SEQ ID NO: 81 ;“c” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 46 and a guide strand having the nucleic acid sequence of SEQ ID NO: 83;“d” represents a miRNA containing a passenger strand having the nucleic acid sequence of SEQ ID NO: 47 and a guide strand having the nucleic acid sequence of SEQ ID NO: 84; and“none” represents cells not treated with an anti-DMPK miRNA.
FIG. 9 is a graph showing the ability of various siRNA molecules described herein to
downregulate DMPK expression in HEK293 cells, as described in Example 4, below. Values along the y- axis represent normalized DMPK expression, and the x-axis shows the anti-DMPK siRNA molecules tested. The first entry on the x-axis corresponds to treatment of HEK293 cells with transfection vehicle only, and the second entry on the x-axis represents treatment with an siRNA having a scrambled nucleic acid sequence as a negative control. siRNA molecules having a specified sequence identifier number are described herein, for example, in Table 4, below. siRNA molecules labeled“Anti-DMPK” followed by an alphanumeric identifier are commercially available from Thermo Fisher Scientific.
Detailed Description
The compositions and methods described herein are useful for reducing the occurrence of spliceopathy and for treating disorders associated with ribonucleic acid (RNA) dominance, such as myotonic dystrophy and amyotrophic lateral sclerosis, among others. The compositions described herein include nucleic acids containing interfering RNA constructs that suppress the expression of RNA transcripts containing aberrantly expanded repeat regions. This activity provides an important physiological benefit, as various RNA transcripts harboring such repeat expansions exhibit a heightened avidity for RNA splicing factors. This avidity manifests in sequestration of RNA splicing factors away from other pre-mRNA substrates, thereby disrupting the proper splicing of these transcripts. Without being limited by mechanism, the compositions described herein may ameliorate this pathology by diminishing the expression of RNA transcripts harboring expanded nucleotide repeats, thus releasing sequestered splicing factors so that they may properly regulate the splicing of various other pre-mRNA transcripts. For example, the compositions and methods described herein may be used to treat disorders, such as myotonic dystrophy, associated with expression of dystrophia myotonica protein kinase (DMPK) RNA transcripts containing an expanded CUG trinucleotide repeat region. Similarly, the compositions and methods described herein may be used to treat amyotrophic lateral sclerosis, characterized by elevated expression of C90RF72 RNA transcripts containing GGGGCC (SEQ ID NO: 162) hexanucleotide repeats.
The interfering RNA constructs described herein may be in any of a variety of forms, such as short interfering RNA (siRNA), short hairpin RNA (shRNA), or micro RNA (miRNA). The interfering RNAs described herein may additionally be encoded by a vector, such as a viral vector. For example, described herein are adeno-associated viral (AAV) vectors, such as pseudotyped AAV vectors (e.g., AAV2/8 and AAV2/9 vectors) containing transgenes encoding interfering RNA constructs that attenuate the expression of RNA transcripts harboring expanded nucleotide repeats.
The compositions and methods described herein provide, among other benefits, the
advantageous feature of being able to selectively suppress the expression of pathologic RNA transcripts among other RNAs that contain expanded nucleotide repeat regions. This property is particularly beneficial in view of the prevalence of nucleotide repeats in mammalian genomes, such as in the genomes of human patients. Using the compositions and methods described herein, the expression of RNA transcripts that contain pathological nucleotide repeat expansions can be diminished, while preserving the expression of important healthy RNA transcripts and their encoded protein products.
This advantageous feature is based, in part, on the surprising discovery that interfering RNA constructs that anneal to repeat-expanded RNA targets at sites remote from the expanded repeat region can be used to suppress the expression of these RNA transcripts and release splicing factor proteins that would otherwise be sequestered by these molecules. The compositions and methods described herein can thus attenuate the expression and nuclear retention of pathological RNA transcripts without the necessity of containing complementary nucleotide repeat motifs.
The sections that follow provide a description of exemplary interfering RNA constructs that may be used in conjunction with the compositions and methods described herein, as well as a description of vectors encoding such constructs and procedures that may be used to treat disorders associated with spliceopathy, such as myotonic dystrophy and amyotrophic lateral sclerosis. Methods of Treating RNA Dominance and Correcting Spliceopathy
Using the compositions and methods described herein, a patient experiencing a spliceopathy and/or having a disease associated with RNA dominance, such as myotonic dystrophy, among others, can be administered a nucleic acid containing an interfering RNA construct, or a vector encoding the same, so as to reduce the expression of RNA transcripts containing expanded repeat regions. Without being limited by mechanism, this activity provides the beneficial effect of releasing RNA-binding proteins that bind with high avidity to the repeat expansion regions of pathologic RNA transcripts. The release of such RNA-binding proteins is important, as the proteins sequestered by binding to repeat-expanded RNA transcripts include splicing factors that would ordinarily be available to modulate the proper splicing of various pre-mRNA transcripts. In patients having RNA dominance disorders, such as myotonic dystrophy, splicing factors such as muscleblind-like protein, which regulates the splicing of various transcripts that encode proteins having important roles in regulating muscle function, are sequestered from important pre-mRNA substrates. The compositions and methods described herein may treat RNA dominance disorders by promoting the degradation of RNA transcripts containing expanded nucleotide repeat regions, thereby effectuating the release of significant RNA-binding proteins from such transcripts.
Myotonic Dystrophy Type I
Myotonic dystrophy type I is the most common form of muscular dystrophy in adults, and occurs with an estimated frequency of 1 in 7,500 (Harper P S., Myotonic Dystrophy. London: W.B. Saunders Company; 2001 ). This disease is an autosomal dominant disorder caused by expansion of a non-coding CTG repeat in the human DMPK1 gene. DMPK1 is a gene encoding a cytosolic serine/threonine kinase (Brook et al. , Cell. 68:799-808 (1992)). The expanded CTG repeat is located in the 3' untranslated region (UTR) of DMPK1 . This mutation leads to RNA dominance, a process in which expression of RNA containing an expanded CUG repeat (CUGexp) induces cell dysfunction (Osborne R J and Thornton C A., Human Molecular Genetics. 15:R162-R169 (2006)).
The mutant form of the DMPK mRNA, harboring large CUG repeats, are fully transcribed and polyadenylated, but remain trapped in the nucleus (Davis et al., Proc. Natl. Acad. Sci. U.S.A 94:7388-
7393 (1997)). These mutant, nuclear-retained mRNAs are one of the most important pathological features of myotonic dystrophy type I. The DMPK gene normally has from about 5 to about 37 CTG repeats in the 3' UTR. In myotonic dystrophy type I, this number is significantly expanded, and may be in the range, for example, of from 50 to greater than 4,000 repeats. The CUGexp tract in the ensuing RNA transcript interacts with RNA-binding splicing factor proteins, including muscleblind-like protein. The enhanced avidity engendered by the expanded CUG repeat region causes the mutant transcript to retain such splicing factor proteins in nuclear foci. The toxicity of this mutant RNA stems from the sequestration of RNA-binding splicing factor proteins away from other pre-mRNA substrates, including those that encode proteins that have important roles in regulating muscle function.
In myotonic dystrophy type I, skeletal muscle is the most severely affected tissue, but the disease also has important effects on cardiac and smooth muscle, ocular lens, and the brain. Among muscle tissue, the cranial, distal limb, and diaphragm muscles are often preferentially affected. Manual dexterity is compromised early, which causes several decades of severe disability. The median age at death is 55 years, which usually from respiratory failure (de Die-Smulders C E, et al. , Brain 121 (Pt 8):1557-1563 (1998)). Symptoms of myotonic dystrophy include, without limitation, myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids (ptosis), weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts. In children, symptoms may also include
developmental delays, learning problems, language and speech difficulties, and personality development challenges.
Pathogenic DMPK Transcripts
Myotonic dystrophy patients that may be treated using the compositions and methods described herein include patients, such as human patient, having myotonic dystrophy type I, and that express a DMPK RNA transcript harboring a CUG repeat expansion. Exemplary DMPK RNA transcripts that may be expressed by a patient undergoing treatment with the compositions and methods described herein are set forth in GenBank Accession Nos. NM_001081560.1 , NT_01 1 109.15 (from nucleotides 18540696 to 18555106), NT 039413.7 (from nucleotides 16666001 to 16681000), NM_032418.1 , AI007148.1 , AI304033.1 , BC024150.1 , BC056615.1 , BC075715.1 , BU519245.1 , CB247909.1 , CX208906.1 , CX732022.1 , 560315.1 , 560316.1 , NM_001081562.1 , and NM_001 100.3.
Suppression of Pathologic DMPK RNA Expression
Using the compositions and methods described herein, a patient, such as a patient suffering from myotonic dystrophy (e.g., myotonic dystrophy type I) may be administered a vector encoding, or a composition containing, an interfering RNA that anneals to and suppresses the expression of pathologic
DMPK mRNA transcripts. The compositions and methods described herein may selectively attenuate the expression of DMPK mRNA transcripts containing expanded CUG repeats, such as DMPK mRNA transcripts containing from about 50 to about 4,000, or more, CUG repeats. For example, the interfering
RNA molecules described herein may activate ribonucleases, such as nuclear ribonucleases, that specifically digest nuclear-retained DMPK transcripts harboring CUG repeat expansions. The decrease in mutant DMPK mRNA expression may be a decrease of, for example, about 1 % or more, such as a decrease of 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, relative to the expression of DMPK mRNA transcripts containing expanded CUG trinucleotide repeat regions by the patient prior to administration of a therapeutic agent described herein, such as a vector or nucleic acid described herein. Methods that can be used to assess RNA expression levels are known in the art and include RNA-seq assays and polymerase chain reaction techniques described herein.
Correction of Spliceopathy
In some embodiments, the compositions and methods described herein can be used to correct one or more spliceopathies in a patient, such as a patient suffering from myotonic dystrophy (e.g., myotonic dystrophy type I). Without being limited by mechanism, the ability of the interfering RNA molecules described herein to anneal to, and suppresses the expression of, pathologic DMPK transcripts (e.g., DMPK transcripts containing expanded CUG repeat regions) can release splicing factors, such as muscleblind-like protein, that would otherwise be sequestered by way of binding to the CUG repeats.
This release of splicing factors may, in turn, effectuate corrective splicing of one or more RNA transcript substrates of these splicing factors. For example, upon administration of the vector or composition to a patient suffering from myotonic dystrophy, the patient may exhibit an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA containing exon 22, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles. The increase in expression of SERCA1 mRNA transcripts containing exon 22 may be an increase of, for example, about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of SERCA1 mRNA containing exon 22 by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold, 1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold,
3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4-fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold,
4.7-fold, 4.8-fold, 4.9-fold, 5-fold, 5.1 -fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold,
5.9-fold, 6-fold, 6.1 -fold, 6.2-fold, 6.3-fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7-fold, 7.1 - fold, 7.2-fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6-fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2-fold, 8.3- fold, 8.4-fold, 8.5-fold, 8.6-fold, 8.7-fold, 8.8-fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5- fold, 9.6-fold, 9.7-fold, 9.8-fold, 9.9-fold, 10-fold, or more), as assessed, for example, using an RNA or protein detection assay described herein.
In some embodiments, upon administration of a vector or composition described herein to a patient suffering from myotonic dystrophy, the patient may exhibit a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA containing exon 7a, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles. The decrease in expression of CLCN1 mRNA transcripts containing exon 7a may be a decrease of, for example, about 1 % to about 100% (e.g., a decrease in expression of CLCN1 mRNA containing exon 7a by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%,
47%, 48%, 49%, 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%,
65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or
100%), as assessed, for example, using an RNA or protein detection assay described herein.
Additionally or alternatively, upon administration of a vector or composition described herein to a patient suffering from myotonic dystrophy, the patient may exhibit a decrease in expression of ZO-2 associated speckle protein (ZASP) containing exon 1 1 , for example, in the tibialis anterior,
gastrocnemius, and/or quadriceps muscles. The decrease in expression of ZASP mRNA transcripts containing exon 1 1 may be a decrease of, for example, about 1 % to about 1 00% (e.g., a decrease in expression of ZASP mRNA containing exon 1 1 by about 1 %, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 1 1 %, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21 %, 22%, 23%, 24%, 25%, 26%, 27%, 28%,
29%, 30%, 31 %, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41 %, 42%, 43%, 44%, 45%, 46%,
47%, 48%, 49%, 50%, 51 %, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%,
65%, 66%, 67%, 68%, 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81 %, 82%,
83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), as assessed, for example, using an RNA or protein detection assay described herein.
Additionally or alternatively, upon administration of a vector or composition described herein to a patient suffering from myotonic dystrophy, the patient may exhibit an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 (RYR1 ), cardiac muscle troponin, and/or skeletal muscle troponin, such as an increase of about 1 .1 -fold to about 10-fold, or more (e.g., an increase in expression of correctly spliced RNA transcripts encoding insulin receptor, RYR1 , cardiac muscle troponin, and/or skeletal muscle troponin by about 1 .1 -fold, 1 .2-fold, 1 .3-fold, 1 .4-fold, 1 .5-fold,
1 .6-fold, 1 .7-fold, 1 .8-fold, 1 .9-fold, 2-fold, 2.1 -fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1 -fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4- fold, 4.1 -fold, 4.2-fold, 4.3-fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5-fold, 5.1 -fold, 5.2- fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6-fold, 6.1 -fold, 6.2-fold, 6.3-fold, 6.4- fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7-fold, 7.1 -fold, 7.2-fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6- fold, 7.7-fold, 7.8-fold, 7.9-fold, 8-fold, 8.1 -fold, 8.2-fold, 8.3-fold, 8.4-fold, 8.5-fold, 8.6-fold, 8.7-fold, 8.8- fold, 8.9-fold, 9-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5-fold, 9.6-fold, 9.7-fold, 9.8-fold, 9.9-fold, 10- fold, or more), as assessed, for example, using an RNA or protein detection assay described herein. Improvement in Muscle Function
The beneficial treatment effects of the compositions and methods described herein, such as the ability of the interfering RNA molecules described herein, and the vectors encoding the same, to (i) suppress pathologic DMPK RNA expression and/or (ii) restore correct splicing of proteins involved in regulating muscle function may manifest clinically in a variety of ways. For example, patients having myotonic dystrophy, such as myotonic dystrophy type I, may exhibit an improvement in cranial, distal limb, and/or diaphragmatic muscle function. The improvement in muscle function may be observed, for example, as an increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions. For example, using the compositions and methods described herein, a patient suffering from myotonic dystrophy (e.g., myotonic dystrophy type I) may exhibit an increase in cranial, distal limb, and/or diaphragmatic muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions. The increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions may be, for example, an increase of 1 % or more, such as an increase of from 1 % to 25%, from 1 % to 50%, from 1 % to 75%, from 1 % to 100%, from 1 % to 500%, from 1 % to 1 ,000%, or more, such as an increase in muscle mass, frequency of muscle contractions, and/or magnitude of muscle contractions of about 1 %, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 80%, 900%, 1 ,000%, or more.
Particularly, in patients having myotonic dystrophy (e.g., myotonic dystrophy type I), the beneficial therapeutic effects of the interfering RNA molecules described herein, and of the vectors encoding the same, may manifest as a reduction in myotonia. Thus, using the compositions and methods described herein, a patient having myotonic dystrophy (e.g., myotonic dystrophy type I) may be administered an interfering RNA molecule or vector encoding the same so as to facilitate and/or accelerate muscle relaxation. For example, the compositions and methods described herein may be used to accelerate muscle relaxation by suppressing the onset of spontaneous action potentials caused by fluctuations in chloride ion concentration. Without being limited by mechanism, this beneficial activity may be caused by the restoration of correct splicing of CLCN1 mRNA, for example, such that the expression of CLCN1 mRNA containing exon 7a in the patient is reduced. As CLCN1 channel protein regulates chloride ion concentration, correcting the splicing pattern of CLCN1 mRNA transcripts may engender a reduction in the onset of spontaneous action potentials and an improvement in muscle relaxation speed, thereby ameliorating myotonia.
Suppression of myotonia can be evaluated using a variety of techniques known in the art, for example, by way of electromyography. Particularly, electromyography on the left and right quadriceps, left and right gastrocnemius muscles, left and right tibialis anterior muscles, and/or lumbar paraspinals muscles can be performed to assess the effects of the compositions and methods described herein on myotonia in a patient, such as a human patient having myotonic dystrophy. Electromyography protocols have been described, for example, in Kanadia et al., Science 302:1978-1980 (2003)). For example, electromyography may be performed using 30-gauge concentric needle electrodes and a minimum of 10 needle insertions for each muscle. In this way, an average myotonia grade may be determined for a subject, such as a human patient or a model organism (e.g., a murine model of muscular dystrophy described herein). This grade can then be compared to the average myotonia grade of the patient or model organism determined prior to administration of a therapeutic agent described herein (e.g., an interfering RNA molecule or a vector encoding the same). A finding that the average myotonia grade has decreased following administration of the therapeutic agent can serve as an indication of successful treatment of myotonic dystrophy and as an indicator of successful amelioration of the symptom of myotonia.
Amelioration of Additional Myotonic Dystrophy Symptoms
Using the compositions and methods described herein, a patient having myotonic dystrophy, such as myotonic dystrophy type 1 , may be administered an interfering RNA molecule or vector encoding the same so as to attenuate or altogether eliminate one or more symptoms of myotonic dystrophy. Aside from the myotonia described above, symptoms of myotonic dystrophy include, without limitation, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, ptosis, weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts. In children, symptoms may also include
developmental delays, learning problems, language and speech difficulties, and personality development challenges. The compositions and methods described herein may be used to alleviate one or more, or all, of the foregoing symptoms.
Duration of Therapeutic Effects
The compositions and methods described herein provide beneficial clinical effects that may last for extended periods of time. For example, using one or more of the interfering RNA molecules described herein, and/or vector(s) encoding the same, a patient having myotonic dystrophy (e.g., myotonic dystrophy type I) may exhibit (i) a reduction in pathologic DMPK RNA expression (e.g., a reduction in expression of DMPK RNA harboring from about 50 to about 4,000 CUG repeats, or more), (ii) an improvement in muscle function (such as an improvement in muscle mass and/or muscle activity, e.g., in the cranial, distal limb, and diaphragm muscle) and/or (iii) alleviation of one or more symptoms of myotonic dystrophy, for a period of one or more days, weeks, months, or years. For example, using the compositions and methods described herein, the beneficial therapeutic effects described herein may be achieved for a period of at least 30 days, at least 35 days, at least 40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 76 days, at least 77 days, at least 78 days, at least 79 days, at least 80 days, at least 85 days, at least 90 days, at least 95 days, at least 100 days, at least 105 days, at least 1 10 days, at least 1 15 days, at least 120 days, or at least 1 year.
Murine Models of Myotonic Dystrophy
To examine the therapeutic effects of an interfering RNA molecule described herein, or those of a vector encoding the same, an appropriate mouse model may be utilized. For example, the HSA (human skeletal actin) LR (long repeat) mouse model is an established model for myotonic dystrophy type 1 (see, e.g., Mankodi et al., Science 289:1769 (2000), the disclosure of which is incorporated herein by reference as it pertains to the HSALR mouse. These mice carry a human skeletal actin (hACTAI ) transgene containing an expanded CTG region. Particularly, the hACTAI transgene in HSALR mice contains 220 CTG repeats inserted in the 3' UTR of the gene. Upon transcription, the hACTAI -CUGexp RNA transcript accumulates in nuclear foci in skeletal muscles and results in myotonia similar to that observed in human myotonic dystrophy type 1 , for example, due to the binding of CUG repeat expansions to splicing factors and the sequestration of these splicing factors from pre-mRNA transcripts encoding genes that play an important role in regulating muscle function (see, e.g., Mankodi et al., Mol. Cell 10:35 (2002), and Lin et al., Hum. Mol. Genet. 15:2087 (2006), the disclosures of each of which are incorporated herein by reference as they pertain to the HSALR mouse). Thus, amelioration of myotonic dystrophy type I symptoms in the HSALR mouse by suppression of the expression of hACTAI RNA transcripts harboring CUG expanded repeat regions may be a predictor of amelioration of similar symptoms in human patients by suppression of the expression of pathologic DMPK RNA transcripts. HSALR myotonic dystrophy type I mice can be generated using methods known in the art, for example, by insertion into the genome of FVB/N mice of a hACTAI transgene with 250 CUG repeats in the 3' UTR of human skeletal actin. The transgene is subsequently expressed in the mice as a CUG repeat expansion in hACTAI RNA. This repeat-expanded RNA is retained in the nucleus, forming nuclear inclusions similar to those observed in human tissue samples of patients with myotonic dystrophy.
As described above, in the HSALR mouse model, the accumulation of expanded CUG RNA in the nucleus leads to the sequestration of poly(CUG)-binding splicing factor proteins, such as muscleblind-like protein (Miller et al., EMBO J. 19:4439 (2000)). This splicing factor, which controls alternative splicing of the SERCA1 gene, is thus sequestered in expanded CUG foci in HSALR mice. This sequestration triggers dysregulation of the alternative splicing of the SERCA1 gene. To evaluate the therapeutic effect of the interfering RNA molecules described herein, and/or of vectors encoding the same, these compositions may be designed so as to anneal to a region of the hACTAI RNA transcript, for example, at a site distal from the CUG repeat expansion. This may be accomplished, for example, by designing an interfering
RNA molecule that is at least 85% complementary (e.g., at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, or 100% complementary) to a segment of hACTAI RNA that does not overlap with the CUG repeat expansion region. The suppression of repeat-expanded hACTAI RNA, and the concomitant increase in correctly spliced SERCA1 mRNA (and, thus, functional SERCA1 protein), can then be assessed using RNA and protein detection methods known in the art and described herein. For example, to monitor an increase in the expression of correctly spliced SERCA1 mRNA transcripts (e.g., SERCA1 mRNA transcripts containing exon 22, following administration of an interfering RNA molecule designed to anneal to, and suppress the expression of, pathologic hACTAI RNA, total RNA may be purified from the HSALR mouse at one or more, or all, of the tibialis anterior, gastrocnemius, and quadriceps muscle using the RNeasy Lipid Tissue Mini Kit (Qiagen®), according to the manufacturer's instructions. RT-PCR may be performed with, for example, the Superscript III One-Step RT-PCR System and Platinum Taq Polymerase (Invitrogen®), using gene-specific primers for cDNA synthesis and PCR amplification. The forward and reverse primers for SERCA1 have been described, for example, in Bennett and Swayze, Annu Rev. Pharmacol. 50:259-293 (2010)). PCR products may be separated on agarose gels, stained with SybrGreen I Nucleic Acid Gel Stain (Invitrogen®), and imaged using a Fujifilm LAS-3000 Intelligent Dark Box. Restoration of correct splicing of the SERCA1 gene by an interfering RNA molecule, or vector encoding the same, for example, in the tibialis anterior, gastrocnemius, and/or quadriceps muscles of the HSALR mouse, may be a predictor of the therapeutic efficacy of an interfering RNA molecule, or vector encoding the same, that anneals to a similar site on human DMPK RNA.
Additional murine models of myotonic dystrophy include LC15 mice, Line A, which are transgenic mice containing the entire human DMPK 3'UTR (developed by Wheeler et al, University of Rochester). These mice are the second generation of mice backcrossed to an FVB background. The DMPK transgene is expressed in these mice as a CUG repeat in the DMPK RNA transcript, which is retained in the nucleus, thereby forming nuclear inclusions similar to those observed in human tissue samples of patients with myotonic dystrophy. LC15 mice may express DMPK RNA transcripts containing from about 350 to about 400 CUG repeats. These mice display early signs of myotonic dystrophy type I and do not display any myotonia in their muscle tissues.
Yet another murine model of myotonic dystrophy that may be used to assess the therapeutic efficacy of an interfering RNA molecule described herein or a vector encoding the same is the DMSXL model. DMSXL mice are generated by way of successive breeding of mice having a high level of CTG repeat instability, and, as a result, DMSXL mice express DMPK RNA transcripts containing >1 ,000 CUG trinucleotide repeats in the 3’ UTR. DMSXL mice and methods for producing the same are described in detail, for example, in Gomes-Pereira et al., PLoS Genet. 3:e52 (2007), and Huguet et al., A, PLoS Genet. 8:e1003043 (2012), the disclosures of each of which are incorporated herein by reference in their entirety. Additional Disorders Characterized by Nuclear Retention of Repeat- Expanded RNA
In addition to myotonic dystrophy type I, disorders characterized by the expression and nuclear retention of RNA transcripts harboring expanded repeat regions and that may be treated using the compositions and methods described herein include myotonic dystrophy type II and amyotrophic lateral sclerosis, among others. In the case of myotonic dystrophy type II, patients may express a mutant version of the cellular nucleic acid binding protein (CNBP) gene (also known as the zinc finger protein 9 (ZNF9) gene) harboring a CCUG (SEQ ID NO: 164) repeat expansion. In cases of patients having amyotrophic lateral sclerosis, patients may express mutant versions of C90RF72 harboring expanded GGGGCC (SEQ ID NO: 162) repeats. The nucleic acid sequence of several isoforms of C90RF72 mRNA are shown in Table 3, below. In all instances, patients having these disorders may be treated by administration of interfering RNA molecules (or vectors encoding the same) that anneal to and suppress the expression of the mutant RNA transcript, thereby releasing RNA-binding proteins that would ordinarily bind other substrates but are instead sequestered by virtue of high-avidity binding to the repeat expansion regions in the mutant transcripts expressed by such patients. Methods for monitoring the reduction in the expression of nuclear-retained RNA transcripts, such as pathologic CNBP and C90RF72 transcripts harboring CCUG (SEQ ID NO: 164) and GGGGCC (SEQ ID NO: 162) repeats, respectively, include various molecular biology techniques known in the art and described herein.
Table 3. Nucleic acid sequences of exemplary isoforms of C90RF72 mRNA
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Interfering RNA
Using the compositions and methods described herein, a patient having a spliceopathy and/or a disorder characterized by RNA dominance may be administered an interfering RNA molecule, a composition containing the same, or a vector encoding the same, so as to suppress the expression of a mutant RNA transcript containing an expanded repeat region. For example, in the case of myotonic dystrophy type I, the target RNA transcript to be suppressed is human DMPK RNA containing expanded CUG repeat regions in the 3’ UTR of the transcript. In the case of myotonic dystrophy type II, the target RNA transcript to be suppressed is human ZNF9 RNA containing expanded CCUG (SEQ ID NO: 164) repeat regions. In the case of amyotrophic lateral sclerosis, the target RNA transcript to be suppressed is human C90RF72 RNA containing expanded GGGGCC (SEQ ID NO: 162) repeat regions.
Exemplary interfering RNA molecules that may be used in conjunction with the compositions and methods described herein for the treatment of RNA dominance disorders, such as myotonic dystrophy type I and others, are siRNA molecules, miRNA molecules, and shRNA molecules, among others. In the case of siRNA molecules, the siRNA may be single stranded or double stranded. miRNA molecules, in contrast, are single-stranded molecules that form a hairpin, thereby adopting a hydrogen-bonded structure reminiscent of a nucleic acid duplex. In either case, the interfering RNA may contain an antisense or“guide” strand that anneals (e.g., by way of complementarity) to the repeat-expanded mutant RNA target. The interfering RNA may also contain a“passenger” strand that is complementary to the guide strand and, thus, may have the same nucleic acid sequence as the RNA target.
Exemplary interfering RNA molecules that anneal to mutant DMPK containing expanded CUG repeat motifs and that may be used in conjunction with the compositions and methods described herein for the treatment of myotonic dystrophy type I are shown in Table 4, below. A graphical representation of the sites on a target DMPK RNA transcript to which the following interfering RNA molecules anneal by way of sequence complementarity is shown in FIG. 1 .
Table 4. Exemplary RNAi molecules useful for suppressing mutant DMPK RNA expression
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0001
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Exemplary miRNA constructs useful in conjunction with the compositions and methods described herein are those that have a combination of passenger and guide strands shown in Table 5, below. Table 5. Exemplary anti-DMPK miRNA guide strand/passenger strand combinations
Figure imgf000065_0002
Figure imgf000066_0001
Vectors for Delivery of Interfering RNA
Viral Vectors for Interfering RNA Delivery
Viral genomes provide a rich source of vectors that can be used for the efficient delivery of a gene of interest into the genome of a target cell in a patient (e.g., a mammalian cell, such as a human cell). Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes are typically incorporated into the genome of a target cell by generalized or specialized transduction. These processes occur as part of the natural viral replication cycle, and do not require added proteins or reagents in order to induce gene integration. Examples of viral vectors that may be used in conjunction with the compositions and methods described herein are AAV, retrovirus, adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g., influenza virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses, such as picornavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g., vaccinia, modified vaccinia Ankara (MVA), fowlpox and canarypox). Other viruses that may be used in conjunction with the compositions and methods described herein include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis virus, for example. Examples of retroviruses include: avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al ., Eds., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor virus, bovine leukemia virus, feline leukemia virus, feline sarcoma virus, avian leukemia virus, human T-cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia virus, Mason Pfizer monkey virus, simian immunodeficiency virus, simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other examples of vectors are described, for example, in US Patent No. 5,801 ,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene therapy.
AA V Vectors for Interfering RNA Delivery
In some embodiments, interfering RNA constructs described herein are incorporated into recombinant AAV (rAAV) vectors in order to facilitate their introduction into a cell, such as a target cardiac cell (e.g., a muscle cell) in a patient. rAAV vectors useful in the conjunction with the compositions and methods described herein include recombinant nucleic acid constructs that contain (1 ) a transgene encoding an interfering RNA construct described herein (such as an siRNA, shRNA, or miRNA described herein) and (2) nucleic acids that facilitate and expression of the heterologous genes. The viral nucleic acids may include those sequences of AAV that are required in cis for replication and packaging (e.g., functional ITRs) of the DNA into a virion. Such rAAV vectors may also contain marker or reporter genes. Useful rAAV vectors include those having one or more of the naturally-occurring AAV genes deleted in whole or in part, but retain functional flanking ITR sequences. The AAV ITRs may be of any serotype (e.g., derived from serotype 2) suitable for a particular application. Methods for using rAAV vectors are described, for example, in Tal et al., J. Biomed. Sci. 7:279-291 (2000), and Monahan and Samulski, Gene Delivery 7:24-30 (2000), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery. The nucleic acids and vectors described herein can be incorporated into a rAAV virion in order to facilitate introduction of the nucleic acid or vector into a cell. The capsid proteins of AAV compose the exterior, non-nucleic acid portion of the virion and are encoded by the AAV cap gene. The cap gene encodes three viral coat proteins, VP1 , VP2 and VP3, which are required for virion assembly. The construction of rAAV virions has been described, for example, in US Patent Nos. 5,173,414; 5,139,941 ; 5,863,541 ; 5,869,305; 6,057,152; and 6,376,237; as well as in Rabinowitz et al„ J. Virol. 76:791 -801 (2002) and Bowles et al. , J. Virol. 77:423-432 (2003), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.
rAAV virions useful in conjunction with the compositions and methods described herein include those derived from a variety of AAV serotypes including AAV 1 , 2, 3, 4, 5, 6, 7, 8 and 9. Construction and use of AAV vectors and AAV proteins of different serotypes are described, for example, in Chao et al.,
Mol. Ther. 2:619-623 (2000); Davidson et al., Proc. Natl. Acad. Sci. USA 97:3428-3432 (2000); Xiao et al., J. Virol. 72:2224-2232 (1998); Halbert et al., J. Virol. 74:1524-1532 (2000); Halbert et al., J. Virol. 75:6615-6624 (2001 ); and Auricchio et al., Hum. Molec. Genet. 10:3075-3081 (2001 ), the disclosures of each of which are incorporated herein by reference as they pertain to AAV vectors for gene delivery.
Also useful in conjunction with the compositions and methods described herein are pseudotyped rAAV vectors. Pseudotyped vectors include AAV vectors of a given serotype (e.g., AAV2) pseudotyped with a capsid gene derived from a serotype other than the given serotype (e.g., AAV1 , AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9, among others). For example, a representative pseudotyped vector is an AAV2 vector encoding a therapeutic protein pseudotyped with a capsid gene derived from AAV serotype 8 or AAV serotype 9. Techniques involving the construction and use of pseudotyped rAAV virions are known in the art and are described, for example, in Duan et al., J. Virol. 75:7662-7671 (2001 ); Halbert et al., J. Virol. 74:1524-1532 (2000); Zolotukhin et al., Methods, 28:158-167 (2002); and Auricchio et al., Hum. Molec. Genet., 10:3075-3081 (2001 ).
AAV virions that have mutations within the virion capsid may be used to infect particular cell types more effectively than non-mutated capsid virions. For example, suitable AAV mutants may have ligand insertion mutations for the facilitation of targeting AAV to specific cell types. The construction and characterization of AAV capsid mutants including insertion mutants, alanine screening mutants, and epitope tag mutants is described in Wu et al., J. Virol. 74:8635-45 (2000). Other rAAV virions that can be used in methods of the invention include those capsid hybrids that are generated by molecular breeding of viruses as well as by exon shuffling. See, e.g., Soong et al., Nat. Genet., 25:436-439 (2000) and Kolman and Stemmer, Nat. Biotechnol. 19:423-428 (2001 ). Additional Methods for the Delivery of Interfering RNA
Transfection techniques
Techniques that can be used to introduce a transgene, such as a transgene encoding an interfering RNA construct described herein, into a target cell (e.g., a target cell from or within a human patient suffering from RNA dominance) are known in the art. For example, electroporation can be used to permeabilize mammalian cells (e.g., human target cells) by the application of an electrostatic potential to the cell of interest. Mammalian cells, such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al. , Nucleic Acids Research 15:131 1 (1987), the disclosure of which is incorporated herein by reference. A similar technique, Nucleofection™, utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. Nucleofection™ and protocols useful for performing this technique are described in detail, e.g., in Distler et al., Experimental Dermatology 14:315 (2005), as well as in US 2010/03171 14, the disclosures of each of which are incorporated herein by reference.
Additional techniques useful for the transfection of target cells include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human target cell. Squeeze-poration is described in detail, e.g., in Sharei et al., Journal of Visualized Experiments 81 :e50980 (2013), the disclosure of which is incorporated herein by reference.
Lipofection represents another technique useful for transfection of target cells. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for example, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for example, in US Patent No. 7,442,386, the disclosure of which is incorporated herein by reference. Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex. Exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane are activated dendrimers (described, e.g., in Dennig, Topics in Current Chemistry
228:227 (2003), the disclosure of which is incorporated herein by reference) and diethylaminoethyl
(DEAE)-dextran, the use of which as a transfection agent is described in detail, for example, in Gulick et al., Current Protocols in Molecular Biology 40:1:9.2:9.2.1 (1997), the disclosure of which is incorporated herein by reference. Magnetic beads are another tool that can be used to transfect target cells in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for example, in US 2010/0227406, the disclosure of which is incorporated herein by reference.
Another useful tool for inducing the uptake of exogenous nucleic acids by target cells is laserfection, a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cells and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g., in Rhodes et al. , Methods in Cell Biology 82:309 (2007), the disclosure of which is incorporated herein by reference.
Microvesicles represent another potential vehicle that can be used to modify the genome of a target cell according to the methods described herein. For example, microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g., a genome-modifying protein, such as a nuclease, can be used to efficiently deliver proteins into a cell that subsequently catalyze the site- specific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence. The use of such vesicles, also referred to as Gesicles, for the genetic modification of eukaryotic cells is described in detail, e.g., in Quinn et al., Genetic Modification of Target Cells by Direct Delivery of Active Protein [abstract]. In: Methylation changes in early embryonic genes in cancer [abstract], in: Proceedings of the 18th Annual Meeting of the American Society of Gene and Cell Therapy; 2015 May 13,
Abstract No. 122.
Incorporation of Genes Encoding Interfering RNA by Gene Editing
In addition to the above, a variety of tools have been developed that can be used for the incorporation of a transgene, such as a transgene encoding an interfering RNA construct described herein, into a target cell, and particularly into a human cell. One such method that can be used for incorporating polynucleotides encoding interfering RNA constructs into target cells involves the use of transposons. Transposons are polynucleotides that encode transposase enzymes and contain a polynucleotide sequence or gene of interest flanked by 5’ and 3’ excision sites. Once a transposon has been delivered into a cell, expression of the transposase gene commences and results in active enzymes that cleave the gene of interest from the transposon. This activity is mediated by the site-specific recognition of transposon excision sites by the transposase. In some instances, these excision sites may be terminal repeats or inverted terminal repeats. Once excised from the transposon, the transgene of interest can be integrated into the genome of a mammalian cell by transposase-catalyzed cleavage of similar excision sites that exist within the nuclear genome of the cell. This allows the transgene of interest to be inserted into the cleaved nuclear DNA at the complementary excision sites, and subsequent covalent ligation of the phosphodiester bonds that join the gene of interest to the DNA of the mammalian cell genome completes the incorporation process. In certain cases, the transposon may be a retrotransposon, such that the gene encoding the target gene is first transcribed to an RNA product and then reverse-transcribed to DNA before incorporation in the mammalian cell genome. Exemplary transposon systems are the piggybac transposon (described in detail in, e.g., WO 2010/085699) and the sleeping beauty transposon (described in detail in, e.g., US 2005/01 12764), the disclosures of each of which are incorporated herein by reference as they pertain to transposons for use in gene delivery to a cell of interest.
Another tool for the integration of target transgenes into the genome of a target cell is the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, a system that originally evolved as an adaptive defense mechanism in bacteria and archaea against viral infection. The
CRISPR/Cas system includes palindromic repeat sequences within plasmid DNA and an associated Cas9 nuclease. This ensemble of DNA and protein directs site specific DNA cleavage of a target sequence by first incorporating foreign DNA into CRISPR loci. Polynucleotides containing these foreign sequences and the repeat-spacer elements of the CRISPR locus are in turn transcribed in a host cell to create a guide RNA, which can subsequently anneal to a target sequence and localize the Cas9 nuclease to this site. In this manner, highly site-specific cas9-mediated DNA cleavage can be engendered in a foreign polynucleotide because the interaction that brings cas9 within close proximity of the target DNA molecule is governed by RNA:DNA hybridization. As a result, one can design a CRISPR/Cas system to cleave any target DNA molecule of interest. This technique has been exploited in order to edit eukaryotic genomes (Hwang et al. , Nature Biotechnology 31 :227 (2013)) and can be used as an efficient means of site-specifically editing target cell genomes in order to cleave DNA prior to the incorporation of a gene encoding a target gene. The use of CRISPR/Cas to modulate gene expression has been described in, for example, US Patent No. 8,697,359, the disclosure of which is incorporated herein by reference as it pertains to the use of the CRISPR/Cas system for genome editing. Alternative methods for site- specifically cleaving genomic DNA prior to the incorporation of a transgene of interest in a target cell include the use of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). Unlike the CRISPR/Cas system, these enzymes do not contain a guiding polynucleotide to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes. The use of ZFNs and TALENs in genome editing applications is described, e.g., in Urnov et al., Nature Reviews Genetics 1 1 :636 (2010); and in Joung et al., Nature Reviews Molecular Cell Biology 14:49 (2013), the disclosure of each of which are incorporated herein by reference as they pertain to compositions and methods for genome editing.
Additional genome editing techniques that can be used to incorporate polynucleotides encoding target transgenes into the genome of a target cell include the use of ARCUS™ meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA. The use of these enzymes for the incorporation of genes encoding target genes into the genome of a mammalian cell is advantageous in view of the defined structure-activity relationships that have been established for such enzymes. Single chain meganucleases can be modified at certain amino acid positions in order to create nucleases that selectively cleave DNA at desired locations, enabling the site-specific incorporation of a target transgene into the nuclear DNA of a target cell. These single-chain nucleases have been described extensively in, for example, US Patent Nos. 8,021 ,867 and US 8,445,251 , the disclosures of each of which are incorporated herein by reference as they pertain to compositions and methods for genome editing.
Methods of Detecting RNA Transcript Expression
The expression level of a pathological RNA transcript, such as a DMPK RNA transcript harboring an expanded CUG trinucleotide repeat or a C90RF72 RNA transcript harboring an expanded GGGGCC (SEQ ID NO: 162) hexanucleotide can be ascertained, for example, by a variety of nucleic acid detection techniques. Additionally or alternatively, RNA transcript expression can be inferred by evaluating the concentration or relative abundance of an encoded protein produced by translation of the RNA transcript. Protein concentrations can also be assessed, for example, using functional assays. Using these techniques, a reduction in the concentration of pathological RNA transcripts in response to the compositions and methods described herein can be observed, while monitoring the expression of the encoded protein. The sections that follow describe exemplary techniques that can be used to measure the expression level of a pathological RNA transcript and its downstream protein product. RNA transcript expression can be evaluated by a number of methodologies known in the art, including, but not limited to, nucleic acid sequencing, microarray analysis, proteomics, in-situ hybridization (e.g., fluorescence in-situ hybridization (FISH)), amplification-based assays, in situ hybridization, fluorescence activated cell sorting (FACS), northern analysis and/or PCR analysis of RNAs.
Nucleic Acid Detection
Nucleic acid-based methods for detection of RNA transcript expression include imaging-based techniques (e.g., Northern blotting or Southern blotting), which may be used in conjunction with cells obtained from a patient following administration of, for example, a vector encoding an interfering RNA described herein or a composition containing such an interfering RNA construct. Northern blot analysis is a conventional technique well known in the art and is described, for example, in Molecular Cloning, a Laboratory Manual, second edition, 1989, Sambrook, Fritch, Maniatis, Cold Spring Harbor Press, 10 Skyline Drive, Plainview, NY 1 1803-2500. Typical protocols for evaluating the status of genes and gene products are found, for example in Ausubel et al. , eds., 1995, Current Protocols In Molecular Biology, Units 2 (Northern Blotting), 4 (Southern Blotting), 15 (Immunoblotting) and 18 (PCR Analysis). RNA detection techniques that may be used in conjunction with the compositions and methods described herein to evaluate the suppression of RNA transcripts harboring expanded nucleotide repeat regions, such as DMPK RNA transcripts harboring expanded CUG trinucleotide repeats and C90RF72 RNA transcripts harboring expanded GGGGCC (SEQ ID NO: 162) hexanucleotide repeats, further include microarray sequencing experiments (e.g., Sanger sequencing and next-generation sequencing methods, also known as high-throughput sequencing or deep sequencing). Exemplary next generation sequencing technologies include, without limitation, lllumina sequencing, Ion Torrent sequencing, 454 sequencing, SOLiD sequencing, and nanopore sequencing platforms. Additional methods of sequencing known in the art can also be used. For example, transgene expression at the mRNA level may be determined using RNA-Seq (e.g., as described in Mortazavi et al. , Nat. Methods 5:621 -628 (2008), the disclosure of which is incorporated herein by reference in their entirety). RNA-Seq is a robust technology for monitoring expression by direct sequencing the RNA molecules in a sample. Briefly, this methodology may involve fragmentation of RNA to an average length of 200 nucleotides, conversion to cDNA by random priming, and synthesis of double-stranded cDNA (e.g., using the Just cDNA DoubleStranded cDNA Synthesis Kit from Agilent Technology®). Then, the cDNA is converted into a molecular library for sequencing by addition of sequence adapters for each library (e.g., from lllumina®/Solexa), and the resulting 50-100 nucleotide reads are mapped onto the genome.
RNA expression levels may be determined using microarray-based platforms (e.g., single nucleotide polymorphism arrays), as microarray technology offers high resolution. Details of various microarray methods can be found in the literature. See, for example, U.S. Pat. No. 6,232,068 and Pollack et al., Nat. Genet. 23:41 -46 (1999), the disclosures of each of which are incorporated herein by reference in their entirety. Using nucleic acid microarrays, mRNA samples are reverse transcribed and labeled to generate cDNA. The probes can then hybridize to one or more complementary nucleic acids arrayed and immobilized on a solid support. The array can be configured, for example, such that the sequence and position of each member of the array is known. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. Expression level may be quantified according to the amount of signal detected from hybridized probe-sample complexes. A typical microarray experiment involves the following steps: 1 ) preparation of fluorescently labeled target from RNA isolated from the sample, 2) hybridization of the labeled target to the microarray, 3) washing, staining, and scanning of the array, 4) analysis of the scanned image and 5) generation of gene expression profiles. One example of a microarray processor is the Affymetrix GENECFIIP® system, which is commercially available and comprises arrays fabricated by direct synthesis of oligonucleotides on a glass surface. Other systems may be used as known to one skilled in the art. Amplification-based assays also can be used to measure the expression level of a particular RNA transcript, such as a DMPK RNA transcript harboring an expanded CUG trinucleotide repeat or a C90RF72 RNA transcript harboring an expanded GGGGCC (SEQ ID NO: 162) hexanucleotide repeat.
In such assays, the nucleic acid sequence of the transcript acts as a template in an amplification reaction (for example, PCR, such as qPCR). In a quantitative amplification, the amount of amplification product is proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the expression level of the transcript of interest, corresponding to the specific probe used, according to the principles described herein. Methods of real-time qPCR using TaqMan probes are well known in the art. Detailed protocols for real-time qPCR are provided, for example, in Gibson et al., Genome Res. 6:995-1001 (1996), and in Heid et al. , Genome Res. 6:986-994 (1996), the disclosures of each of which are incorporated herein by reference in their entirety. Levels of RNA transcript expression as described herein can be determined, for example, by RT-PCR technology.
Probes used for PCR may be labeled with a detectable marker, such as, for example, a radioisotope, fluorescent compound, bioluminescent compound, a chemiluminescent compound, metal chelator, or enzyme.
Protein Detection
Expression of an RNA construct may also be inferred by analyzing expression of the protein encoded by the construct. Protein levels can be assessed using standard detection techniques known in the art. Protein expression assays suitable for use with the compositions and methods described herein include proteomics approaches, immunohistochemical and/or western blot analysis, immunoprecipitation, molecular binding assays, ELISA, enzyme-linked immunofiltration assay (ELIFA), mass spectrometry, mass spectrometric immunoassay, and biochemical enzymatic activity assays. In particular, proteomics methods can be used to generate large-scale protein expression datasets in multiplex. Proteomics methods may utilize mass spectrometry to detect and quantify polypeptides (e.g., proteins) and/or peptide microarrays utilizing capture reagents (e.g., antibodies) specific to a panel of target proteins to identify and measure expression levels of proteins expressed in a sample (e.g., a single cell sample or a multi cell population).
Exemplary peptide microarrays have a substrate-bound plurality of polypeptides, the binding of an oligonucleotide, a peptide, or a protein to each of the plurality of bound polypeptides being separately detectable. Alternatively, the peptide microarray may include a plurality of binders, including, but not limited to, monoclonal antibodies, polyclonal antibodies, phage display binders, yeast two-hybrid binders, aptamers, which can specifically detect the binding of specific oligonucleotides, peptides, or proteins. Examples of peptide arrays may be found in U.S. Patent Nos. 6,268,210, 5,766,960, and 5,143,854, the disclosures of each of which are incorporated herein by reference in their entirety. Mass spectrometry (MS) may be used in conjunction with the methods described herein to identify and characterize transgene expression in a cell from a patient (e.g., a human patient) following delivery of the transgene. Any method of MS known in the art may be used to determine, detect, and/or measure a protein or peptide fragment of interest, e.g., LC-MS, ESI-MS, ESI-MS/MS, MALDI-TOF-MS, MALDI-TOF/TOF-MS, tandem MS, and the like. Mass spectrometers generally contain an ion source and optics, mass analyzer, and data processing electronics. Mass analyzers include scanning and ion-beam mass spectrometers, such as time-of-flight (TOF) and quadruple (Q), and trapping mass spectrometers, such as ion trap (IT), Orbitrap, and Fourier transform ion cyclotron resonance (FT-ICR), may be used in the methods described herein. Details of various MS methods can be found in the literature. See, for example, Yates et al., Annu. Rev. Biomed. Eng. 1 1 :49-79, 2009, the disclosure of which is incorporated herein by reference in its entirety.
Prior to MS analysis, proteins in a sample obtained from the patient can be first digested into smaller peptides by chemical (e.g., via cyanogen bromide cleavage) or enzymatic (e.g., trypsin) digestion. Complex peptide samples also benefit from the use of front-end separation techniques, e.g., 2D-PAGE, HPLC, RPLC, and affinity chromatography. The digested, and optionally separated, sample is then ionized using an ion source to create charged molecules for further analysis. Ionization of the sample may be performed, e.g., by electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), photoionization, electron ionization, fast atom bombardment (FAB)/liquid secondary ionization (LSIMS), matrix assisted laser desorption/ionization (MALDI), field ionization, field desorption, thermospray/plasmaspray ionization, and particle beam ionization. Additional information relating to the choice of ionization method is known to those of skill in the art.
After ionization, digested peptides may then be fragmented to generate signature MS/MS spectra. Tandem MS, also known as MS/MS, may be particularly useful for analyzing complex mixtures. Tandem MS involves multiple steps of MS selection, with some form of ion fragmentation occurring in between the stages, which may be accomplished with individual mass spectrometer elements separated in space or using a single mass spectrometer with the MS steps separated in time. In spatially separated tandem MS, the elements are physically separated and distinct, with a physical connection between the elements to maintain high vacuum. In temporally separated tandem MS, separation is accomplished with ions trapped in the same place, with multiple separation steps taking place over time. Signature MS/MS spectra may then be compared against a peptide sequence database (e.g., SEQUEST). Post- translational modifications to peptides may also be determined, for example, by searching spectra against a database while allowing for specific peptide modifications. Pharmaceutical Compositions
The interfering RNA constructs, as well as the vectors and compositions encoding or containing these constructs, may be incorporated into a vehicle for administration into a patient, such as a human patient suffering from RNA dominance, as described herein. Pharmaceutical compositions containing vectors, such as viral vectors, that encode an interfering RNA construct described herein can be prepared using methods known in the art. For example, such compositions can be prepared using, e.g., physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980); incorporated herein by reference), and in a desired form, e.g., in the form of lyophilized formulations or aqueous solutions.
Mixtures of the nucleic acids and viral vectors described herein may be prepared in water suitably mixed with one or more excipients, carriers, or diluents. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions
(described in US 5,466,468, the disclosure of which is incorporated herein by reference). In any case the formulation may be sterile and may be fluid to the extent that easy syringability exists. Formulations may be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For example, a solution containing a pharmaceutical composition described herein may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCI solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion. Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations may meet sterility, pyrogenicity, general safety, and purity standards as required by FDA Office of Biologies standards.
Routes of Administration and Dosing
Viral vectors, such as AAV vectors and others described herein, containing a transgene encoding an interfering RNA construct described herein may be administered to a patient (e.g., a human patient) by a variety of routes of administration. The route of administration may vary, for example, with the onset and severity of disease, and may include, e.g., intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intradermal, transdermal, parenteral, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, and oral administration. Intravascular administration includes delivery into the vasculature of a patient. In some embodiments, the administration is into a vessel considered to be a vein (intravenous), and in some administration, the administration is into a vessel considered to be an artery (intraarterial). Veins include, but are not limited to, the internal jugular vein, a peripheral vein, a coronary vein, a hepatic vein, the portal vein, great saphenous vein, the pulmonary vein, superior vena cava, inferior vena cava, a gastric vein, a splenic vein, inferior mesenteric vein, superior mesenteric vein, cephalic vein, and/or femoral vein. Arteries include, but are not limited to, coronary artery, pulmonary artery, brachial artery, internal carotid artery, aortic arch, femoral artery, peripheral artery, and/or ciliary artery. It is contemplated that delivery may be through or to an arteriole or capillary.
Treatment regimens may vary, and often depend on disease severity and the age, weight, and sex of the patient. Treatment may include administration of vectors (e.g., viral vectors) or other agents described herein as useful for the introduction of a transgene into a target cell in various unit doses. Each unit dose will ordinarily contain a predetermined-quantity of the therapeutic composition.
Examples
The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used, made, and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Example 1. Development and evaluation of adeno-associated viral vectors encoding miRNA constructs for the treatment of disorders associated with RNA dominance
Objective
This example describes a series of experiments conducted in order to characterize the development and evaluation of rAAV vectors encoding miRNA constructs against human DMPK and murine HSALR, which is expressed in mouse models of the RNA dominance disorder, myotonic dystrophy. Myotonic dystrophy (DM) is caused by expansion of a microsatellite repeat that leads to expression of a toxic expanded repeat mRNA. Another RNA dominance disorder, facioscapulohumeral muscular dystrophy (FSHD), is caused by contraction of a D4Z4 macrosatellite repeat that leads to expression of DUX4, a toxic protein in adult muscle. The goal of the experiments described in this example is to develop AAV vectors encoding miRNA constructs that target muscle DM and FSHD-related mRNAs, so as to prevent muscle dysfunction and loss in individuals with disease.
Materials and Methods
To develop rAAV-RNAi therapy for myotonic dystrophy type 1 (DM1 ), a human skeletal actin gene (HSA) directed interfering RNA hairpin was designed and produced so that its efficacy could be tested in the HSALR mouse model of DM1 . The HSALR mouse was produced with insertion of an expanded CTG repeat in the 3’ UTR of the HSA gene, a similar genetic context to the disease-causing repeat expansion in the DMPK gene in humans. The HSALR mouse displays many of the genetic and phenotypic changes associated with DM1 in skeletal muscle, including myotonia, splicing changes in a variety of mRNAs, and nuclear inclusions (foci). Among the aims of this study was to translate the approach of reducing expression of aberrant HSALR RNA transcripts containing expanded CUG repeat regions to develop a paradigm for suppressing the human disease target gene, DMPK.
To this end, RNAi expression cassettes with 19-22 bp target recognition sequences were tested for a variety of applications. The RNAi hairpins were based on miR30a endogenous sequence. The single-stranded rAAV genomes were packaged in an rAAV6 capsid for targeting muscle. rAAV6 HSA RNAi constructs were delivered by intravenous injection (IV) previously into the tail vein of HSALR mice at 4 weeks of age (n=7-9).
Results
As shown in FIGS. 2A - 2C, three generations of rAAV-RNAi vectors were developed to target several genes for testing and development of therapeutic RNAi. The rAAV plasmid pARAP4 includes the human alkaline phosphatase reporter gene (Hu Aik Phos) reporter gene, expressed from the Rous
Sarcoma Virus (RSV) promoter, and the SV40 polyadenylation sequence, pA. The inverted terminal repeats (ITRs) originate from rAAV2 and genomes are packaged in rAAV6 capsids. The newest vector modification removes the RSV promoter sequence to prevent Hu Aik Phos expression that limited rAAV- RNAi efficacy at higher doses due muscle cell toxicity.
As show in FIGS. 3A - 3C, HSALR mice show characteristics of muscular dystrophy resembling DM in humans. The HSALR transgene is derived from insertion of a (CTG)2so repeat in the 3’ UTR of the HSA gene. When the transgene is expressed in mouse skeletal muscle, myotonic discharges are evident, splicing alterations occur in a variety of mRNAs, and nuclear foci containing the expanded transgenic mRNA and splicing factors are present.
As shown in FIG. 4, HSALR mice were transduced with rAAV6 HSA miR DM10. Human placental alkaline phosphatase (AP) staining indicates presence of the viral genome with active reporter gene expression, and H&E staining of cryosections from treated mice is also shown. Timepoint, 8 weeks post injection, 4 week-old HSALR mice.
As shown in FIGS. 5A and 5B, FIGS. 6A - 6E, and FIGS. 7A - 7C, rAAV-RNAi vectors encoding miRNA constructs complimentary to HSALR transcripts reduced the expression of pathologic HSALR RNA and effectuated the release of RNA-binding splicing factors that would otherwise be sequestered by the CUG repeat expansion, as evidenced by the restoration of correct splicing of SERCA1 mRNA (FIGS. 6C and 6D). rAAV6 HSA miR DM10 systemic injection improves splicing of SERCA1 and CLCN1 in the tibialis anterior (TA) muscle. In contrast, a different RNAi hairpin, miR DM4, was not as effective at reversing these splicing defects.
Selection of DMPK regions for RNAi
Selection of DMPK RNA target sequences for incorporation into miRNA-based hairpins was done using guidelines for siRNA design. Candidate target sequences were eliminated based on predicted seed sequence matches at other loci or in alternatively spliced regions. Additional screening included analysis using Bowtie for short sequence alignment to the human genome and extensive BLAST searches. Exemplary interfering RNA constructs against human DMPK are shown in Table 4, above, and are represented graphically in FIG. 1 .
Conclusions
As demonstrated in these experiments, local injection of vectors lacking the Hu Aik Phos promoter in muscle improves the splicing-related phenotype of the HSALR mice, as measured by the increase in amount of SERCA1 mRNA adult splicing product. Splicing for SERCA1 mRNA was approximately 95% corrected and demonstrates that improvements in technology have the potential to increase the efficacy of this approach.
Additionally, these results demonstrate that rAAV6-mediated delivery of the HSA hairpins improves many molecular and phenotypic characteristics of DM1 modeled in the HSALR mouse, including myotonia, disease-related splicing changes, and sequestration of splicing factors. Moreover, using the compositions and methods described herein, vectors carrying U6-expressed DMPK miRNAs can reduce endogenous DMPK mRNA in HEK293 cells following transfection. These data indicate the utility for an RNAi-mediated gene therapy to treat DM1 .
rAAV-mediated therapy is effective for spinal muscular atrophy and is progressing in clinical trials for Duchenne muscular dystrophy. Studies in non-human primates demonstrate that AAV can transduce muscle efficiently with regional limb delivery and persist for as long as 10 years. These studies support development of rAAV-mediated RNAi gene therapy for the treatment of dominant muscle diseases in humans, such as myotonic dystrophy type I, among others described herein.
Example 2. Treatment of myotonic dystrophy in a human patient by administration of a viral vector encoding a miRNA against DMPK
Using the compositions and methods described herein, a physician of skill in the art may administer to a patient having myotonic dystrophy type I a viral vector encoding a miRNA that anneals to, and reduces the expression of, mutant DMPK RNA transcripts containing expanded CUG repeat regions. The vector may be an AAV vector, such as a pseudotyped AAV2/8 or AAV2/9 vector. The vector may be administered by way of one or more routes of administration described herein, such as by intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intramuscular, or subcutaneous injection. The encoded miRNA may be a miRNA characterized herein, such as a miRNA having the nucleic acid sequence of any one of SEQ ID Nos: 40-161 .
Following administration of the vector, the physician may monitor the progression of the disorder and the efficacy of the treatment by assessing, for example, the concentration of correctly spliced mRNA transcripts encoding SERCA1 , CLCN1 , and/or ZASP, using an RNA detection technique described herein. The physician may also monitor the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein product resulting from the correctly spliced transcripts. Additionally or alternatively, the physician may monitor the concentration of mutant DMPK RNA transcripts expressed by the patient, particularly,
DMPK transcripts having from about 50 to about 4,000, or more, CUG trinucleotide repeats. A finding that (i) the concentration of correctly spliced SERCA1 , CLCN1 , and/or ZASP mRNA transcripts has increased, (ii) the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein products resulting from translation of the correctly spliced mRNA transcripts has increased, and/or (iii) the concentration of mutant DMPK RNA transcripts harboring expanded CUG trinucleotide repeat regions has decrease may serve as an indicator that the patient has been successfully treated. The physician may also monitor the progression of one or more symptoms of the disease, such as myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids
(ptosis), weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts. In children, symptoms may also include
developmental delays, learning problems, language and speech difficulties, and personality development challenges. A finding that one or more, or all, of the foregoing symptoms has been ameliorated may also serve as a clinical indicator of successful treatment.
Example 3. Treatment of myotonic dystrophy in a human patient by administration of an siRNA oligonucleotide against DMPK
Using the compositions and methods described herein, a physician of skill in the art may administer to a patient having myotonic dystrophy type I an siRNA oligonucleotide that anneals to, and reduces the expression of, mutant DMPK RNA transcripts containing expanded CUG repeat regions. The oligonucleotide may have, for example, the nucleic acid sequence of any one of SEQ ID NOs: 3-39.
Following administration of the oligonucleotide, the physician may monitor the progression of the disorder and the efficacy of the treatment by assessing, for example, the concentration of correctly spliced mRNA transcripts encoding SERCA1 , CLCN1 , and/or ZASP, using an RNA detection technique described herein. The physician may also monitor the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein product resulting from the correctly spliced transcripts. Additionally or alternatively, the physician may monitor the concentration of mutant DMPK RNA transcripts expressed by the patient, particularly, DMPK transcripts having from about 50 to about 4,000, or more, CUG trinucleotide repeats.
A finding that (i) the concentration of correctly spliced SERCA1 , CLCN1 , and/or ZASP mRNA transcripts has increased, (ii) the concentration of functional SERCA1 , CLCN1 , and/or ZASP protein products resulting from translation of the correctly spliced mRNA transcripts has increased, and/or (iii) the concentration of mutant DMPK RNA transcripts harboring expanded CUG trinucleotide repeat regions has decrease may serve as an indicator that the patient has been successfully treated. The physician may also monitor the progression of one or more symptoms of the disease, such as myotonia, muscle stiffness, disabling distal weakness, weakness in the face and jaw muscles, difficulty in swallowing, drooping of the eyelids (ptosis), weakness of neck muscles, weakness in arm and leg muscles, persistent muscle pain, hypersomnia, muscle wasting, dysphagia, respiratory insufficiency, irregular heartbeat, heart muscle damage, apathy, insulin resistance, and cataracts. In children, symptoms may also include developmental delays, learning problems, language and speech difficulties, and personality development challenges. A finding that one or more, or all, of the foregoing symptoms has been ameliorated may also serve as a clinical indicator of successful treatment. Example 4. Ability of anti-DMPK siRNA molecules to suppress DMPK1 expression in cultured HEK293 cells
This example describes the results of experiments conducted in order to evaluate the ability of anti-DMPK siRNA molecules, such as various siRNA molecules described in Table 4 herein, to attenuate the expression of DMPK1 mRNA in cultured human cells. For purposes of comparison, in addition to testing siRNA molecules described in Table 4, above, a scrambled siRNA molecule and commercially available anti-DMPK siRNA molecules were tested as well.
To conduct these experiments, HEK293 cells (2 x 105 cells/well) were transfected in triplicate with either 5 pM of a candidate anti-DMPK siRNA molecule (such as an siRNA molecule described in Table 4, above) or 5 pM scrambled negative siRNA control (Silencer® Select siRNA, Ambion by Life
Technologies) using 1 pL Lipofectamine™ RNAiMAX (Thermo Fisher Scientific). Mock transfections of cells treated only with 1 pL Lipofectamine™ RNAiMAX were included for normalization. RNA was harvested after 48 hours using the RNeasy Plus Mini Kit (Qiagen). cDNA generated was subsequently generated using Superscript™ III Reverse Transcriptase (Thermo Fisher Scientific) using 150ng of RNA per sample. qPCR was performed to detect DMPK1 knockdown. qPCR experiments were set up in triplicate using the TaqMan™ Fast Advanced Master Mix, and reactions were performed using a
QuantStudio 3 RT-PCR instrument (Thermo Fisher Scientific). DMPK1 expression values were normalized to GAPDH (TaqMan™ Gene expression assay ID Hs02786624_g1 ) using QuantStudio 3 software.
The results of these experiments are shown in FIG. 9. As evidenced by this figure, various siRNA molecules described in Table 4, above, are capable of downregulating DMPK1 expression in live human cells. The data shown graphically in FIG. 9 are provided in numerical form in Table 6, below.
Table 6. Suppression of DMPK1 expression in HEK293 cells by siRNA molecules in FIG. 9
Figure imgf000082_0001
Figure imgf000083_0001
Other Embodiments
All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the invention that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
Other embodiments are within the claims.
What is claimed is:

Claims

Claims
1 . A viral vector comprising one or more transgenes, each encoding an interfering ribonucleic acid (RNA) of at least 17 nucleotides in length, wherein each interfering RNA comprises a portion that anneals to an endogenous RNA transcript comprising an expanded repeat region, and wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript that does not overlap with the expanded repeat region.
2. The viral vector of claim 1 , wherein the endogenous RNA transcript encodes human dystrophia myotonica protein kinase (DMPK).
3. The viral vector of claim 2, wherein the expanded repeat region comprises 50 or more CUG trinucleotide repeats.
4. The viral vector of claim 2, wherein the expanded repeat region comprises from about 50 to about 4,000 CUG trinucleotide repeats.
5. The vector of any one of claims 2-4, wherein the vector further comprises a transgene encoding a human DMPK RNA transcript that does not anneal to the interfering RNA.
6. The vector of claim 5, wherein the human DMPK RNA transcript is less than 85% complementary to the interfering RNA.
7. The viral vector of any one of claims 2-6, wherein the endogenous RNA transcript comprises a portion having at least 85% sequence identity to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
8. The viral vector of claim 7, wherein the endogenous RNA transcript comprises a portion having at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
9. The viral vector of claim 8, wherein the endogenous RNA transcript comprises a portion having at least 95% sequence identity to the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
10. The viral vector of claim 9, wherein the endogenous RNA transcript comprises a portion having the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.
1 1 . The viral vector of any one of claims 2-10, wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of exons 1 -15 of human DMPK.
12. The viral vector of any one of claims 2-1 1 , wherein the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary to the nucleic acid sequence of a segment within any one of exons 1 -1 5 of human DMPK.
13. The viral vector of claim 12, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
14. The viral vector of claim 13, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
15. The viral vector of claim 14, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
16. The viral vector of any one of claims 2-10, wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within any one of introns 1 -14 of human DMPK.
17. The viral vector of any one of claims 2-10 and 16, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 85% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
18. The viral vector of claim 17, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
19. The viral vector of claim 18, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
20. The viral vector of claim 19, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
21 . The viral vector of any one of claims 2-10, wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript comprising an exon-intron boundary within human DMPK.
22. The viral vector of any one of claims 2-10 and 21 , wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 85% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
23. The viral vector of claim 22, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
24. The viral vector of claim 23, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
25. The viral vector of claim 24, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
26. The viral vector of any one of claims 2-10, wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript within the 5’ untranslated region (UTR) or 3’
UTR of human DMPK.
27. The viral vector of any one of claims 2-10 and 26, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 85% complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
28. The viral vector of claim 27, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within the 5’
UTR or 3’ UTR of human DMPK.
29. The viral vector of claim 28, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within the 5’
UTR or 3’ UTR of human DMPK.
30. The viral vector of claim 29, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
31 . The viral vector of any one of claims 12-30, wherein the segment is from about 10 to about 80 nucleotides in length.
32. The viral vector of claim 31 , wherein the segment is from about 15 to about 50 nucleotides in length.
33. The viral vector of claim 32, wherein the segment is from about 17 to about 23 nucleotides in length.
34. The viral vector of any one of claims 2-10, wherein the portion of each interfering RNA anneals to a segment of the endogenous RNA transcript having the nucleic acid sequence of any one of SEQ ID NOs: 3-39.
35. The viral vector of any one of claims 2-34, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches.
36. The viral vector of claim 35, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches.
37. The viral vector of claim 36, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches.
38. The viral vector of any one of claims 2-34, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches.
39. The viral vector of any one of claims 2-38, wherein the interfering RNA comprises a portion having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
40. The viral vector of claim 39, wherein the interfering RNA comprises a portion having at least 90% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
41 . The viral vector of claim 40, wherein the interfering RNA comprises a portion having at least 95% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
42. The viral vector of claim 41 , wherein the interfering RNA comprises a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3-1 61 .
43. The viral vector of claim 1 , wherein the endogenous RNA transcript comprises human chromosome 9 open reading frame 72 (C90RF72) and an expanded repeat region.
44. The viral vector of claim 43, wherein the expanded repeat region comprises from about 25 to about 1 ,600 GGGGCC hexanucleotide repeats.
45. The viral vector of claim 43, wherein the expanded repeat region comprises greater than 30 GGGGCC hexanucleotide repeats.
46. The viral vector of any one of claims 43-45, wherein the endogenous RNA transcript comprises a portion having at least 85% sequence identity to the nucleic acid sequence of SEQ ID NO: 163, 165, or 166.
47. The viral vector of claim 46, wherein the endogenous RNA transcript comprises a portion having at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 163, 165, or 166.
48. The viral vector of claim 47, wherein the endogenous RNA transcript comprises a portion having at least 95% sequence identity to the nucleic acid sequence of SEQ ID NO: 163, 165, or 166.
49. The viral vector of claim 48, wherein the endogenous RNA transcript comprises a portion having the nucleic acid sequence of SEQ ID NO: 163, 165, or 166.
50. The viral vector of any one of claims 43-49, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 85% complementary to the nucleic acid sequence of a segment within human C90RF72.
51 . The viral vector of claim 50, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within human C90RF72.
52. The viral vector of claim 51 , wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within human C90RF72.
53. The viral vector of claim 52, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within human C90RF72.
54. The viral vector of any one of claims 50-53, wherein the segment is from about 10 to about 80 nucleotides in length.
55. The viral vector of claim 54, wherein the segment is from about 15 to about 50 nucleotides in length.
56. The viral vector of claim 55, wherein the segment is from about 17 to about 23 nucleotides in length.
57. The viral vector of any one of claims 43-56, wherein the interfering RNA anneals to the endogenous RNA transcript comprising human C90RF72 with from one to eight nucleotide mismatches.
58. The viral vector of claim 57, wherein the interfering RNA anneals to the endogenous RNA transcript comprising human C90RF72 with from one to five nucleotide mismatches.
59. The viral vector of claim 58, wherein the interfering RNA anneals to the endogenous RNA transcript comprising human C90RF72 with from one to three nucleotide mismatches.
60. The viral vector of any one of claims 43-56, wherein the interfering RNA anneals to the endogenous RNA transcript comprising human C90RF72 with no more than two nucleotide mismatches.
61 . The viral vector of any one of claims 1 -60, wherein the interfering RNA is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA).
62. The viral vector of claim 61 , wherein the interfering RNA is a miRNA, optionally wherein the miRNA is a U6 miRNA.
63. The viral vector of claim 62, wherein the viral vector comprises a primary miRNA (pri-miRNA) transcript encoding a mature miRNA.
64. The viral vector of claim 62, wherein the viral vector comprises a pre-miRNA transcript encoding a mature miRNA.
65. The viral vector of any one of claims 1 -64, wherein the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron.
66. The viral vector of claim 65, wherein the promoter is a desmin promoter, a phosphoglycerate kinase (PGK) promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a promoter within intron 1 of ocular paired like homeodomain 3 (PITX3).
67. The viral vector of any one of claims 1 -66, wherein the viral vector is selected from the group consisting of adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, poxvirus, baculovirus, herpes simplex virus, vaccinia virus, and a synthetic virus.
68. The viral vector of claim 67, wherein the viral vector is an AAV.
69. The viral vector of claim 68, wherein the AAV is an AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrhI O, or AAVrh74 serotype.
70. The viral vector of claim 68, wherein the viral vector is a pseudotyped AAV.
71 . The viral vector of claim 70, wherein the pseudotyped AAV is AAV2/8.
72. The viral vector of claim 70, wherein the pseudotyped AAV is AAV2/9.
73. The viral vector of claim 72, wherein the AAV comprises a recombinant capsid protein.
74. The viral vector of claim 67, wherein the synthetic virus is chimeric virus, mosaic virus, or pseudotyped virus, and/or comprises a foreign protein, synthetic polymer, nanoparticle, or small molecule.
75. A nucleic acid encoding or comprising an interfering RNA, wherein the interfering RNA comprises a portion having at least 85% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
76. The nucleic acid of claim 75, wherein the interfering RNA comprises a portion having at least 90% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
77. The nucleic acid of claim 76, wherein the interfering RNA comprises a portion having at least 95% sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
78. The nucleic acid of claim 77, wherein the interfering RNA comprises a portion having the nucleic acid sequence of any one of SEQ ID NOs: 3-161 .
79. The nucleic acid of any one of claims 75-78, wherein the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of exons 1 -15 of human DMPK.
80. The nucleic acid of any one of claims 75-79, wherein the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
81 . The nucleic acid of claim 80, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
82. The nucleic acid of claim 81 , wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
83. The nucleic acid of claim 82, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of exons 1 -15 of human DMPK.
84. The nucleic acid of any one of claims 75-78, wherein the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within any one of introns 1 -14 of human DMPK.
85. The nucleic acid of any one of claims 75-78 and 83, wherein the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
86. The nucleic acid of claim 85, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
87. The nucleic acid of claim 86, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
88. The nucleic acid of claim 87, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within any one of introns 1 -14 of human DMPK.
89. The nucleic acid of any one of claims 75-78, wherein the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK comprising an exon- intron boundary within human DMPK.
90. The nucleic acid of any one of claims 75-78 and 89, wherein the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
91 . The nucleic acid of claim 90, wherein the portion of each interfering RNA has a nucleic acid sequence that is least 90% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
92. The nucleic acid of claim 91 , wherein the portion of each interfering RNA has a nucleic acid sequence that is least 95% complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
93. The nucleic acid of claim 92, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment comprising an exon-intron boundary within human DMPK.
94. The nucleic acid of any one of claims 75-78, wherein the portion of each interfering RNA anneals to a segment of an endogenous RNA transcript encoding human DMPK within the 5’ UTR or 3’ UTR of human DMPK.
95. The nucleic acid of any one of claims 75-78 and 94, wherein the portion of each interfering RNA has a nucleic acid sequence that is least 85% complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
96. The nucleic acid of claim 95, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 90% complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
97. The nucleic acid of claim 96, wherein the portion of each interfering RNA has a nucleic acid sequence that is at least 95% complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
98. The nucleic acid of claim 97, wherein the portion of each interfering RNA has a nucleic acid sequence that is completely complementary to the nucleic acid sequence of a segment within the 5’ UTR or 3’ UTR of human DMPK.
99. The nucleic acid of any one of claims 80-98, wherein the segment is from about 10 to about 80 nucleotides in length.
100. The nucleic acid of claim 99, wherein the segment is from about 15 to about 50 nucleotides in length.
101 . The nucleic acid of claim 100, wherein the segment is from about 17 to about 23 nucleotides in length.
102. The nucleic acid of any one of claims 75-101 , wherein the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with from one to eight nucleotide mismatches.
103. The nucleic acid of claim 102, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to five nucleotide mismatches.
104. The nucleic acid of claim 103, wherein the interfering RNA anneals to the endogenous RNA transcript encoding human DMPK with from one to three nucleotide mismatches.
105. The nucleic acid of any one of claims 75-101 , wherein the interfering RNA anneals to an endogenous RNA transcript encoding human DMPK with no more than two nucleotide mismatches.
106. The nucleic acid of any one of claims 75-105, wherein the interfering RNA is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), or a micro RNA (miRNA).
107. The nucleic acid of claim 106, wherein the interfering RNA is a miRNA, optionally wherein the miRNA is a U6 miRNA.
108. The nucleic acid of claim 107, wherein the nucleic acid comprises a primary miRNA (pri- miRNA) transcript encoding a mature miRNA.
109. The nucleic acid of claim 107, wherein the nucleic acid comprises a pre-miRNA transcript encoding a mature miRNA.
1 10. The nucleic acid of any one of claims 75-109, wherein the interfering RNA is operably linked to a promoter that induces expression of the interfering RNA in a muscle cell or neuron.
1 1 1 . The nucleic acid of claim 1 10, wherein the promoter is a desmin promoter, a PGK promoter, a muscle creatine kinase promoter, a myosin light chain promoter, a myosin heavy chain promoter, a cardiac troponin C promoter, a troponin I promoter, a myoD gene family promoter, an actin alpha promoter, an actin beta promoter, an actin gamma promoter, or a muscle-specific promoter residing within intron 1 of ocular PITX3.
1 12. A vector comprising the nucleic acid of any one of claims 75-1 1 1 .
1 13. The vector of claim 1 12, wherein the vector further comprises a transgene encoding a human DMPK RNA transcript that does not anneal to the interfering RNA.
1 14. The vector of claim 1 13, wherein the human DMPK RNA transcript is less than 85% complementary to the interfering RNA.
1 15. A composition comprising the nucleic acid of any one of claims 75-1 1 1 , wherein the composition is a liposome, vesicle, synthetic vesicle, exosome, synthetic exosome, dendrimer, or nanoparticle.
1 16. A pharmaceutical composition comprising the vector of any one of claims 1 -74 and 1 12-1 14 or the composition of claim 1 15 and a pharmaceutically acceptable carrier, diluent, or excipient.
1 17. A method of reducing the occurrence of spliceopathy in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the vector of any one of claims 1 -74 and 1 12-1 14 or the composition of claim 1 15 or 1 16.
1 18. The method of claim 1 17, wherein the patient has myotonic dystrophy.
1 19. The method of claim 1 17 or 1 18, wherein upon administration of the vector or composition to the patient, the patient exhibits an increase in corrective splicing of RNA transcript substrates of muscleblind-like protein.
120. The method of any one of claims 1 17-1 19, wherein upon administration of the vector or composition to the patient, the patient exhibits an increase in expression of sarcoplasmic/endoplasmic reticulum calcium ATPase 1 (SERCA1 ) mRNA comprising exon 22.
121 . The method of any one of claims 1 17-120, wherein upon administration of the vector or composition to the patient, the patient exhibits a decrease in expression of chloride voltage-gated channel 1 (CLCN1 ) mRNA comprising exon 7a.
122. The method of any one of claims 1 17-121 , wherein upon administration of the vector or composition to the patient, the patient exhibits a decrease in expression of ZO-2 associated speckle protein (ZASP) comprising exon 1 1 .
123. The method of any one of claims 1 19-122, wherein upon administration of the vector or composition to the patient, expression of the SERCA1 , CLCN1 , and/or ZASP mRNA increases by from about 1 .1 -fold to about 10-fold.
124. The method of any one of claims 1 17-123, wherein upon administration of the vector or composition to the patient, the patient exhibits an increase in corrective splicing of RNA transcripts encoding insulin receptor, ryanodine receptor 1 , cardiac muscle troponin, and/or skeletal muscle troponin.
125. A method of treating a disorder characterized by nuclear retention of RNA comprising an expanded repeat region in a human patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the vector of any one of claims 1 -74 and 1 12-1 14 or the composition of claim 1 15 or 1 16.
126. The method of claim 125, wherein the disorder is myotonic dystrophy or amyotrophic lateral sclerosis.
127. The method of any one of claims 1 17-126, wherein the vector or composition is administered to the patient by way of intravenous, intrathecal, intracerebroventricular, intraparenchymal, intracisternal, intradermal, transdermal, parenteral, intramuscular, intranasal, subcutaneous, percutaneous, intratracheal, intraperitoneal, intraarterial, intravascular, inhalation, perfusion, lavage, or oral
administration.
128. A kit comprising the vector of any one of claims 1 -74 and 1 12-1 14 or the composition of claim 1 15 or 1 16, wherein the kit further comprises a package insert instructing a user of the kit to administer the vector or composition to a human patient to reduce the occurrence of a spliceopathy in the patient.
129. A kit comprising the vector of any one of claims 1 -74 and 1 12-1 14 or the composition of claim 1 15 or 1 16, wherein the kit further comprises a package insert instructing a user of the kit to administer the vector or composition to a human patient to treat a disorder characterized by nuclear retention of RNA comprising an expanded repeat region.
130. The kit of claim 129, wherein the disorder is myotonic dystrophy or amyotrophic lateral sclerosis.
PCT/US2019/032423 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders WO2019222354A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
MA51938A MA51938B1 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing splicing abnormalities and treating rna dominance disorders
JP2020563947A JP2021522836A (en) 2018-05-15 2019-05-15 Compositions and methods for reducing splice opacity and treating RNA dominance disorders
AU2019268346A AU2019268346A1 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating RNA dominance disorders
EP19803882.0A EP3793566A4 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders
CN201980047374.XA CN112469421A (en) 2018-05-15 2019-05-15 Compositions and methods for reducing splicing disorders and treating RNA dominant disorders
US17/054,474 US20210269825A1 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders
KR1020207036197A KR20210010549A (en) 2018-05-15 2019-05-15 Compositions and methods for reducing splicing abnormalities and treating RNA dominant diseases
MX2020012269A MX2020012269A (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders.
CA3098249A CA3098249A1 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders
BR112020023298-0A BR112020023298A2 (en) 2018-05-15 2019-05-15 compositions and methods for reducing spliceopathy and treating RNA dominance disorders
SG11202011151VA SG11202011151VA (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders
PH12020551913A PH12020551913A1 (en) 2018-05-15 2020-11-10 Compositions and methods for reducing spliceopathy and treating rna dominance disorders
CONC2020/0015239A CO2020015239A2 (en) 2018-05-15 2020-12-03 Compositions and Methods for Reducing Splicing Disease and for Treating RNA Dominance Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671769P 2018-05-15 2018-05-15
US62/671,769 2018-05-15

Publications (1)

Publication Number Publication Date
WO2019222354A1 true WO2019222354A1 (en) 2019-11-21

Family

ID=68540673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/032423 WO2019222354A1 (en) 2018-05-15 2019-05-15 Compositions and methods for reducing spliceopathy and treating rna dominance disorders

Country Status (15)

Country Link
US (1) US20210269825A1 (en)
EP (1) EP3793566A4 (en)
JP (1) JP2021522836A (en)
KR (1) KR20210010549A (en)
CN (1) CN112469421A (en)
AU (1) AU2019268346A1 (en)
BR (1) BR112020023298A2 (en)
CA (1) CA3098249A1 (en)
CL (1) CL2020002955A1 (en)
CO (1) CO2020015239A2 (en)
MA (1) MA51938B1 (en)
MX (1) MX2020012269A (en)
PH (1) PH12020551913A1 (en)
SG (1) SG11202011151VA (en)
WO (1) WO2019222354A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196862A1 (en) * 2022-04-06 2023-10-12 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
WO2024006770A1 (en) * 2022-06-27 2024-01-04 Astellas Gene Therapies, Inc. Compositions and methods for the treatment of myotonic dystrophies

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220719A2 (en) * 2022-05-13 2023-11-16 University Of Washington Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977333A (en) * 1992-02-06 1999-11-02 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
US20180094267A1 (en) * 2016-09-30 2018-04-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20120322861A1 (en) * 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
EP2595664B1 (en) * 2010-07-19 2018-10-17 Ionis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
MX2017008500A (en) * 2014-12-24 2018-02-01 Uniqure Ip Bv Rnai induced huntingtin gene suppression.
WO2017079291A1 (en) * 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
US11118185B2 (en) * 2016-03-01 2021-09-14 University Of Florida Research Foundation, Incorporated AAV vectors for treatment of dominant retinitis pigmentosa
JP7342936B2 (en) * 2018-08-10 2023-09-12 富士通株式会社 Communication methods, devices and communication systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977333A (en) * 1992-02-06 1999-11-02 Massachusetts Institute Of Technology DNA sequence encoding the myotonic dystrophy gene and uses thereof
US20180094267A1 (en) * 2016-09-30 2018-04-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BISSET, DR ET AL.: "Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy", HUMAN MOLECULAR GENETICS, vol. 24, no. 17, 16 June 2015 (2015-06-16), pages 4971 - 4983, XP055656933 *
BORTOLANZA, S ET AL.: "AAV6-mediated Systemic shRNA Delivery Reverses Disease in a Mouse Model of Facioscapulohumeral Muscular Dystrophy", MOLECULAR THERAPY, vol. 19, no. 11, 9 August 2011 (2011-08-09), pages 2055 - 2064, XP055656938 *
HU , J ET AL.: "Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus", CHEMISTRY AND BIOLOGY, vol. 22, no. 11, 12 November 2015 (2015-11-12), pages 1505 - 1511, XP029306633 *
LANGLOIS, MA ET AL.: "Cytoplasmic and Nuclear Retained DMPK mRNAs Are Targets for RNA Interference in Myotonic Dystrophy Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 17, 18 February 2005 (2005-02-18), pages 16949 - 16954, XP055147962, DOI: 10.1074/jbc.M501591200 *
See also references of EP3793566A4 *
SOBCZAK, K ET AL.: "RNA Interference Targeting CUG Repeats in a Mouse Model of Myotonic Dystrophy", MOLECULAR THERAPY, vol. 21, no. 2, 27 November 2012 (2012-11-27), pages 380 - 387, XP055656936 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
WO2023196862A1 (en) * 2022-04-06 2023-10-12 Genzyme Corporation Targeted gene therapy for dm-1 myotonic dystrophy
WO2024006770A1 (en) * 2022-06-27 2024-01-04 Astellas Gene Therapies, Inc. Compositions and methods for the treatment of myotonic dystrophies

Also Published As

Publication number Publication date
CN112469421A (en) 2021-03-09
KR20210010549A (en) 2021-01-27
CO2020015239A2 (en) 2021-03-08
AU2019268346A1 (en) 2020-12-24
CL2020002955A1 (en) 2021-04-23
MX2020012269A (en) 2021-04-28
MA51938B1 (en) 2022-10-31
CA3098249A1 (en) 2019-11-21
MA51938A1 (en) 2021-11-30
US20210269825A1 (en) 2021-09-02
JP2021522836A (en) 2021-09-02
BR112020023298A2 (en) 2021-03-09
EP3793566A1 (en) 2021-03-24
SG11202011151VA (en) 2020-12-30
EP3793566A4 (en) 2022-03-16
PH12020551913A1 (en) 2021-06-14

Similar Documents

Publication Publication Date Title
US20200407750A1 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
US20210269825A1 (en) Compositions and methods for reducing spliceopathy and treating rna dominance disorders
US20210123073A1 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
WO2022067228A1 (en) Trans-splicing system for tissue-specific replacement of rna sequences
WO2018035311A1 (en) Compositions and methods for modulating gene expression using reading frame surveillance
JP7500429B2 (en) Compositions and methods for the treatment of dominantly inherited catecholaminergic polymorphic ventricular tachycardia - Patent Application 20070123333
AU2022345283A1 (en) Frataxin gene therapy
JP7244547B2 (en) Adeno-associated virus compositions and methods of use thereof for restoring F8 gene function
WO2024056902A2 (en) Compositions and methods for treating neurological diseases
WO2024161022A2 (en) Compositions and methods for treating neurological diseases
WO2024006770A1 (en) Compositions and methods for the treatment of myotonic dystrophies
WO2024126696A1 (en) Compositions and methods for treating neurological diseases
WO2024006775A2 (en) Compositions and methods for the treatment of myotonic dystrophies
WO2024206672A1 (en) Nucleic acid off-switches and methods and uses thereof
WO2024154102A1 (en) Compositions and methods for administration of therapeutic and diagnostic agents to the central nervous system
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
CN117980482A (en) Genome editing of RBM20 mutations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19803882

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3098249

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020563947

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020023298

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20207036197

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019803882

Country of ref document: EP

Effective date: 20201215

ENP Entry into the national phase

Ref document number: 2019268346

Country of ref document: AU

Date of ref document: 20190515

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112020023298

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201114

ENPC Correction to former announcement of entry into national phase, pct application did not enter into the national phase

Ref document number: 112020023298

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.3 NA RPI NO 2613 DE 02/02/2021 POR TER SIDO INDEVIDA.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112020023298

Country of ref document: BR

Kind code of ref document: A2

Free format text: APRESENTAR, EM ATE 60 (SESSENTA) DIAS, TRADUCAO COMPLETA DO PEDIDO, ADAPTADA A NORMA VIGENTE, CONFORME CONSTA NO DEPOSITO INTERNACIONAL INICIAL PCT/US2019/032423 DE 15/05/2019, POIS A MESMA NAO FOI APRESENTADA ATE O MOMENTO.

REG Reference to national code

Ref country code: BR

Ref legal event code: ERR

Ref document number: 112020023298

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2615 DE 17/02/2021 POIS HOUVE COMPLEMENTACAO DO PEDIDO APOS O AGENDAMENTO DA MESMA.

ENP Entry into the national phase

Ref document number: 112020023298

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20201114